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Abstract 
The androgen receptor (AR) is a key transcription factor in prostate cancer (CaP) 
growth and metastases, and is the main target for CaP treatment via the use of anti-
hormonal therapies. Unfortunately, this treatment is only effective in the short-term 
and re-growth of the tumour results in most cases, termed castrate-resistant CaP 
(CRCaP), this is refractory to additional chemotherapies and hence fatal. Expression 
and reactivation of the AR is commonly seen in CRCaP and acts as a driver of advanced 
CaP growth suggesting the receptor remains a suitable target for next generation CaP 
therapies. 
Ubiquitination represents one of the numerous post-translational modifications that 
are vital for many cellular processes, including transcription and regulation of protein 
stability. The AR is a target for ubiquitination by several E3 ubiquitin ligase enzymes 
that can lead to either increased activity or degradation depending on the E3 ligase 
involved. Importantly, the persistence of the AR in CRCaP suggests that deciphering 
the mechanisms that regulate AR stability in this disease state may provide extremely 
useful and novel therapies. A major knowledge gap exists however, in our 
understanding of the reversal of ubiquitination by deubiquitinase enzymes (DUBs) 
within the AR signalling cascade that could be extremely important for the evidenced 
aberrant AR function in CRCaP. Therefore, the aim of this study was to characterise 
deubiquitinase enzymes (DUBs) involved in controlling AR activity and establishing 
potential roles of the enzymes in CaP development.  
A comprehensive siRNA library screen investigating the role of each DUB enzyme in AR 
signalling using the androgen-dependent LNCaP CaP cell line was undertaken and 
ubiquitin specific protease (USP) 12 (USP12) and USP10 were identified as regulators 
of AR activity. USP12 depletion resulted in reduced expression of androgen-responsive 
genes, suggesting USP12 is an activator of AR-mediated transcription, a notion 
confirmed in luciferase reporter assays. USP12 depletion failed to affect AR protein 
levels, but attenuated receptor recruitment to target gene promoters suggesting it is 
required to facilitate activated AR promoter binding. Studies of the phenotypic effects 
of USP12 knockdown revealed reduced LNCaP proliferation, increased cell cycle arrest 
and apoptosis, suggesting that USP12 inhibition could hold therapeutic potential in 
prostate cancer.  
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In contrast, USP10 depletion resulted in increased expression of androgen-response 
genes, and repressed AR transcriptional activity in luciferase reporter assays. Unlike 
USP12, which interacted with AR when over-expressed in COS-7 cells, USP10 did not 
interact with the receptor, leading to the hypothesis that it may exert its effects 
through deubiquitination and stabilisation of the AR co-repressor, and E3 ubiquitin 
ligase, MDM2. A preliminary study to investigate the effects of MDM2 and USP10 co-
transfection was unfortunately unsuccessful but further optimisation would assist in 
elucidating the role of the DUB in the AR signalling cascade. 
In conclusion, two DUB enzymes, USP12 and USP10, were identified to be important in 
modulation of AR activity. USP12 acts as co-activator of the AR and may be a potential 
therapeutic target in CaP. USP10, on the other hand, is a co-repressor of the AR and 
may act through MDM2. 
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1.1 The Prostate 
1.1.1 Functions of the prostate 
The prostate is a small, walnut sized gland important in the male reproductive system. 
It is situated at the neck of the bladder surrounding the urethra. The primary function 
of the prostate is to contribute secretary proteins to the seminal fluid thereby 
sustaining sperm motility and viability whilst maintaining the fluidity of the seminal 
fluid (Hamdy, 2002). 
1.1.2 Zonal anatomy of the prostate 
The human prostate is divided into four zones; the anterior fibromuscular structure, 
the peripheral zone, the central zone and the transition zone (McNeal, 1981) (Figure 
1.1). The anterior fibromuscular structure encapsulates the entire prostate. The 
peripheral zone is adjacent to the anterior fibromuscular stroma and contains the 
central and transition zones. The peripheral zone makes up around 70% of the total 
glandular prostate and is the most common site of prostate cancer (CaP) (Coffey, 
1993). The central zone surrounds the ejaculatory ducts and accounts for 25% of the 
glandular prostate. CaP is rare in this zone (Kirby, 2001). The transition zone consists of 
two symmetrical lobes situated on either side of the urethra. This region is small in 
young men but with age it enlarges to become a more dominant zone. Although only 
around 25% of CaP is found in this region it is the most common site of benign prostate 
hyperplasia (BPH) (McLaughlin et al., 2005). 
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Figure 1.1. Zonal anatomy of the prostate. 
 The prostate consists of the anterior fibromuscular stroma, the peripheral zone, the central zone and the transition 
zone. Adapted from (McLaughlin et al., 2005). 
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1.1.3 Histology of the prostate 
The prostate is a glandular organ and has a characteristic ductal structure. The ducts 
are lined with epithelial cells which are embedded in fibromuscular stromal tissue 
consisting of smooth muscle cells, fibroblasts and endothelium (Foster, 1998).  
Three types of epithelial cell exist in the normal prostate (Lepor, 1993). The luminal 
cells are the principal epithelial cells which express androgen receptor (AR) and are 
dependent upon androgens for growth. These are the cells that produce the proteins 
that are subsequently secreted into the lumen of the prostate ducts. The basal cells 
are sandwiched between the luminal cells and the basement membrane. These cells 
do not contribute to the secretary function of the luminal cells (Lepor, 1993). Although 
the basal cells express functional AR they are not androgen dependent. It is thought 
that it is within this layer that the prostate cancer stem cell resides (Maitland and 
Collins, 2008). The prostate cancer stem cell is thought to be an androgen independent 
cell with stem cell-like properties that reconstitutes the tumour with differentiated 
androgen-dependent cells following androgen ablation therapy and regression of the 
tumour (Maitland and Collins, 2008). Finally the neuroendocrine epithelial cells are 
thought to provide the paracrine signalling which stimulates and regulates the normal 
growth of the prostate. These cells themselves are androgen independent (di 
Sant'Agnese, 1998).  
1.1.4 Prostatic disease and prostate cancer 
1.1.4.1 Benign prostate hyperplasia 
Benign prostate hyperplasia (BPH) is the increased number of normal prostate cells 
which is the most common non-malignant disease of the prostate; with around 50% 
males over 60 and 90% over 85 years of age displaying disease (Lepor, 1993; Hamdy, 
2002). The transition zone enlarges with increased age and can cause disturbance of 
the glandular structure of the prostate as well as causing urinary problems. The 
urethra can become compressed making urination difficult in males with BPH and 
there is an association with urinary infections (McLaughlin et al., 2005). 
BPH is treated with inhibitors of the enzyme 5-α-reductase, which is responsible for 
the conversion of testosterone to the more potent androgen dihydrotestosterone 
(DHT), thereby reducing the levels of androgens. Alternatively, inhibitors of α-
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adrenergic receptor cause relaxing of the bladder tissue to relieve symptoms. Surgical 
trans-urethral resection of the prostate (TURP) can be used where other treatments 
are unsuccessful to decrease prostatic volume around the bladder also relieving 
symptoms (McLaughlin et al., 2005). 
1.1.4.2 Prostatic intra-epithelial neoplasia 
Prostatic intra-epithelial neoplasia (PIN) is the abnormal expansion of prostate cells 
within a benign prostate gland. Atypical cells are often observed and the main region 
of PIN is the peripheral zone, where most cases of CaP occur. PIN is described as an 
intermediate stage between benign prostatic hyperplasia and invasive CaP. Like BPH, 
there is an increased incidence with increased age (Bostwick et al., 2004). 
1.1.4.3 Prostate cancer 
Prostate cancer is an epithelial derived, androgen-dependent disease. Clinically 
localised disease is the most commonly diagnosed stage where the tumour is 
contained within the prostate. This is generally a low grade and highly differentiated 
tumour that is slow to progress (Catalona et al., 1993; Nguyen and Jones, 2011). 
Expansion of cancer cells can lead to invasion through the basement membrane of the 
prostate, known as locally advanced disease, and metastasis to other tissues. 
Metastatic CaP is commonly found in the bone, lung and liver (Yoneda, 1998). It is 
thought that up to 90% of patients with advanced CaP will have some bone metastasis 
(Cooper et al., 2003). Unfortunately many patients relapse after treatment with an 
androgen independent castrate resistant tumour (CRCaP). CRCaP is an aggressive form 
of CaP and is usually associated with increased tumour cell invasion and metastasis 
(Bonaccorsi et al., 2003). The mechanisms of androgen independence are discussed in 
Section 1.2.1.3 (Feldman and Feldman, 2001). 
1.1.4.3.1 Incidence and mortality 
CaP is the most common male cancer in the UK accounting for almost a quarter of 
newly diagnosed cases with 35,000 cases diagnosed annually. It is also the fourth 
leading cause of cancer related deaths worldwide and the second leading cause of 
cancer deaths in men in the UK with approximately 10,000 deaths per year (Cancer 
Research UK, 2011) (Figure 1.2). 
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There has been a steady increase in the incidence of CaP in recent years, possibly due 
to better detection, although mortality rates have not been significantly affected. 
Interestingly, one year and five year survival rates have increased dramatically as more 
cases of CaP are being diagnosed at an earlier stage than previously. One year survival 
has increased from 65% in 1971-1975 to 93% in 2004-2006, five year survival in 2001-
2006 was 77% compared to 31% in 1971-1975 (Cancer Research UK, 2011).  
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Figure 1.2. The most common cancer-related deaths in males in the UK.  
Prostate cancer is the second most common cause of cancer-related death and accounts for approximately 10,000 
deaths per year. Taken from (Cancer Research UK, 2011). 
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1.1.4.3.2 Risk factors 
The single greatest risk factor in CaP is age. The mean age of disease onset is 72-75 
years of age but latent CaP has been observed in men as young as 30 years old (Sakr et 
al., 1996; Cancer Research UK, 2011) (Figure 1.3). 80% of men over the age of 80 years 
have signs of CaP upon autopsy (Sakr et al., 1993). Around 5-10% of total CaP cases 
and 30-40% of early onset cases are thought to be due to familial genetic susceptibility 
(Bratt, 2002). Risk increases 2-fold if a first degree relative, i.e. father or brother, 
develops CaP and increases further if they are below 60 year old. Familial mutations 
within the BRCA1 and BRCA2 tumour suppressor genes, which are also associated with 
breast and ovarian cancer susceptibility, have been found to increase the rate of CaP 
diagnosis (Kirchhoff et al., 2004; van Asperen et al., 2005). 
Race also plays an important role with major differences in incidence observed 
between the western world and African and Asian populations (Gronberg, 2003). 
African American men have been shown to have a higher incidence of CaP than 
Caucasian men whilst Asian populations have a low incidence (Sakr et al., 1996; 
Gronberg, 2003). A study of Japanese men who immigrated to America showed that 
incidence of CaP increased although it was still 50% and 25% lower than Caucasian and 
African American men, respectively (Shimizu et al., 1991). This study identified that 
environmental factors did have a role in risk of CaP however they were not sufficient 
to account for the differences in populations (Shimizu et al., 1991). 
Environmental factors influencing risk include diet and obesity. Diets high in fat, low in 
soy, green tea, vitamin D and E and lycopene have been shown to increase the risk of 
CaP. Soy and vitamin D have been shown in vitro to reduce proliferation of CaP cell 
lines and induce apoptosis (Hori et al., 2011).  
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Figure 1.3. The rate of prostate cancer incidence increases with age.  
The median age of onset is 72-75 years of age. Taken from (Cancer Research UK, 2011). 
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1.1.4.3.3 Detection of prostate cancer 
Prostate cancer is usually diagnosed after histological analysis of 8-12 prostate needle 
core biopsies taken by trans-rectal ultrasound (TRUS) guided biopsy (Damber and Aus, 
2008). However, surrogate biomarkers of CaP have been developed and allow a non-
invasive method of detecting potential tumours (Bok and Small, 2002).(Seruga and 
Tannock, 2011) 
Prostatic acid phosphatase (PAP) was the first marker to be developed, which could be 
detected in the prostatic fluids (Bok and Small, 2002). However, this was superseded 
by prostate specific antigen (PSA) which could detect potential CaP at an earlier stage 
(Stamey et al., 1987; Catalona, 2004). PSA is an androgen regulated gene which 
encodes a secretary protein which is a major component of the seminal fluid. PSA 
detected at levels of greater than 2.5ng/ml in serum suggests possible CaP. Initially the 
threshold was set at 4ng/ml but a study of a large cohort of patients over 12 years 
discovered that many cases were being overlooked (Catalona et al., 1991; D'Amico et 
al., 2004). However, the lowering of the threshold has stimulated an argument that 
CaP is now being over-detected and over-treated as many men will not develop 
symptomatic disease (Welch and Albertsen, 2009; Nguyen and Jones, 2011). 
1.1.4.3.4 Treatment of prostate cancer 
The treatment of CaP can depend on stage of disease as well as the life expectancy and 
general health of the patient. Radical prostatectomy, in which the prostate is surgically 
removed, is commonly used in clinically localised disease. TURP can be used to relieve 
urinary tract symptoms as described for BPH (McLaughlin et al., 2005). 
Endocrine therapy is used to reduce the level of circulating androgens; commonly 
termed androgen ablation therapy (AAT). In the past, surgical removal of the testes 
(castration) was the gold standard of reducing testosterone levels with 60-80% of 
patients responding (Huggins and Hodges, 1941). However, this has now been 
superseded by the use of chemical agents which achieve similar results. Luteinising 
hormone releasing hormone (LHRH) agonists cause suppression of LHRH by 
desensitising and reducing the number of LHRH receptors. This in turn suppresses 
release of luteinising hormone (LH) and subsequently reduces testosterone levels 
(Hamdy, 2002). Similarly, estrogens can cause suppression of LHRH and LH by negative 
feedback on the hypothalamus (Lepor, 1993) Abiraterone is a small molecule inhibitor 
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that has been shown to have effects in CRCaP by blocking the CYP17 enzyme that is 
involved in androgen biosynthesis (Salem and Garcia, 2011). 
An additional class of modulators of the AR signalling axis are the direct AR 
antagonists, such as flutamide and bicalutamide, which competitively bind to the 
receptor, disrupting androgen binding and attenuating transcriptional function of the 
AR (Goktas et al., 1999).  
Chemotherapy is used as a treatment in CRCaP as it no longer responds to AAT. 
Generally this is palliative treatment not curative treatment. Chemotherapy, although 
causing regression of disease and palliation of symptoms was shown not to 
significantly affect survival (Petrylak, 2005b). In 2004, the results of the TAX 327 and 
Southwest Oncology Group (SWOG) 99-16 trials showed for the first time that 
treatment of CRCaP patients with docetaxel increased survival whilst decreasing the 
risk of death compared to patients treated with mitoxantrone and prednisone 
(Petrylak et al., 2004; Tannock et al., 2004). Docetaxel is a semi-synthetic taxane which 
disrupts the disassembly of microtubules during the G2-M phase of the cell cycle 
causing cell death in proliferating cells (Seruga and Tannock, 2011). Recently, newer 
classes of drugs are emerging as potential treatments for CRCaP. Ixabepilone, a 
member of the epothilone class of drugs, has been shown to reduce PSA by greater 
than 50% in approximately 30% of CRCaP patients (Hussain et al., 2005). Several other 
members of this drug class are in phase II clinical trials (Bhandari and Hussain, 2005).  
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1.2 Androgens 
Androgens are essential in the formation of male phenotype from early embryogenesis 
to adulthood as well as the normal development and maintenance of the prostate 
epithelium (Gelmann, 2002). Testosterone, the major circulating androgen, is 
synthesised from cholesterol by the testes in response to LH stimulation (Gao et al., 
2005b). Figure 1.4 shows the basic structure of a steroid hormone, the structure of 
testosterone is illustrated in Figure 1.4b. Serum proteins, such as sex hormone binding 
globulin (SHBG) and albumin, sequester testosterone in the blood (Gao et al., 2005b). 
Once testosterone enters the cell, it is converted by 5-α-reductase to DHT, which binds 
to and up-regulates transcriptional activity of the AR more potently than testosterone 
due to its higher binding affinity to the AR (Feldman and Feldman, 2001). It is 
suggested that the constant exposure of prostate cells to androgens is a driver in the 
development of prostate cancer as animal models of prostate cancer require the 
presence of functional testes or exogenous androgens (Gelmann, 2002). Deficiency in 
5-α-reductase, as well as defects in the function of the AR, results in loss of prostate 
development (Griffin, 1992). 
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Figure 1.4. The structure of a steroid hormone. 
A) The basic structure of a steroid hormone. B) The structure of testosterone.  (Kicman, 2010) 
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1.2.1 The androgen receptor 
The AR is a member of the steroid hormone receptor family of transcription factors. 
The AR gene, a non-essential but critical gene for male phenotype, is located at q11.2-
q12 on the X chromosome and consists of 8 exons which encode the four domains of 
the AR (Figure 1.5) (Migeon et al., 1981; Lubahn et al., 1988; Gelmann, 2002). 
1.2.1.1 Structure of the androgen receptor 
1.2.1.1.1 The transactivation domain 
Exon 1 of the AR gene encodes the N-terminal transactivation domain (NTD). This 
domain confers the majority of the ARs specific transcriptional activity and contains 
the ligand-independent activation function-1 (AF-1) (Gelmann, 2002). Deletion of the 
LBD region results in a constitutively active N-terminal fragment whose activity is 
similar to that of full length ligand bound AR (Simental et al., 1991). The NTD also 
confers the primary interaction site of many co-activators of AR (Gelmann, 2002), such 
as the histone acetyltransferase SRC-1 (Bevan et al., 1999), as well as components of 
the general transcription machinery, including TFIIH (Choudhry et al., 2006).  
The poly-glutamine (CAG) and poly-glycine (GGN) stretches are also located within the 
NTD. These regions of repetitive sequences are highly polymorphic due to slippage of 
DNA polymerase during replication (Gelmann, 2002) and thus vary in length naturally 
throughout the population (Sartor et al., 1999). The poly-glutamine repeat, starting at 
codon 58, can range from 14-35 repeats (Sartor et al., 1999) and its length is inversely 
proportional to AR activity (Buchanan et al., 2004) hence shorter CAG repeats have 
been associated with increased risk of prostate cancer as well as more aggressive 
disease and a higher rate of recurrence (Giovannucci et al., 1997). 
1.2.1.1.2 The DNA-binding domain 
The DNA-binding domain (DBD), which is encoded by exon 2 and the proximal region 
of exon 3, is the most conserved region between members of the steroid hormone 
receptor family (Gelmann, 2002). This 70 amino acid domain contains 8 conserved 
cysteine residues that form two zinc finger structures responsible for mediating 
discriminate contacts with the major groove of DNA (Chmelar et al., 2007). The first 
zinc finger recognises and binds specific DNA sequences termed androgen response 
elements (AREs) that are primarily located in promoter and enhancer regions of AR 
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target genes whilst the second zinc finger facilitates stability of the DNA-bound AR by 
forming indiscriminate contacts with the phosphate-backbone of DNA (Schoenmakers 
et al., 1999). 
1.2.1.1.3 The hinge region 
The hinge region, consisting of the C-terminal part of exon 3 and proximal part of exon 
4, is a small linker domain between the DBD and ligand binding domain (LBD) 
(Gelmann, 2002). This region contains a bipartite nuclear localisation signal (NLS) 
deletion of which attenuates ligand-dependent nuclear translocation. As well as 
containing a NLS sequence, the hinge region is a major site of several post-translational 
modifications including phosphorylation, acetylation, methylation and ubiquitination 
and has also been implicated in receptor dimerisation and correct protein folding 
(Zhou et al., 1994; Faus and Haendler, 2006; Chmelar et al., 2007). The PEST sequence, 
rich in proline, glutamic acid, serine and threonine, is associated with turn-over of 
proteins and is suggested to be a signal for proteasomal degradation (Rogers et al., 
1986; Lin et al., 2002a)  
1.2.1.1.4 The ligand-binding domain 
Finally, the distal part of exon 4 and exons 5 to 8 encode the C-terminal LBD (Gelmann, 
2002). Members of the steroid hormone receptor family, including estrogen receptor, 
progesterone receptor and glucocorticoid receptor, display structurally conserved 
LBDs although they have very little sequence similarity. Unlike other family members, 
however, whose LBD is composed of 12 α-helices (named 1-12), the LBD of AR consists 
of 11 α-helices (Helix 2 is absent, although the numbering of the helices is consistent 
with other family members, (1-12)) (Dehm and Tindall, 2007). For the AR (and other 
steroid hormone receptors), helices 1-11 fold into a barrel-like globular structure that 
forms the ligand-binding pocket into which the DHT binds. Upon androgen binding, the 
flexible helix 12 folds back over the ligand binding pocket to form a lid-like structure, in 
doing so exposing the ligand-dependent activation function (AF-2) domain contained 
within helix 12 (Matias et al., 2000; Gelmann, 2002). The functional AF-2 provides a 
binding surface for various co-regulator proteins, as well as mediating the interaction 
with the FXXLL and WXXLL motifs within the NTD (Alen et al., 1999; Bevan et al., 1999). 
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Figure 1.5. The structure of the androgen receptor.  
The AR gene is located on the X chromosome and consists of 8 exons encoding the four domains of the AR; the N-
terminal domain (NTD), the DNA binding domain (DBD), the hinge and the ligand binding domain (LBD). Adapted 
from (Gelmann, 2002). 
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1.2.1.2 Mechanism of AR action 
In its inactive state, AR is bound by a complex of chaperone proteins, including heat-
shock proteins (HSP) in the cytoplasm (Gelmann, 2002). It is postulated that these 
chaperones hold AR in a stable but partially unfolded conformation ready for ligand 
binding (Bohen et al., 1995). The binding of androgen initiates dissociation of the 
chaperone proteins and permits allosteric re-organisation of the AR resulting in 
receptor dimerisation, intra-molecular N-C-terminal interaction between individual AR 
monomers and exposure of the NLS which potentiates nuclear import (Gelmann, 
2002). 
Once inside the nucleus, the AR binds to AREs within the cis-regulatory elements of 
target genes, such as PSA (Khorasanizadeh and Rastinejad, 2001), and recruits 
components of the basal transcription machinery, and a host of co-regulatory proteins 
to drive target gene expression by RNA polymerase (Shang et al., 2002; Wang et al., 
2005; Chmelar et al., 2007).  
Once AR-mediated transcription is complete the chaperone complex facilitates cyclic 
disassembly of the AR transcription complex and aids recycling of the AR by returning 
it to a primed state ready for reactivation by further ligand binding (Freeman and 
Yamamoto, 2001).  
1.2.1.3 Mechanisms of androgen-independence in prostate cancer 
Many mechanisms of androgen independence have been described in CaP. These 
mechanisms include: (1) increased sensitivity of AR to low levels of androgens; (2) 
promiscuity of the AR towards other ligands; (3) ligand-independent activation by 
kinase pathways; (4) bypass of AR signalling by use of other pro-proliferative and anti-
apoptotic pathways and (5) the cancer stem cell theory of tumour re-population by 
androgen-independent stem-like cells. All lead to increased AR activity following AAT 
resulting in the promotion of proliferation and survival in CaP cells (Feldman and 
Feldman, 2001). 
1.2.1.3.1 Androgen receptor amplification 
It is reported that 30% of CRCaP possess AR gene amplification (Linja et al., 2001). AR 
amplification leads to over-expression of functional AR and therefore permits receptor 
activation in the presence of much lower concentrations of androgen. It is suggested 
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that cells containing AR amplification are selected for during AAT due to their 
proliferative advantage (Taplin et al., 1999). Interestingly patients with AR 
amplification were found to have better survival as their tumours remained better 
differentiated, more closely resembling normal cells, and therefore more likely to 
respond to second line AAT than other CaPs (Palmberg et al., 2000). Similarly, an 
increase in local DHT production by increased activity of 5-α-reductase can lead to 
hypersensitivity of the AR. AAT can reduce circulating testosterone levels by up to 95%, 
although DHT can remain at 40% of normal levels (Labrie et al., 1986). Some males of 
African ethnicity have a polymorphism in 5-α-reductase, in which valine at position 89 
is substituted to a leucine, resulting in a higher rate of conversion of testosterone to 
DHT (Makridakis et al., 1997). 
1.2.1.3.2 Androgen receptor point mutations 
Many point mutations in AR have been identified in CaP. One of the first identified and 
most commonly reported is that of the threonine to alanine substitution at position 
887 in the LBD (T877A) (Veldscholte et al., 1992; Gaddipati et al., 1994). This mutation 
is present in the endogenously expressed AR in the LNCaP CaP cell line and allows the 
AR to become activated by a broader spectrum of ligands including other steroid 
hormones, such as estrogens and clinically relevant anti-androgens, including 
flutamide (Sack et al., 2001). This mutation is also postulated to interfere with co-
regulator interactions with the receptor (Chmelar et al., 2007).  
Substitution of leucine at position 701 to histidine (L701H), again within the AR LBD, 
enhances LBD binding to adrenal corticosteroids at the expense of low level DHT 
during ATT that subsequently activates the receptor (Zhao et al., 1999; Zhao et al., 
2000). Akin to this mode of aberrant AR activation, substitution of histidine 874 to 
tryrosine (H874Y) allows adrenal androgens, non-androgenic steroid and anti-
androgens to activate the receptor (McDonald et al., 2000). 
1.2.1.3.3 Non-steroidal mechanisms of androgen receptor activation 
The outlaw pathway describes a means by which AR can become activated 
independent of its ligand through activation by growth factors such as insulin-like 
growth factor (IGF) and epidermal growth factor (EGF) (Culig et al., 1994). IGF-1 has 
been shown to induce PSA secretion in LNCaP cells by 5-fold (Culig et al., 1994) . It has 
been suggested that these growth factors indirectly induce proliferation by activating 
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complex tyrosine kinase signalling cascades however it has been observed that treating 
cells with casodex can block the effects of growth factors implicating that AR LBD is 
important in this mechanism (Culig et al., 1994). CRCaP cells lines generated from 
xenograft models in mice have been found to commonly over-express Her2/neu (Craft 
et al., 1999). Interestingly, over-expression of this gene in androgen dependent cell 
lines is found to convert them to an androgen independent state (Craft et al., 1999; 
Yeh et al., 1999). Unlike the other growth factors however LBD binding is not thought 
to be involved as this mechanism as casodex treatment does not block the effects of 
HER2/neu over-expression (Yeh et al., 1999).  
Bypassing AR signalling completely and relying on other cellular pathways to promote 
proliferation is another mechanism of androgen-independence. Although not essential 
for CRCaP progression and not expressed in the normal prostate, the Bcl-2 pathway is 
frequently expressed in PIN and castrate resistant CaP (McDonnell et al., 1992; 
Colombel et al., 1993) and is associated with evasion of apoptosis (Colombel et al., 
1993). 
1.2.1.3.4 The cancer stem cell theory 
The cancer stem cell theory suggests that a cancer stem cell, described as a somatic 
cells that have acquired stem-like properties, reside within the basal layer of the 
tumour (Maitland and Collins, 2008) and are essentially androgen-independent. It is 
postulated that these cells remain after AAT due to their therapeutic resistance and 
are able to re-populate the tumour during hormonal therapy. The resulting progeny 
are differentiated tumour cells that are now androgen independent (Maitland and 
Collins, 2008).  
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1.3 Ubiquitination 
Ubiquitination is one of the most important and evolutionarily conserved cellular 
processes involving a series of highly regulated enzymatic reactions that modifies a 
target lysine within substrates with the small protein ubiquitin either as a singular 
moiety or as a complex chain of multiple molecules (Ravid and Hochstrasser, 2008).  
1.3.1 Structure of ubiquitin 
Ubiquitin, encoded by four genes in humans, is transcribed and translated as a pro-
protein that is cleaved to form a 76 amino acid ubiquitin molecule (Kalderon, 1996). 
The Ubb and Ubc genes, located on chromosomes 17p12-11.2 and 12q24.3 
respectively, encode four and nine tandem repeats of ubiquitin as a multimeric pro-
protein (Kimura and Tanaka, 2010). These genes appear redundant, but mouse models 
have shown significant differences; Ubb knockouts are infertile, but otherwise normal, 
while Ubc knockout is embryonic lethal as a consequence of a 60% reduction in total 
ubiquitin levels in embryonic fibroblasts resulting in attenuated fetal liver proliferation 
(Ryu et al., 2007). Infertility of the Ubb knockout mice is due to failure of meiosis in the 
germ cells and it is shown that lower levels of ubiquitin are present in the testis and 
oocytes of these mice (Ryu et al., 2008). The Uba52 and Rps27a genes, located on 
chromosomes 19p13.1-p12 and 2p16 respectively, encode a single copy of ubiquitin 
that is fused to the ribosomal proteins L40 and S27a (Finley et al., 1989; Redman and 
Rechsteiner, 1989). 
Ubiquitin is highly conserved throughout evolution due to strong selective pressure 
(Pickart and Eddins, 2004), with human ubiquitin differing from the yeast protein at 
only 3 positions (Pickart and Eddins, 2004). The structure of ubiquitin is also well 
conserved (Figure 1.6); the ubiquitin-fold structure is found in several members of the 
ubiquitin-like proteins, such as SUMO, Nedd8 and ISG15 (Walters et al., 2002), and all 
of these family members also terminate with a C-terminal di-glycine sequence required 
for substrate conjugation (Jentsch and Pyrowolakis, 2000). Importantly, ubiquitin 
contains seven lysine residues at positions 6, 11, 27, 29, 33, 48 and 63 which allow a 
multitude of poly-ubiquitin chains to form and therefore a diverse range of signals and 
functions to occur (Kim et al., 2007).  
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Figure 1.6. The structure of ubiquitin.  
The seven lysine residues required for chain formation are indicated. Taken from (Pickart and Fushman, 2004). 
  
22 
 
1.3.2 Mechanism of ubiquitination 
In order for ubiquitination to occur an ubiquitin molecule must first be activated and 
transferred via a series of enzymes onto the substrate. This three enzyme cascade 
involves the ubiquitin activating E1 enzymes, the ubiquitin conjugating E2 enzymes and 
the E3 ubiquitin ligases in a process highlighted in Figure 1.7. 
1.3.2.1 Ubiquitin activating E1 enzyme 
In order for ubiquitin to be covalently attached to a substrate it must first be activated 
by the ubiquitin activating E1 enzyme. This ATP-dependent reaction involves the 
formation of an adenylated ubiquitin intermediate, before a further reaction with the 
catalytic cysteine of the E1 enzymes forms a thiol ester bond with the ubiquitin (Pickart 
and Eddins, 2004). The E1 enzyme can bind two ubiquitin molecules at any one time, 
one as an adenylated intermediate and one via the thiol ester bond through its N-
terminal and catalytic cysteine (Cys) domains (Pickart and Eddins, 2004). The final 100 
amino acids of the enzyme form a ubiquitin fold structure and are required for 
interaction with the ubiquitin conjugating enzyme E2 (Jin et al., 2007). 
There are eight human E1 enzymes which activate the wide variety of ubiquitin-like 
proteins (Groettrup et al., 2008). Until recently, only one ubiquitin-specific E1 enzyme, 
UBE1 had been identified (Ciechanover et al., 1982), however the identification of 
UBA6 indicated that additional enzymes were responsible for activating this cascade. 
UBA6 was reported independently by three research groups as an E1 ubiquitin 
activating enzyme, sharing the structural components of UBE1 and 42% sequence 
identity (Chiu et al., 2007; Jin et al., 2007; Pelzer et al., 2007). UBA6 was identified 
firstly as an E1 enzyme for ubiquitin-like FAT10 and the discovery of its ubiquitin E1 
activity represented the first overlap in ubiquitin and ubiquitin-like protein activation 
(Chiu et al., 2007). 
1.3.2.2 E2 ubiquitin conjugating enzyme 
The ubiquitin conjugating E2 enzyme receives activated ubiquitin from the E1 enzyme. 
There are 30 ubiquitin-specific E2 enzymes, divided into four classes, that all have a 
150 amino acid globular catalytic domain which forms the conserved UBC-fold 
structure (van Wijk and Timmers, 2010). Class I enzymes are comprised only of the 
UBC-fold whereas classes II, III and IV have either N-terminal or C-terminal extensions 
or both (Winn et al., 2004). These extended regions are thought to have diverse 
23 
 
functions; influencing stability as well as sites for E1 enzyme, E3 ligase and substrate 
interactions (van Wijk and Timmers, 2010). 
The catalytic Cys residue is located within a catalytic groove in the UBC-fold 
surrounded by conserved amino acids that are involved in the formation of the thiol 
ester bond between the ubiquitin molecule and the E2 enzyme (Pickart and Eddins, 
2004). Interestingly, the surfaces on which the E1 and E3 ligase enzymes interact with 
the E2 overlap whilst the ubiquitin binding surface is separate (Bencsath et al., 2002). 
This suggests that during poly-ubiquitination the E2 must dissociate from the E3 ligase 
in order to receive further activated ubiquitin molecules (Wenzel et al., 2011). 
1.3.2.3 E3 ubiquitin ligase 
There are a four major classes of E3 ubiquitin ligase; the homologous to E6-AP carboxyl 
terminus (HECT), really interesting gene (RING), plant homeogene (PHD) and UFD2 
homology (U-box) E3 ligases (Pickart and Eddins, 2004). All of these ligases adjoin 
ubiquitin to the substrate via an isopeptide bond between the C-terminal glycine of 
ubiquitin and a lysine residue within the substrate. Although approximately 650 E3 
ubiquitin ligases have been identified, bioinformatics analysis of the human genome 
suggests that thousands of proteins potentially possess E3 ubiquitin ligase activity 
(Pickart and Eddins, 2004). 
The HECT E3 ligases accept activated ubiquitin from the E2 enzyme, forming another 
thiol ester intermediate. A region of approximately 350 amino acids in the C terminus 
of E6-AP, the first discovered HECT, is found in all family members. These ligases then 
transfer the ubiquitin to a lysine residue within the target protein (Bernassola et al., 
2008). In contrast, the RING domain containing E3 enzymes act as a bridging factor 
between the substrate and E2 enzymes allowing transfer of activated ubiquitin directly 
(Hershko et al., 1983; Pickart, 2001). These enzymes contain conserved cysteine and 
histidine rich motifs, which bind two zinc ions and are critical for function (Pickart and 
Eddins, 2004). The grouping of the PHD-containing E3 ligases into a separate sub-class 
is controversial as they demonstrate close similarity to the RING family, and are 
suggested to be within the same class (Aravind et al., 2003).  
Finally, the U-box enzymes were originally thought not be E3 ligases but E4 
conjugation factors, acting to promote multi-ubiquitin chain extension of a previously 
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ubiquitinated target (Pickart and Eddins, 2004). However, evidence now suggests that 
these enzymes have both E3 and E4 functions. For example, C-terminus of Hsc70 
interaction protein (CHIP) recognises and targets mis-folded proteins for degradation 
in addition to its E4 function (Imai et al., 2002). Aravind and Koonin et al., postulated 
that U-box enzymes act as E3 ligases through a similar mechanism as the RING ligases; 
adopting a RING domain like structure but without the involvement of any metal ions 
(Aravind and Koonin, 2000). 
Ubiquitination of each substrate protein is tightly regulated and recognition of targets 
is crucial. Substrate specificity is provided, in part, by both the E3 enzyme and the 
E2/E3 combination (Weissman, 2001), although bioinformatics sequence analyses have 
postulated that thousands of possible E3s exist, most of which are yet undiscovered 
(Pickart and Eddins, 2004), suggesting a vastly complex system capable of modifying 
and impacting on a multitude of cellular processes. Thus, specificity of action is of 
paramount importance for the ordered targeting of selected protein substrates. To this 
end, several E3 enzymes require chaperone proteins to bring the substrate to the 
enzyme (Rosser et al., 2007), whilst others require further modification of their 
substrate before it can be recognised, such as phosphorylation of some receptors by 
ligand-binding correlates with their ubiquitination and degradation. Phosphorylation of 
some E3 ligases themselves has also been shown to be necessary for their activation 
providing an additional means of enzyme regulation (Haglund and Dikic, 2005).  
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Figure 1.7 Conjugation of ubiquitin to its substrate.  
E1 enzyme activates ubiquitin in an ATP dependent manner. The ubiquitin is passed to the E2 enzyme before being 
covalently attached to its substrate via either a RING- or HECT-domain containing E3 ligase. 
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1.3.3 Functions of ubiquitination 
Ubiquitination has an effect on a diverse array of cellular function and its activity is 
largely dictated by the specific type of ubiquitin chain that is generated upon the 
target lysine residue of the substrate (Pickart and Fushman, 2004; Ikeda and Dikic, 
2008). Some known functions of particular ubiquitin chains are illustrated in Figure 1.8. 
1.3.3.1 Mono-ubiquitination 
Mono-ubiquitination, or modification of a substrate with a single ubiquitin, and 
multiple mono-ubiquitination events have been shown to be involved in histone 
regulation, endocytosis, viral budding, DNA repair and nuclear export (Haglund et al., 
2003). 
Histones H2A and H2B are approximately 10% and 1% ubiquitinated respectively in 
mammalian cells, whereas in yeast histone H2B is the major ubiquitinated histone 
(Hicke, 2001). Ubiquitination of histones is involved in regulation of transcriptional 
events; histone H2A ubiquitination has been shown to repress transcription while 
modification of histone H2B activates transcription. Furthermore, mutation of the 
histone H2B ubiquitination site or knockdown of the E2 enzyme Rad6 in yeast or of the 
Rad6 homologue Hr6b in mice results in defective meiosis (Roest et al., 1996; Robzyk 
et al., 2000). 
Mono-ubiquitination of ion channels and receptors at the plasma membrane can lead 
to internalisation and lysosomal degradation (Hicke, 2001). It has been shown that the 
single ubiquitin molecule itself processes the internalisation signal. Fusion of mutant 
ubiquitin monomers, where the internal lysine residues have been substituted and 
therefore poly-ubiquitin chains cannot be formed, to receptors promotes 
internalisation (Shih et al., 2000). Moreover, multi-mono-ubiquitination of some 
receptor tyrosine kinases, for example EGFR and PDGFR, has been shown to be 
sufficient for their endosomal trafficking in response to ligand activation (Strous and 
van Kerkhof, 2002; Huang et al., 2006). 
The E3 ligase MDM2 is known to regulate the function of p53 by poly-ubiquitination 
causing its proteasomal degradation (Haupt et al., 1997; Honda et al., 1997; Kubbutat 
et al., 1997). However, it was observed that low levels of MDM2 activity in unstressed 
cells promoted mono-ubiquitination of p53 by MDM2 and its subsequent nuclear 
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export (Boyd et al., 2000; Geyer et al., 2000). It is postulated that this is a regulatory 
mechanism to inhibit the transcriptional activities of p53 (Brooks and Gu, 2006).  
1.3.3.2 Poly-ubiquitination 
The seven lysine (K) residues within ubiquitin allow for distinct poly-ubiquitin chains to 
be formed, each with a specific function. Very little detail is known about the functions 
of K6, K27, K29 or K33-linked poly-ubiquitin chains and only recently has the function 
of K11-linked chains been elucidated, as described below (Pickart and Fushman, 2004; 
Behrends and Harper, 2011). Understanding of K48 and K63-linked poly-ubiquitination 
is much more advanced due to the significant nature of their biological functions 
(Hochstrasser, 1992; Yang et al., 2010). 
Perhaps the most well studied function of this system is degradation of mutated or 
damaged proteins via the proteasome. K48-linked ubiquitin chains, of four or more 
ubiquitin molecules, act as a recognition signal for the 26S proteasome (Hochstrasser, 
1992). This multi-catalytic protease, consisting of a 20S catalytic subunit and a 19S 
regulatory particle, recognises the ubiquitinated proteins and allows them to enter the 
narrow channel of the catalytic subunit leading to proteolysis (Hochstrasser, 1992; 
Pickart and Fushman, 2004). K11 and K29-linked ubiquitin chains have also been 
implicated in proteasomal degradation (Baboshina and Haas, 1996; Koegl et al., 1999; 
Lindsten et al., 2002) although studies have uncovered specific roles of each 
modification type in cell cycle regulation and lysosomal degradation respectively 
(Chastagner et al., 2006; Behrends and Harper, 2011). 
K6-linked ubiquitin chains were recently discovered to be of importance in the 
BRCA1/BARD1-dependent localisation of conjugated ubiquitin to DNA damage foci 
(Wu-Baer et al., 2003; Morris and Solomon, 2004). These chains are utilised in the 
auto-ubiquitination of BRCA1 and are recognised and deubiquitinated by the 
proteasome-associated deubiquitinase enzymes (DUBs) (Nishikawa et al., 2004).  
Ubiquitination of substrates with K63 poly-ubiquitin has been associated with DNA 
damage tolerance as poly-ubiquitination of PCNA has been shown to bypass DNA 
lesions (Hoege et al., 2002). K63 linkages are also implicated in kinase activation, 
inflammatory responses, ribosomal synthesis and protein trafficking (Pickart and 
Fushman, 2004). Akt is poly-ubiquitinated by TRAF6, forming K63-linked ubiquitin 
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chains, which results in Akt recruitment to the plasma membrane and subsequent 
activation. Furthermore, K63-linked chains are thought to be involved in the 
interaction of adaptor proteins with Akt, facilitating activation (Yang et al., 2009). 
TRAF6 is also known to ubiquitinate TAK1 in response to TGFβ stimulation, triggering 
TAK1 auto-phosphorylation and kinase activation (Sorrentino et al., 2008). K63 poly-
ubiquitination is on the most part non-proteolytic, although they can interact with the 
proteasome and when this occurs they are deubiquitinated more rapidly than K48 
chains (Jacobson et al., 2009). 
Ubiquitination also has a role to play in immune signalling. The E3 ligase TRIM was 
found to mediate K27-linked poly-ubiquitination of NEMO causing IRF3 and NFκB 
activation and resulting in antiviral immune response (Arimoto et al., 2010). 
Furthermore, T-cell receptor ζ was found to become K33 poly-ubiquitinated, affecting 
its protein associations and phosphorylation status; providing a mechanism of 
ubiquitin mediated T-cell signal transduction (Huang et al., 2010).  
Moreover, linear ubiquitin chains have been recently associated with immune 
signalling. Multimeric linear ubiquitin chains are produced as a result of transcription 
of the ubiquitin Ubb and Ubc genes and it was thought that this type of ubiquitin was 
produced exclusively in this manner and that it had no further functionality than to be 
processed into singular ubiquitin molecules ready for conjugation (Behrends and 
Harper, 2011). However, the discovery of the linear ubiquitin assembly complex 
(LUBAC) and that linear ubiquitination of NEMO results in NFκB activation revealed 
that this unusual chain type has biological significance (Haas et al., 2009; Tokunaga et 
al., 2009). 
To add further complexity to the ubiquitin system, studies have shown that poly-
ubiquitin chains can be formed utilising multiple lysine linkages within a single chain 
and there is evidence that multi-protein chains can be formed containing both 
ubiquitin and a member of the ubiquitin-like protein family such as SUMO or Nedd8. 
The significance and function of these more complex modifications is not known (Ikeda 
and Dikic, 2008). 
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Figure 1.8. The known functions of mono-, multi-mono- and poly-ubiquitination.  
Poly-ubiquitin chains can be linked through lysine residues K6, 11, 27,29,33,48 and 63. 
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1.4 Deubiquitinase enzymes and regulation of ubiquitination 
Deubiquitinase enzymes (DUBs) provide an important regulatory role in the ubiquitin 
pathway by removing ubiquitin moieties from target proteins (Wilkinson, 1997). 
Among other functions, they regulate the rate of protein substrate turnover and 
maintain the pools of free ubiquitin (Amerik and Hochstrasser, 2004). 
1.4.1 Structure and catalytic activity of deubiquitinase enzymes 
Approximately 100 DUB enzymes have been identified within the human genome 
(Reyes-Turcu et al., 2009), although some of them are yet to be characterised as 
catalytically active. These ubiquitin proteases have been classified in to five subfamilies 
based on sequence, structure and mechanistic properties. The first four subfamilies 
are cysteine (Cys) proteases; namely the ubiquitin-specific processing proteases (USP), 
the ubiquitin carboxyl-terminal hydrolases (UCH), the ovarian tumour related 
proteases (OTU-related) and Josephine domain DUBs (Amerik and Hochstrasser, 2004). 
The fifth subfamily consists of zinc-dependent metalloproteases containing the 
JAMM/MPN+ domain (Maytal-Kivity et al., 2002). Examples of the structures of the 
five DUB sub-families are illustrated in Figure 1.9. 
1.4.1.1 Ubiquitin-specific processing proteases (USPs) 
The ubiquitin specific proteases or USP family is the largest and most diverse family of 
DUBs containing approximately 58 identified members (Ventii and Wilkinson, 2008). 
These enzymes contain the USP domain which consists of the conserved cysteine (Cys) 
and histidine (His) boxes that house the catalytically important cysteine, histidine and 
aspartate residues known as the catalytic triad residues (Nijman et al., 2005b). The size 
of the USP domain can vary between enzymes, as some contain large sequence 
insertions which have been shown to affect enzyme activity as well as ubiquitin 
binding and cellular localisation (Nijman et al., 2005b). However, it is important to note 
that although sequence similarity is low, the active site structure of the catalytic USP 
domain is super-imposable amongst all family members (Amerik and Hochstrasser, 
2004). 
Crystal structures have revealed that in general, the USP domain has a palm, thumb 
and fingers-like structure with the catalytic site sitting between the ‘palm’ and ‘thumb’ 
domains (Hu et al., 2002) (Figure 1.9). The role of the ‘fingers’ is to interact with the 
distal most ubiquitin in the chain (Komander et al., 2009a). Insights into the 
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mechanistic function of the USP catalytic reaction, and the other DUB Cys protease 
subfamilies, were provided by studies of the classical Cys protease papain (Storer and 
Menard, 1994). The catalytic triad of Cys, His and aspartic acid or asparagine (Asp or 
Asn) residues align allowing nucleophilic attack on the isopeptide bond between the C-
terminal of ubiquitin and the lysine within the substrate with which it is conjugated. An 
acyl intermediate between the catalytic Cys and the carboxyl group of ubiquitin is 
formed which is further hydrolysed by a water molecule (Komander et al., 2009a). 
Analysis of apo-USP domains, those which are not bound to ubiquitin, has revealed 
that unlike classical cysteine proteases, they are in a non-catalytic configuration 
(Komander et al., 2009a). Binding of substrate causes a conformational change either 
to align the catalytic triad residues or to remove structures that block access to the 
catalytic site (Amerik and Hochstrasser, 2004). However, this configuration is not true 
of all USP domains as the DUB enzyme CYLD has been shown to be ready for catalysis 
in an unbound form (Komander et al., 2008). 
1.4.1.2 Ubiquitin carboxy-terminal hydrolases (UCHs) 
The ubiquitin carboxy-terminal hydrolases or UCHs were named due to their activity 
towards small amides and esters at the C-terminus of the ubiquitin molecule 
(Wilkinson, 1997). This family of DUBs again resembles the classical cysteine proteases 
containing a 230 amino acid catalytic core comprised of the catalytic triad residues and 
3 dimensional structures similar to the USPs (Amerik and Hochstrasser, 2004). These 
enzymes also share a similar mechanism of catalysis to the USPs (Amerik and 
Hochstrasser, 2004). A predominant loop covers the active site of the UCHL3 enzyme 
which is several-fold smaller than loops of other un-folded DUBs meaning that it 
therefore dictates the substrates that UCHs can hydrolyse due to size constraints 
(Johnston et al., 1997; Popp et al., 2009). The substrate must be able to fit through the 
loop in order to access the catalytic residues therefore it is predicted that these 
proteases would only be able to act upon products of degradation, such as ubiquitin 
chains or on the ubiquitin precursor proteins to replenish cellular ubiquitin levels 
(Larsen et al., 1998; Popp et al., 2009). However, studies have now shown that larger, 
un-folded substrates can be accommodated (Johnston et al., 1999). 
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1.4.1.3 Ovarian tumour related proteases (OTUs) 
The ovarian tumour related (OTU-related) proteases were identified by bioinformatics 
analysis of genes that had homology to the ovarian tumour gene in drosophila 
melanogaster (Steinhauer et al., 1989). There are approximately 14 human OTU 
proteins that have not all been assessed for DUB activity (Nijman et al., 2005b). The 
OTU core domain consists of a 5 stranded β-sheet surrounded by helical domains that 
differ between family members (Reyes-Turcu et al., 2009). The catalytic core 
resembles that of the USP and UCH DUBs, although variations in the catalytic triad 
residues have been identified that may impact on catalytic activity (Amerik and 
Hochstrasser, 2004; Nanao et al., 2004) (Figure 1.9). For example, the drosophila OTU 
protein has a serine residue in place of the catalytic Cys, although it is unknown if this 
DUB is enzymatically active (Messick et al., 2008; Reyes-Turcu et al., 2009). 
1.4.1.4 Josephin domain proteases 
Ataxin-3 (ATXN3) is the best described Josephin domain protease whilst the other 
predicted family members remain relatively under-characterised (Nijman et al., 
2005b). The catalytic triad is again conserved and the catalytic core structure is similar 
to the USP and UCHs. However, ATXN3 has an extended helical arm that is proposed to 
regulate access to the active site (Mao et al., 2005; Nicastro et al., 2009). Furthermore, 
structural studies of ATXN3 bound to ubiquitin have indicated that a second ubiquitin 
molecule may bind to the back of the helix allowing ATXN-3 to bind 2 ubiquitin 
molecules simultaneously (Nicastro et al., 2009). 
1.4.1.5 JAMM/MPN+ proteases 
The fifth subfamily to be described represent metalloproteases that bind two zinc ions 
in order to proteolytically cleave ubiquitin and are distinct from the Cys proteases USP, 
UCH, OTU and Josephin domain DUB enzymes (Komander et al., 2009a). The first Zn2+ 
is involved intimately in catalysis by activating a water molecule to attack the 
isopeptide bond between the ubiquitin and its substrate, whilst the second Zn2+ 
stabilises the motif involved in recognising the distal ubiquitin (Maytal-Kivity et al., 
2002). JAMM/MPN+ DUBs have been found in association with the 26S proteasome, 
the COP9 signalosome and the ESCRT machinery implicating them in regulation of the 
ubiquitin-proteasome system as well as endosomal sorting (Cope et al., 2002; Yao and 
Cohen, 2002; McCullough et al., 2006).   
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Figure 1.9. The structure of the catalytic domains of the deubiquitinase enzyme sub-families. 
Examples of the inactive and active catalytic domain of the deubiquitinase enzymes (DUBs) are illustrated by the 
green and blue structures respectively. The interaction of the active domains with ubiquitin is also shown; ubiquitin is 
represented by the yellow structure. A) An example of the catalytic domain of a member of the USP family. B) An 
example of the catalytic domain of a member of the UCH family. C) An example of the catalytic domain of a member 
of the OTU family. D) An example of the catalytic domain of a member of the Josephin domain family. D) An example 
of the catalytic domain of a member of the JAMM/MPN+ family. Adapted from (Komander et al., 2009a) 
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1.4.2 Physiological functions of deubiquitinase enzymes 
A selection of the biochemical functions of the DUB enzymes are illustrated in Figure 
1.10. These functions allow DUBs to counteract and regulate the ubiquitination events 
described in Section 1.3.3. Like ubiquitination, DUB enzymes have been implicated in 
almost every cellular process.  
1.4.2.1 Ubiquitin precursor processing  
Ubiquitin is transcribed from the Ubb and Ubc genes as a multimeric 4 and 9 tandem 
repeat pro-protein and from the Uba52 and RPS27a genes as a single moiety fused to 
ribosomal proteins (Kimura and Tanaka, 2010). In order for this newly transcribed 
ubiquitin to be used in the ubiquitin-proteasome system it must first be processed into 
single usable ubiquitin molecules (Wilkinson, 1997). Ubiquitin multimers and fusion 
proteins between ubiquitin and ribosomal subunits are cleaved at the α-amino group of 
the glycine residue at position 76 (Amerik et al., 2000). Currently no DUB has been 
specifically identified for this exclusive function; enzymes that catalyse pro-protein 
cleavage are involved in many other ubiquitin-related processes (Wilkinson, 1997). 
However, multiple DUBs show activity towards linear ubiquitin chains and USP5 (also 
known as Isopeptidase T) has activity towards unanchored poly-ubiquitin chains (Dayal et 
al., 2009). Pro-protein processing acts not only to regulate the levels of free ubiquitin but 
also as a quality control mechanism; if DUBs cannot process the precursors due to 
mutation or problem in folding then these molecule will not enter the ubiquitin system 
(Amerik and Hochstrasser, 2004). 
1.4.2.2 Deubiquitination coupled to proteasomal degradation  
Ubiquitin conjugates need to be removed from substrates targeted to the proteasome 
before proteolysis. This allows for recycling of free ubiquitin that acts to assist 
physiological rates of protein turnover by replenishing depleted pools of unconjugated 
ubiquitin protein (Song and Rape, 2008). Moreover, removing ubiquitin before 
substrate degradation avoids blockage of the narrow catalytic channel of the 
proteasome allowing efficient entry of targeted proteins (Verma et al., 2002). Three 
DUBs have been closely linked to the proteasome, USP14, UCH37 and POH1. USP14 
associates with the S2 subunit within the 19S regulatory particle of the 26S 
proteasome (Hu et al., 2005; Hanna et al., 2006), while in contrast, UCH37 and POH1, 
are integral subunits of the 19S particle itself (Hamazaki et al., 2006; Qiu et al., 2006; 
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Yao et al., 2006). Together, these DUBs are responsible for the removal of poly-
ubiquitin chains from proteins during degradation. UCH37 and USP14 are thought to 
be redundant as depletion of both is required to cause a build-up of free ubiquitin 
chains (Koulich et al., 2008). However, USP14 is up-regulated upon depletion of the 
free pool of ubiquitin suggesting it is essential in the recycling process (Hu et al., 2005). 
Released poly-ubiquitin chains must undergo further disassembly, comparable to pro-
protein processing, to remove potential competition with substrates for proteasome 
binding and degradation. In human cells, USP5 and USP13 are responsible for 
disassembling unanchored poly-ubiquitin chains down to the monomeric level (Reyes-
Turcu et al., 2008; Dayal et al., 2009). These DUBs have a zinc-finger (ZnF)-UBP domain, 
which coordinates zinc ions to specifically recognise the di-glycine motif on the C-
terminal tail of the ubiquitin chain (Reyes-Turcu et al., 2006). USP5 specifically 
recognises K29, K48 and K63-linked poly-ubiquitin chains (Dayal et al., 2009), whilst the 
specific chains targeted by USP13 are unknown.  
Proteins may also be degraded via the lysosome, a cytoplasmic organelle containing 
acid hydrolase enzymes. In this case deubiquitination is not required for degradation 
but only as a means of maintaining levels of free ubiquitin (Komander et al., 2009a). 
Mono-ubiquitination is important for the internalisation of surface proteins and 
further K63-linked poly-ubiquitination is thought to assist in this process (Hicke and 
Dunn, 2003). USP8, a homologue of yeast Doa4, is required for removal of ubiquitin 
chains in this scenario (Kato et al., 2000; Mizuno et al., 2005). 
1.4.2.3 Ubiquitin chain removal and editing 
DUBs are required for a level of ubiquitination ‘proof-reading’ within the cell. Proteins 
may be rescued, by chain shortening or chain removal, from the degradation pathway. 
For example, in response to DNA damage a K63-linked ubiquitin chain would result in 
cell cycle progression without DNA repair. However, editing of this chain to a mono-
ubiquitinated mark would dramatically change the fate of the cell by triggering DNA 
damage repair (Hicke, 2001; Weissman, 2001). Removal of ubiquitin changes can also 
affect protein stability. There are many examples of DUBs that are intimately 
associated with E3 ligases that are known to regulate themselves through auto-
ubiquitination (Li et al., 2002b; Nijman et al., 2005b). A well characterised example is 
that of the relationship between USP7 and MDM2. MDM2 regulates its own catalytic 
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activity towards p53, a prominent tumour suppressor gene, by auto-ubiquitination. 
MDM2-mediated ubiquitination of p53 leads to p53 proteasomal degradation and 
subsequent down-regulation of its downstream effects such as cellular senescence and 
apoptosis (Brooks and Gu, 2006). Auto-ubiquitination of MDM2 is reversed by USP7 
which causes stabilisation of MDM2 and promotion of its activity towards p53. 
However, USP7 can also interact with and deubiquitinate p53, stabilising the protein 
and promoting p53 activity. Interestingly, both p53 and MDM2 are recognised by the 
N-terminal domain of USP7 which recognises the same two closely spaced motifs in 
both proteins (Meulmeester et al., 2005; Sheng et al., 2006). 
Editing is also an important mechanism of specificity determination within the 
ubiquitin system. The DUB enzyme can only remove ubiquitin from chains and for this 
reason it is not unexpected that DUBs are often found in complexes with E3 ligases; 
regulating their activity and also their stability (Nijman et al., 2005b). The DUB CYLD 
negatively regulates NFκB signalling by opposing the E3 ligase activity of TRAF2, TRAF6 
and NEMO (Kovalenko et al., 2003; Trompouki et al., 2003). Furthermore, A20, a 
member of the OUT sub-family of DUBs, also regulates NFκB signalling through chain 
editing. However, this enzyme not only processes the removal of ubiquitin but also 
uses its intrinsic E3 ligase activity to edit the K63-linked ubiquitination of adaptor 
proteins, such as RIP1, to K48-linked chains resulting in proteasomal degradation 
(Heyninck and Beyaert, 2005). 
1.4.2.4 Control of transcription 
Ubiquitination of histone H2A and H2B are important in transcriptional regulation. 
Histone H2A ubiquitination is transcriptionally repressive therefore deubiquitination 
allows for active transcription. USP16 is a histone H2A specific DUB and depletion of 
USP16 causes an increase in Hox gene expression. It was postulated that this DUB may 
regulate levels of ubiquitinated histone H2A at promoters and regulatory regions of 
these genes (Joo et al., 2007; Reyes-Turcu et al., 2009). 
USP22 is a histone H2B specific DUB that is part of the SAGA complex (Zhang et al., 
2008). This complex regulates transcriptional activation and elongation by 
deubiquitination of histone H2B, allowing recruitment of RNA polymerase II kinase 
Ctk1. This recruitment in turn allows phosphorylation of RNA polymerase II at serine 2 
and elongation to occur (Wyce et al., 2004). Moreover, USP22 links deubiquitination to 
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mRNA export from the nucleus as the SAGA complex also binds to export factors which 
interact with the nuclear pore complex (Daniel and Grant, 2007). In yeast, 
deubiquitination of ubiquitinated histone H2B by Upb10 in rDNA and telomeric regions 
maintains gene silencing by association with histone deacetylase proteins (Gardner et 
al., 2005). 
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Figure 1.10. Some of the multiple functions of deubiquitinase enzymes.  
DUBs are involved in processing and editing of ubiquitin chains allowing for negative regulation of the processes of 
ubiquitination. 
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1.4.3 Specificity of deubiquitinase enzymes 
To conduct specific roles, DUBs must first be able to recognise and hydrolyse the 
correct substrates. Ubiquitin specific DUBs must firstly distinguish between ubiquitin 
and the closely related ubiquitin-like proteins, such as SUMO-1 and Nedd8 (Komander 
et al., 2009a). This is achieved by extensive contacts between the DUB and the distal 
most ubiquitin; as much as 40% of the ubiquitin surface area is bound by the DUB (Zhu 
et al., 2007b). Secondly, the ubiquitin C-terminus, which extends into the catalytic 
domain of the DUB, contains a unique amino acid sequence, Leu71-Arg72-Leu73-
Arg74-Gly75-Gly76; it is Arg74 and Gly75 that are critical for recognition (Komander et 
al., 2009a). 
Furthermore, DUBs discriminately cleave ubiquitin chains and are capable of catalysing 
either the specific cleavage of the terminal ubiquitin in a chain or whole chains of 
ubiquitin. It is thought that certain lysine-linked ubiquitin chains have a ‘closed’ 
structure whilst others have a more ‘open’ accessible structure. USP14, a component 
of the proteasome, specifically recognises and catalyses K48-linked chains to facilitate 
ubiquitin recycling and substrate degradation (Hu et al., 2005). The crystal structure of 
the JAMM/MPN+ sub-family member AMSH-LP in complex with a K63 di-ubiquitin 
chain has been solved, the only structure of its kind, and revealed that AMSH-LP 
contacts all the residues involved in the K63-linkage and has extensive interactions 
with the second ubiquitin molecule. Its recognises a motif containing glutamine 62 and 
glutamic acid 64 within the first ubiquitin molecule that is only accessible in K63-linked 
chains due to the closed conformation of other chains types (Sato et al., 2008). 
Conversely, CYLD recognises both K63 and linear ubiquitin chains (Komander et al., 
2008). Interestingly, CYLD has an extended loop located near the enzymes active site 
that appears to recognise and select against K48-linked substrates (Komander et al., 
2009b). K63-linkages are very similar to linear chains of ubiquitin as they both have an 
extended open structure. However, these chains are hydrolysed in different ways; K63 
chains, and all other lysine-linked ubiquitin chains, require isopeptide bond cleavage 
whilst linear ubiquitin chains are linked via a peptide bond. It has been found that most 
USP domain DUBs can cleave linear ubiquitin chains to a low efficiency so perhaps 
those that recognise K63-linked chains also have a function in linear and immature 
ubiquitin processing (Komander et al., 2009a). 
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Cleavage of the final ubiquitin that is attached directly to the lysine of the substrate 
protein is performed by exo-DUBs, whilst internal linkage cleavage is performed by 
endo-DUBs. The structure of the catalytic domain can determine which type of activity 
a DUB has. For example, the finger domain of USP14 makes contacts with 40% of the 
surface area of the distal ubiquitin in a chain thereby blocking access of the DUB to 
internal linkage sites (Hu et al., 2005). In contrast, CYLD lacks the finger domain and 
catalyses cleavage of internal isopeptide bonds (Komander et al., 2008). Removal of 
mono-ubiquitin from a substrate, as a result of a ubiquitination event or cleavage of a 
ubiquitin chain by a DUB, requires substrate specific interactions as this isopeptide 
bond is the same in all cases i.e. it has no lysine specificity (Komander et al., 2008). 
USP5 and USP13, as described previously, are ubiquitin recycling DUBs that mediate 
the breakdown of unanchored ubiquitin chains by recognition of a broad range of 
ubiquitin chains (Dayal et al., 2009). 
1.4.4 Regulation of deubiquitinase enzymes 
In order to prevent inappropriate protease activity of DUBs towards cellular proteins 
they are tightly regulated by multiple mechanisms. Regulation of DUB enzyme 
transcription represents one mechanism of cellular control in which DUBs are 
expressed in the cell at specific times. For example, Dub-1 and Dub-2 are transcribed 
rapidly in mouse lymphocytes in response to interleukins due to the presence of a 
cytokine response element in their gene promoters and hence are only present during 
immune response (Zhu et al., 1997; Jaster et al., 1999).  
Post-translational modification of DUBs is an additional control mechanism that 
regulates catalytic activity as well as DUB abundance in cells. For example, CYLD is 
phosphorylated in response to interaction with NEMO thereby inhibiting its ability to 
suppress NFκB signalling through deubiquitination of E3 ligase TRAF2 (Kovalenko et al., 
2003). Poly-ubiquitination of USP4 increases its activity towards its substrate Rho52, 
an E3 ligase which in turn ubiquitinates USP4 and down-regulates its activity (Wada 
and Kamitani, 2006). Lastly, SUMOylation of USP25, in which SUMO is conjugated to a 
target lysine in USP25, affects its binding affinity for ubiquitin therefore inhibiting its 
activity (Meulmeester et al., 2008).  
Conformational changes provide a structural method of regulation. Some DUBs, such 
as USP7, require binding of substrate to properly align the catalytic residues (Hu et al., 
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2002). Allosteric re-organisation of internal structures that occlude the active site has 
also been shown to be important for activating some DUBs activity. For example, the 
unordered active site loop of UCHL3 is restructured into a α-helix upon substrate 
binding and interacts with the C-terminus of ubiquitin, therefore displacing it from the 
active site (Johnston et al., 1997), while in contrast, the active site loop of yeast Otu1 is 
reorganised into a β-strand upon ubiquitin binding (Nanao et al., 2004). In addition, 
the active site of USP8 is blocked by the finger structure of the USP domain; in order 
for a substrate to effectively access the catalytic residues it must first bind and displace 
this large domain (Avvakumov et al., 2006). 
Protein-protein interactions between DUBs and scaffolding or adaptor proteins not 
only regulate their activity, but also may assist in their specificity for substrates. The 
proteasome-associated DUBs, USP14, UCH37 and POH1 are found to have little activity 
until they are associated with the 26S proteasome as the interactions bring about 
conformational changes. USP14 has 300-fold greater activity when bound to the S2 
subunits of the 19S regulatory particle (Leggett et al., 2002).  
1.4.5 Deubiquitinase enzymes in disease 
Several DUBs were first identified through their relationship to disease phenotypes. 
Autosomal dominant mutations of CYLD were found in patients with familial 
cylindromatosis who develop skin tumours of the head and neck (Bignell et al., 2000; 
Bowen et al., 2005). CYLD functions to down-regulate NFκB signalling through removal 
of K63-linked poly-ubiquitin chains from TRAF2, TRAF6 and NEMO, important 
regulators of the NFκB signal cascade. This in turn stops the inhibitor of κB (IκB) from 
becoming degraded and releasing NFκB for gene activation function (Kovalenko et al., 
2003). In cells where CYLD is depleted, and hence NFκB displays aberrant activity, an 
increased resistance to apoptosis is observed providing a possible mechanism for 
tumour formation (Brummelkamp et al., 2003). 
USP6 was the first DUB to be identified as an oncogene after it was observed that 
over-expression in cells lead to a transformed phenotype (Onno et al., 1993; Papa and 
Hochstrasser, 1993). The initial transcript was isolated from a Ewing’s sarcoma and was 
found to be causative of aneurismal bone cysts. A translocation between 
chromosomes 16 and 17, t(16;17)(q22;p13) which results in the full length USP6 gene 
under the control of the osteoblast cadherin 11 promoter was identified in 
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approximately 66% of patients in a 52 patient study and results in up-regulation of 
USP6 expression (Oliveira et al., 2005). Interestingly, catalytic activity of the DUB was 
found not to be important in the malignant transformation properties of USP6 as the 
first identified transcript was a splice variant containing no catalytic domain (Shen et 
al., 2005). 
Ataxin-3 is linked to the neurodegenerative disorder Machado-Joseph disease (Paulson 
et al., 1997). Extension of ATXN3’s poly-glutamine stretch confirms a toxic gain of 
function effect for this DUB due to altered protein associations and formation of toxic 
aggregates (Paulson, 1999; Perez et al., 1999). UCHL1 is also linked to neuro-
degeneration by mutations that confer both protection and susceptibility towards 
Parkinson’s disease. The first mutation identified substituted isoleucine 93 to a 
methionine (I93M) and was found to diminish the catalytic activity of UCHL1 towards 
ubiquitin and also lower its E3 ligase activity (Leroy et al., 1998). UCHL1 is also found in 
Lewy bodies, protein aggregates of normal and abnormal proteins (Singhal et al., 
2008). Conversely, a mutation of serine 18 to tyrosine (S18Y) is protective against 
Parkinson’s disease and delays onset of the disease (Maraganore et al., 1999). This is 
thought to be due to inhibition of UCHL1 E3 ligase activity by inhibiting dimer 
formation. UCHL1 is also linked to Alzheimer’s disease where a low level of functional 
UCHL1 is inversely proportional to accumulation of amyloid protein aggregates 
(Ichihara et al., 1995; Choi et al., 2004). Additionally UCHL1 has been implicated in 
many malignancies including lung, breast and colon (Okochi-Takada et al., 2006; Wang 
et al., 2008; Fang et al., 2010). 
1.4.5.1 Deubiquitinase enzymes as drug targets 
There are two potential methods for inhibiting DUBs; (1) inhibiting the enzymatic 
activity by targeting the active site; (2) interfering with the DUB-substrate interaction 
(Singhal et al., 2008). Several DUB inhibitors are used in the context of research 
including ubiquitin-aldehyde (Ub-al) and ubiquitin vinyl sulfone (UbVS). Ub-al and 
UbVS are ubiquitin derivatives that cannot be hydrolysed resulting in the accumulation 
of poly-ubiquitinated products. Ub-al has been utilised in structural studies of DUBs 
bound to ubiquitin (Love et al., 2007). These inhibitors, however, are broadly specific 
to the Cys proteases and are not thought to be good candidates for drug development 
programmes (Colland, 2010). 
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High-throughput screening of compounds against specific DUBs has identified several 
potential therapeutic compounds. Two small molecule inhibitors of UCHL1 have been 
developed that show up to 100-fold specificity for UCHL1 over UCHL3 and other DUBs 
(Liu et al., 2003). Firstly, a series of istatin o-acyl oxime derivatives have been shown to 
counteract UCHL1 anti-proliferative effect in lung cancer and neuroblastoma cell lines. 
These inhibitors are directed towards the UCHL1 active site (Liu et al., 2003). Secondly, 
a series of non-competitive, non-active site directed 3-amino-2-oxo-7H-theino[2,3-
b]pyridine-6-one inhibitors are also in development (Mermerian et al., 2007). A series 
of dihydro-pyrrole skeleton inhibitors have also been developed against UCHL3 which 
are thought to competitively bind to the enzymes active site (Hirayama et al., 2007).  
Hybrigenics, a pharmaceutical company, have also developed small molecule inhibitors 
towards USP7 and USP8. HBX41,108 reversibly inhibits USP7 deubiquitinase activity 
resulting in stabilisation and activation of p53 leading to inhibition of cell growth and 
promotion of apoptosis in p53 positive colon cancer cell lines (Colland et al., 2009). 
HBX90,397 is a closely related compound to the USP7 inhibitor, although it has been 
shown to have anti-proliferative and pro-apoptotic effects due to its inhibition of USP8 
(Colland, 2010). Currently, no DUB inhibitors are in clinical trial. 
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1.5 The role of ubiquitination and deubiquitination in prostate cancer 
Defects in the ubiquitin system can have devastating effects. Loss of function 
mutations in enzymes involved in protein turn-over can lead to protein stabilisation 
whereas gain of function will lead to accelerated degradation or loss of ‘healthy’ 
proteins. Mutations that result in the loss of E1 enzyme function are lethal 
(Ciechanover, 2003). In cancer, stabilisation of oncogenes and growth factors along 
with degradation of tumour suppressors lead to aberrant growth and proliferation of 
cancer cells. BRCA1, a well-studied tumour suppressor gene, is a RING domain-
containing E3 ligase; mutations of this catalytic domain is common for breast and 
ovarian cancer predisposition (Hashizume et al., 2001). In CaP, several E3 ligases and 
DUBs act as AR co-regulators potentiating the notion that aberrant activity of these 
enzymes may drive deregulated AR activity and CaP development. 
1.5.1 E3 ubiquitin ligases in prostate cancer 
Firstly, proteasome function is suggested to be important for AR transcriptional 
activity. In a study by Lin et al., it was found that proteasomal inhibitor MG132 caused 
decreased AR expression and nuclear translocation as well as disrupting the interaction 
between AR and its co-regulators ARA70 and TIF2 (Lin et al., 2002a). Contradictory to 
this, another study by Sheflin et al., reported an increase in AR expression after MG132 
treatment (Sheflin et al., 2000). The authors speculate that the proteasome may act 
directly as a co-regulator of AR due to enhanced activity upon over expression of a 20S 
proteasome subunit, PSMA7. They also suggest the PEST sequence of the hinge region 
as being important for the proteasomal recognition as it could be a target for 
ubiquitination (Sheflin et al., 2000), although this remains unknown. Furthermore, a 
study by Godfrey et al reported that degradation of the AR by the proteasome was 
important for aiding stress-induced cell death by an AR-mediated mechanism (Godfrey 
et al., 2010). 
A number of E3 ligases interact with the AR including C-terminal HSP-interacting 
protein (CHIP), murine double minute (MDM2), p53-induced protein with a RING-H2 
domain (PIRH2) and E6 associated protein (E6-AP). Rees et al., found that CHIP binds 
directly to AR after phosphorylation of the hinge region (Rees et al., 2006). A further 
study reported over-expression of CHIP in LNCaP cells lead to decreased AR levels by 
acting as an inhibitor of AR folding (Cardozo et al., 2003). MDM2 cooperates with 
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HDAC1 to co-repress AR leading to its degradation (Gaughan et al., 2005). MDM2 
promotes degradation of AR in a phosphorylation dependent manner; phosphorylation 
of both AR and MDM2 by AKT is required (Lin et al., 2002a). MDM2 is well 
characterised as a negative regulator of p53 (Brooks and Gu, 2006) and interestingly 
knockdown of MDM2 in LNCaP cells restores sensitivity to AAT by increasing p53 
expression (Mu et al., 2008). Importantly, 30-40% of prostate tumours over-express 
MDM2 making this a potential therapeutic target (Mu et al., 2008). 
Conversely, PIRH2 and E6-AP act to increase AR activity. PIRH2 interacts with AR co-
activator TIP60 leading to degradation of HDAC1 and therefore increased AR 
transcriptional activity (Logan et al., 2006). Immuno-histochemical data correlates 
PIRH2 expression to grade of CaP, suggesting over-expression of PIRH2 may enhance 
AR activity in prostate malignancy (Logan et al., 2006). E6-AP regulates a number of 
nuclear hormone receptors including AR (Ramamoorthy and Nawaz, 2008). Androgen 
treatment recruits E6-AP to the PSA promoter and enhances AR transcriptional activity 
(Khan et al., 2006). However, contradictory data suggests that E6-AP degrades AR 
(Khan et al., 2006). Interestingly, all the above mentioned enzymes also play a role in 
p53 ubiquitination (Traidej et al., 2000; Brooks and Gu, 2006; Duan et al., 2006; 
Tripathi et al., 2007). TRIM68 is another E3 ligase that acts as a co-activator of AR 
transcriptional activity. TRIM68 was found to directly interact with AR and its co-
activators TIP60 and p300 leading to increased AR activity. TRIM68 was found to be 
preferentially over-expressed in CaP cell lines and human CaP tissue was found to also 
over-express compared to normal prostate (Miyajima et al., 2008). 
Although ubiquitination of the AR is well studied, the specific sites and sites of 
ubiquitination have remained unclear. Recently, Xu et al., were the first to identify AR 
ubiquitination sites targeted by RNF6, a novel E3 ligase (Xu et al., 2009). This study 
showed that RNF6-induced ubiquitination of AR is required for AR-mediated 
transcription via direct modification of two lysines within the LBD, namely K845 and 
K847. These ubiquitinated residues are then able to recruit the AR co-activator ARA54 
to facilitate gene expression of androgen-responsive genes (Xu et al., 2009). It is likely 
that each E3 ligase targeting the AR has specific target sites within the AR that are not 
limited to K845 and K847 of the LBD hence the study by Xu et al., represents the 
beginning of AR ubiquitination site identification not the end. 
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1.5.2 Deubiquitinase enzymes in prostate cancer 
Members of the DUB enzyme family have also been implicated in AR regulation and 
prostate cancer. USP7, a regulator of both MDM2 and p53, has been found to be over-
expressed in CaP and is associated with deubiquitination and reduced nuclear 
localisation of PTEN, a protein phosphatase of the AKT pathway that is frequently lost 
in CaP progression (Song et al., 2008). UCHL1 has been identified as being expressed in 
CaP cell lines that have undergone neuroendocrine differentiation. Interestingly, only 
the AR-negative DU145 and PC-3 cell lines expressed UCHL1 (Leiblich et al., 2007). 
USP2a protects CaP cells from apoptosis by promoting p53 degradation via MDM2 
deubiquitination and stabilisation. USP2a was found to be over-expressed in CaP 
tumours and correlated with over-expression of MDM2. Tumours with low USP2a 
expression had a high level of p53-induced pro-apoptotic gene expression and better 
prognosis (Priolo et al., 2006). USP2a is also involved in the stabilisation of fatty acid 
synthase (FAS), which is also over-expressed in CaP (Graner et al., 2004). 
Two DUBs have been reported as direct regulators of AR, USP10 and more recently 
USP26. USP10 was identified as an AR interacting protein in a proteomic study of PC-3 
cell lines stably over-expressing ectopic AR (Faus et al., 2005). Over-expression of 
USP10 was observed to stimulate AR activity by increasing its binding to both selective 
and non-selective AREs. The authors of this study hypothesise that this DUB is involved 
in the editing of ubiquitin chains from proteasome-targeting poly-ubiquitin chains to 
mono- or tri-ubiquitin chains which can be transcriptionally activating (Faus et al., 
2005). Additionally, USP10 has been identified to regulate the ubiquitination of histone 
H2A.Z thereby driving AR-mediated transcription of target genes. Depletion of USP10 
results in retention of ubiquitinated histone H2A.Z at AR-target gene promoters and 
deubiquitination of this ubiquitinated histone by USP10 caused an increase in PSA and 
KLK2 expression (Draker et al., 2011). 
USP26 was identified in a siRNA knockdown screen looking for DUBs that modulated 
AR transcriptional activity (Dirac and Bernards, 2010). Knockdown of USP26 in the 
HepG2 hepatocellular carcinoma cell line over-expressing ectopic AR caused an 
increase in AR activity, suggesting that the DUB is an AR co-repressor. However, over-
expression of USP26 in the HEK293 kidney cell line confusingly caused an increase in 
AR activity. The authors suggest that this discrepancy is due to different ubiquitin 
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targets being hydrolysed in the different cell lines; mono-ubiquitination in HepG2 
thereby inhibiting activation of AR activity and poly-ubiquitination in HEK293. 
Nevertheless, USP26 was found to interact directly with AR, co-localised with AR in the 
nucleus upon androgen stimulation and influence AR deubiquitination (Dirac and 
Bernards, 2010). 
Given the complexity of the ubiquitination system in mammalian cells, and the 
evidence implicating various ubiquitination and deubiquitination pathways in AR 
regulation and CaP, new targets for CaP therapy may exist within these systems that 
must be identified, characterised and exploited for more effective treatments. 
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1.6 Aims 
The AR is a known target for ubiquitination by several E3 ubiquitin ligase enzymes that 
can lead to either increased activity or degradation depending on the E3 ligase 
involved. Importantly, the ability of the AR to evade therapy in CRCaP suggests that 
deciphering the mechanisms that regulate AR stability in this disease state may 
provide extremely useful and novel therapies. A gap in the knowledge of the reversal 
of ubiquitination by deubiquitinase enzymes (DUBs) within AR signalling exists and the 
characterisation of these enzymes could be important in elucidating mechanisms for 
the aberrant AR function observed in CRCaP. 
The aims of this study are: 
 Identify DUBs involved in AR signalling by utilising an siRNA knockdown library 
screen in the androgen-sensitive LNCaP cell line 
 To characterise the function of the identified DUBs within the AR signalling 
cascade and prostate cancer 
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2 Chapter 2: Material and Methods 
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2.1 General material and methods 
The University guideline ‘Safe Working with Micro-organisms’ was observed when 
handling biological samples. All chemicals were handled in accordance with COSHH 
regulations. 
2.1.1 Materials and reagents 
Routinely used chemicals were analytical or molecular grade and purchased from 
Sigma-Aldrich or Fisher Scientific, unless otherwise stated. siRNA oligonucleotides and 
conventional and quantitative PCR (QPCR) primers were purchased from Sigma-
Aldrich. 
2.1.2 Plasmid vectors 
pCDNA3-AR, pARE3-luc, pPSA-luc, pCMV-β-gal and pCMV5 empty vector have been 
described previously by (Brady et al., 1999). pFLAG-AR was a kind gift from Ralf 
Janknecht (Oklahoma University, Rochester, MN) (Shin and Janknecht, 2007). pYFP-AR 
was a kind gift from Jan Trapman (Erasmus Medical Centre, The Netherlands). pCMV-
HA-USP10 and pGEX-6P-1-USP10 were kind gifts from Bernard Haendler (TRG, Berlin, 
Germany) (Faus et al., 2005). pDEST-FLAG-HA-USP12 (Sowa et al., 2009), pRK5-HA-
Ubiquitin (Lim et al., 2005) and pCMV-Myc3-MDM2 (Zhang et al., 2003) were 
purchased from Addgene. 
2.2 Generation of p3XFLAG-CMV-10™-USP12 and p3XFLAG-CMV-10™-
USP12C48A 
2.2.1 Agarose gel electrophoresis 
All products of PCR, digestion, gel extraction and plasmid preparations were analysed 
by agarose gel electrophoresis on 1% agarose gels (1% agarose in Tris acetate EDTA 
(TAE) buffer). Samples were mixed with DNA sample buffer (30% sucrose, 100 mM 
EDTA pH8, 0.05% bromophenol blue) before loading alongside Hyperladder I DNA 
marker (Bioline). Samples were run at 100 V for approximately 40 minutes and gels 
were stained with GelRed (Biotium) and visualised using GelDoc™ DNA analysis 
equipment (Bio-Rad). 
2.2.2 PCR 
USP12 was amplified from pDEST-FLAG-HA-USP12 using the following primers; forward 
primer: TCT AGA ATG GAA ATC CTA ATG ACA; reverse primer: GGA TCC TCA GTC CCG 
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AGA CTG ATA. The PCR reaction contained 1 nM of each primer, 1 x reaction buffer 
(containing MgCl2), 0.2 mM dNTPs, 100 ng pDEST-FLAG-HA-USP12 and 1.5 units of Taq 
polymerase (Bioline) in a total volume of 10 μl. PCR reactions were performed on PCR 
express thermal cycler HBX110 (Thermo Hybaid). 
2.2.3 Diagnostic digestion and vector ligation 
The resultant USP12 amplicon was cut from an agarose gel, DNA extracted using the 
QIAquick spin gel extraction kit (as described by the manufacturer, Qiagen) and ligated 
into the pCR2.1 vector using the TA cloning kit according to the manufacturer’s 
recommendations (Invitrogen). Briefly, ligation reactions were set up containing 25 ng 
of vector and approximately 10 ng of USP12 amplicon with 4 units of T4 DNA ligase in a 
total volume of 10 μl. Ligation reactions were incubated at 14oC overnight and were 
transformed into competent E.coli as described in Section 2.2.4. Transformants were 
selected by blue/white selection on ampicillin and bromo-chloro-indolyl-
galactopyranoside (X-gal)-containing LB agar plates. 
Small-scale plasmid preparations (minipreps) of colonies containing potentially 
recombinant pCR2.1-USP12 plasmids were performed using the GenElute plasmid 
miniprep kit (as described by the manufacturer, Sigma-Aldrich) and resultant plasmid 
DNA digested with the Xba I and Bam HI restriction enzymes (Fermentas) for 1 hour at 
37oC. Released fragments were size-verified by agarose gel electrophoresis prior to 
sub-cloning into the p3xFLAG-CMV-10™ vector (Sigma-Aldrich) following the same 
ligation protocol. Recombinant p3XFLAG-CMV-10™-USP12 vectors were identified by 
diagnostic Xba I and Bam HI restriction digests and subsequently subject to large-scale 
plasmid preparation (maxiprep) using an endotoxin-free plasmid maxiprep kit 
(Qiagen). Resultant plasmids were sequenced by Cogenics (UK). 
2.2.4 Bacterial transformation 
Transformation of NEB 5-alpha competent E.coli (New England Biolabs Inc.) was 
routinely conducted for all ligation reactions and recombinant plasmid DNA in 
accordance with the manufacturer’s recommendations. Briefly, 1 μl of plasmid DNA 
was incubated with 25 μl of competent bacterial cell on ice for 25 minutes. The 
bacteria were then subject to heat shock by incubation at 42oC for 90 seconds and 
chilled on ice for a further 5 minutes. 950 μl of SOC media was subsequently added to 
each sample and incubated at 37oC for 45 minutes prior to plating on relevant 
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antibiotic-containing LB agar plates and incubating at 37oC overnight. For blue/white 
selection 40 μl of 40 mg/ml X-gal and 40 μl of 100 mM isopropyl-D-1-
thiogalactopyranoside (IPTG) were added to antibiotic-containing LB agar plates prior 
to plating of bacteria. 
2.2.5 Site directed mutagenesis 
Site directed mutagenesis of p3XFLAG-CMV-10™-USP12 was performed using the 
Quikchange site-directed mutagenesis kit (Stratagene) to substitute one of the critical 
catalytic residues of USP12 to generate an inactive mutant enzyme. In accordance with 
the manufacturers protocol, a PCR reaction utilising a forward primer: GTC AAT TTT 
GGG AAT ACC GCC TAC TGC AAT TCA GTT CTT CAA GCA; and reverse primer: TGC TTG 
AAG AAC TGA ATT GCA GTA GGC GGT ATT CCC AAA ATT GAC was used to substitute 
the catalytic cysteine at position 48 to an alanine. Reactions contained 125 ng of each 
primer, 1 μl of dNTPs, 1 x reaction buffer and 2.5 units of Pfu turbo DNA polymerase in 
a total volume of 50 μl. PCR reactions were performed on the PCR express thermal 
cycler (Thermo Hybaid) and resultant PCR products treated with Dpn I restriction 
enzyme (Stratagene) for 1 hour at 37oC to remove template DNA. Subsequently, 
products were transformed into XL1-blue supercompetent E.coli (Stratagene) following 
the protocol highlighted in Section 2.2.4. 
2.3 Tissue culture  
Mammalian tissue culture experiments were undertaken in a class II tissue culture 
laminar flow hood, adhering to aseptic technique. Tissue culture plastic-ware (flasks, 
multi-well plates etc.) and sterile plastic pipettes were purchased from Corning Life 
Sciences. All tissue culture media and reagents were purchased from Sigma-Aldrich. 
2.3.1 Cell lines 
All cell lines were originally obtained from American Type Culture Collection (ATCC), 
unless otherwise stated. Cell lines were grown and maintained in RPMI-1640 media 
(with HEPES modification) supplemented with 10% foetal calf serum (FCS) and 1% L-
glutamine (20mM) (termed serum-containing media) at 37oC in a humidified 
atmosphere of 5% CO2. 
The androgen sensitive LNCaP cell line (lymph node carcinoma of the prostate) was 
used as an androgen sensitive model of prostate cancer. This cell line was originally 
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derived from a supraclavicular lymph node metastasis of a 50 year old Caucasian 
patient with prostate cancer in 1977 (Horoszewicz et al., 1980). A sub-clone of this cell 
line with an integrated pPSA luciferase (luc) reporter, LNCaP-7B7, was utilised in 
luciferase assays investigating the effects of siRNA knockdown on AR transcriptional 
activity and was a kind gift from Jan Trapman (Erasmus Medical Centre, The 
Netherlands). The AR negative cell line, PC-3 was derived from a bone marrow 
metastasis of a Caucasian patient with an advanced grade, poorly differentiated 
prostate cancer after androgen ablation therapy (Kaighn et al., 1979). 
For transfection studies, COS-7 and U2OS cells were utilised. COS-7 is a kidney 
fibroblast-like cell line from the African Green Monkey, Cercopithecus aethiops. This 
cell line has been transformed by expression of the SV40 T antigen. U2OS are a human 
bone sarcoma cell line derived from a 15 year old female patient in 1964 (Ponten and 
Saksela, 1967). 
Where media depleted of androgens was required, dextran-coated charcoal (DCC)-
treated FCS was used. DCC treatment removes endogenous androgens from the FCS. 
This medium is termed steroid-depleted medium.  
Cells were tested for mycoplasma routinely in 1 month intervals at the Northern 
Institute for Cancer Research using the Mycoalert mycoplasma detection kit 
(Cambrex). 
2.3.2 Cell Passaging 
Cells were grown on T175 cm2 culture flasks to approximately 70% confluency and 
passaged every 2-3 days. Briefly, culture media was removed from cells before washing 
in pre-warmed PBS. Trypsin was applied to detach cells for approximately 5 minutes at 
37oC and then neutralised by the addition of serum-containing media. Cells were 
pelleted by centrifugation at 2000 rpm for 5 minutes before resuspension in the 
appropriate volume of media. Cell numbers were calculated using a haemocytometer. 
2.3.3 Cryopreservation of cell lines 
In order to maintain cell lines routine cryopreservation was performed. Cells were 
passaged as described above. 2-5 x 106 cells were resuspended in 1 ml of freezing 
media (80% serum-containing, 10% FCS, 10% dimethylsulfoxide (DMSO)). Stocks were 
then stored at -80oC in cryovials. 
54 
 
Cryopreserved cells were re-cultured by defrosting cells at 37oC and transferring them 
into 9 ml pre-warmed serum-containing media. Cells were pelleted by centrifugation at 
2000 rpm for 5 minutes before being resuspended in appropriate volume of serum-
containing media to remove excess DMSO. Cells were then plated onto T25 cm2 or T75 
cm2 flasks. After 24 hours, culture media was replaced in order to remove any dead 
cells. 
2.4 Transient siRNA knockdown of mammalian cells 
LNCaP and LNCaP-7B7 cells were subject to RNA interference using small interfering 
RNA (siRNA) by reverse transfection using Lipofectamine™ RNAiMax (Invitrogen) in 
accordance with the manufacturer’s protocol. All siRNAs were used at a final 
concentration of 25 nM (Table 2.1). As a negative control an siRNA which does not 
affect gene expression within the cells was used, this was termed scrambled (SCR) 
siRNA (catalogue number 1022076, Qiagen). 
Briefly, SCR, AR siRNA and siRNA against each DUB target were transferred into 500 μl 
of basal media (RPMI-1640 supplemented with 10% L-glutamine) and mixed with 
Lipofectamine™ RNAiMax prior to plating onto 6-well plates for 30 minutes 
equilibration. 1.5 x 105 cells were then seeded onto each well of the plates containing 
the transfection mixtures in 1.5 ml steroid-depleted media. Non-transfected (NT) 
controls were included containing only basal media and Lipofectamine™ RNAiMax. For 
cell cycle or apoptosis analyses, cells were subject to knockdown using the same 
protocol, but cells were seeded in serum-containing media.  
For proliferation assays (Section 2.12), 2 x 103 LNCaP cells per well were subject to 
siRNA knockdown on a 96-well plate format. A final concentration of 25 nM siRNA was 
transfected in 20 μl basal media using 0.2 μl Lipofectamine™ RNAiMax. Cells were 
seeded in serum-containing media. 
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Table 2.1. Sequence of siRNAs used to knockdown targets  
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2.5 Transient plasmid DNA transfection 
For luciferase reporter assays, stated cell lines were seeded onto 24-well plates at a 
density of 8 x 103 cells per well. Cells were transfected with 50 ng pFLAG-AR, 100 ng 
pARE3-luc reporter, 100 ng pCMV-β-gal reporter and various amounts of p3XFLAG-
CMV-10™-USP12 (25-100 ng), p3XFLAG-CMV-10™-USP12C48A (50 ng), pCMV-HA-USP10 
(25-100 ng) and pCMV-Myc3-MDM2 (50-100 ng) as stated using Lipofectamine™ LTX 
(Invitrogen) or TransITR-LT1 (Mirus) in concordance with the manufacturers protocol. 
All transfections were balanced with empty pCMV5 vector. 
Plasmids were aliquoted into 100 μl basal media and transfection reagent added at a 
ratio of 1μg DNA: 3 μl transfection reagent. Complexes were left to equilibrate at room 
temperature for 30 minutes and then added to cells in a total volume of 600 μl media 
(100 μl transfection mixture and 500 μl serum-containing media). Cells remained in 
transfection mix until media was changed to steroid-depleted media prior to DHT 
treatments. 
For immunoprecipitation studies, 1 μg of pCDNA3-AR and 1 μg of p3XFLAG-CMV-10™-
USP12 were transfected into 3 x 105 COS-7 cells on 90 mm dishes. Plasmids were 
aliquoted into 1 ml basal media and transfection reagent added in the ratio described 
above. Transfection mixtures were then added onto the cells in a total volume of 10 ml 
media (1 ml of transfection mixture and 9 ml serum-containing media). 
2.6 Gene expression analysis 
2.6.1 Isolation of RNA 
All techniques were carried out under RNase-free conditions using filter tips (Axygen). 
Diethylpyrocarbonate (DEPC) treated water was made by adding 1 ml of DEPC to 1 litre 
of distilled water for 12 hours. The DEPC water was then autoclaved. All solutions for 
RNA work were made using DEPC water. 
RNA was isolated from cells in a 6-well plate format using the EZ RNA extraction kit 
(Geneflow). Briefly, media was removed from cells and washed with PBS before 0.5 ml 
homogenisation solution was added. Following 5 minutes incubation at room 
temperature to ensure complete homogenisation, samples were transferred to 
eppendorf tubes and 0.5 ml extraction solution was added. Samples were vortexed 
and incubated at room temperature for 10 minutes before being centrifuged at 13000 
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rpm for 15 minutes at 4oC. The aqueous phase, containing the RNA, was collected into 
a separate eppendorf tube and precipitated by adding 0.5 ml propan-2-ol and 
incubating overnight at -20oC. The RNA pellet was collected by centrifugation at 7600 
rpm for 8 minutes at 4oC. The pellet was washed in 75% ethanol before being dissolved 
in 20 μl DEPC water. RNA was stored at -80oC. 
RNA concentration and purity was assessed using a Nanodrop ND-1000 UV-vis 
spectrophotometer (Thermo Scientific). The RNA integrity was assessed by the 
260/280 ratio (the ratio of absorbance at 260 nm and 280 nm). Optimal 260/280 ratio 
for RNA is 2.0.  
2.6.2 Reverse transcription 
1 μg of isolated RNA was diluted in a total volume of 12.7 μl DEPC water and incubated 
at 65oC for 5 minutes before 2 minutes at 37oC to remove secondary structure. All 
reverse transcription reagents were purchased from Promega. An enzyme master mix 
containing 4 μl Moloney Murine Leukaemia Virus (MMLV) reverse transcriptase (RT) 
buffer, 2 μl 4mM dNTPs (dATP, dCTP, dGTP, dTTP), 1 μl 5μM oligo dT and 0.3 μl MMLV-
RT enzyme per sample was prepared. 7.3 μl of master mix was added to each sample 
and incubated at 37oC for 1 hour. In order to inactivate the MMLV-RT enzyme, samples 
were placed at 95oC for 5 minutes. Resulting cDNA was stored at -20oC. 
2.6.3 QRT-PCR 
Expression of mRNA was analysed using quantitative real time PCR (QPCR). QPCR 
measures the accumulation of PCR products following each amplification cycle by 
detecting the amount of a fluorescent reporter. SyBr Green (Invitrogen) is a 
fluorescent reporter which intercalates with the DNA. Upon binding DNA the signal of 
the SyBr Green is enhanced and can be detected. 
Real time PCR primers were designed using Primer Express 2.0 (Applied Biosystems; 
Table 2.2). These were used to analyse mRNA expression using the absolute 
quantification method on an ABI 7900 sequence detection system (Applied 
Biosystems). HPRT1 was used as a housekeeping gene to normalise expression levels 
and results were analysed using the SDS 2.2 software (Applied Biosystems). 
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Table 2.2. Sequence of QPCR primers used for mRNA expression analysis 
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2.7 Chromatin Immunoprecipitation (ChIP) analysis 
ChIP was performed as described in Schmidt et al. Briefly, 2x106 LNCaP cells were 
subject to transient transfection in steroid-depleted media using either SCR or USP12 
siRNA for 72 hours prior to 10 nM DHT treatment for 120 minutes. Cells were fixed in 
1% formaldehyde for 10 minutes and glycine treated for 5 minutes prior to cell 
scraping and centrifugation. Resultant pellets were washed in PBS and lysed in LB1 
solution (50 mM HEPES-KOH, pH 7.5; 140 mM NaCl; 1 mM EDTA; 10% glycerol; 0.5% 
NP-40; 0.25% Triton-X-100) for 10 minutes with gentle agitation at 4oC. The lysate was 
centrifuged at 1500g for 5 minutes prior to lysis in 10 ml LB2 buffer (10 mM Tris-HCl, 
pH 8; 200 mM NaCl; 1 mM EDTA; 0.5 mM EGTA) at 4oC for 10 minutes with gentle 
agitation. Lysates were centrifuged as before and resultant pellets re-suspended in 0.5 
ml LB3 buffer (10 mM Tris-HCl, pH 8; 100 mM NaCl; 1 mM EDTA; 0.5 mM EGTA; 0.1% 
Na-Deoxycholate; 0.5% N-lauroylsarcosine). Samples were subject to a pre-optimised 
sonication programme using a Bioruptor™ (Diagenode) incorporating 12 cycles of 30 
seconds on/30 seconds off at the ‘Hi’ setting and then centrifuged for 10 minutes at 
13,000g. DNA concentration for each supernatant was measured using a Nanodrop 
spectrometer and 50 μg of chromatin was transferred into a fresh tube and diluted 5-
fold in LB3 buffer containing 1% Triton-X-100. 10% of each solution was taken as input 
and frozen until the next day. 
50 μl per sample of Dynabeads conjugated to Protein A (Invitrogen) was transferred 
into fresh tubes and blocked with 3 washes of PBS containing 0.5% bovine serum 
albumin (PBS-BSA) prior to incubation with 2 μg anti-AR or HA (control) antibodies 
overnight at 4oC. Dynabeads were then washed twice with PBS-BSA to remove any 
unbound antibody and the 50 μg chromatin samples prepared the previous day were 
added to the appropriate Dynabead samples and mixed overnight at 4oC. Dynabeads 
were subsequently washed 6 times in RIPA buffer (50 mM HEPES-KOH, pH 7.5; 500 
mM LiCl; 1 mM EDTA; 1% NP-40; 0.7% Na-Deoxycholate) and once in Tris-buffered 
saline (20 mM Tris-HCl, pH 7.6; 150 mM NaCl) prior to incubation overnight in 200 μl 
elution buffer (50 mM Tris-HCl, pH 8; 10 mM EDTA) at 65oC to elute protein-DNA 
complexes from beads and to reverse formaldehyde-induced cross-links. In addition, 
input samples taken the previous day were defrosted and, like the 
immunoprecipitated samples, subject to elution/cross-link reversal. Samples were 
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diluted 1-fold in TE buffer and subject to proteolytic digestion using 4 μl 20 mg/ml 
proteinase K (Invitrogen) for 1 hour at 55oC. DNA was purified using a GenElute™ 
genomic DNA miniprep kit (Sigma-Aldrich) and subject to quantitative PCR using 
primers specific to ARE I and ARE III regions of the PSA promoter/enhancer (shown in 
Table 2.2). 
Data is presented as % Input using the following formula: % Input = 100 x 2^(CT 
Adjusted Input sample - CT immunoprecipitated sample) (CT refers to cycle threshold). 
Three individual repeats of the experiment were conducted and data combined to give 
an average % Input over the three experiments.  
2.8 Protein expression analysis 
2.8.1 SDS-polyacrylamide electrophoresis 
Cell lysates were generated by adding sodium dodecyl sulphate (SDS) sample buffer 
(0.125 M Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 10% β-mercaptoethanol, 0.005% 
bromophenol blue) to cells in culture which had been washed in PBS. Samples were 
then placed at 100oC for 10 minutes to assist lysis and to denature the proteins. 
All samples were separated on 10% gels, except for GST-tagged protein purification 
samples which were separated on 15% gels, prepared in Bio-Rad PROTEAN-III 
apparatus (Bio-Rad). Firstly a resolving gel was poured and allowed to polymerise 
before the stacking gel was overlaid and insertion of an appropriate sized well comb. 
Gels were made using the components shown in Table 2.3. Buffer A contained 375 nM 
Tris-HCL, pH8.8, 0.1% SDS whilst buffer B contained 125 nM Tris-HCL, pH6.8, 0.1% SDS. 
15 μl of protein lysate was loaded per well and a molecular weight marker, Spectra™ 
Multicolour broad range protein ladder (Fermentas), was run alongside. Samples were 
electrophoresed at 180V for approximately 60 minutes in reservoir buffer (25 mM Tris-
HCL, 190 mM glycine, 0.1% SDS). 
Samples for Western blotting were transferred onto Hybond C nitrocellulose 
membrane (GE healthcare) between pieces of Whatman paper in a Bio-Rad mini-
PROTEAN-III Western transfer cell. Transfer was performed overnight at 30 V at room 
temperature or for 1 hour at 100V at 4oC, in transfer buffer (25 nM Tris-HCl, pH 8.3, 
0.15 M glycine, 10% methanol). 
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Coomassie staining of polyacrylamide gels was performed for all GST protein induction 
and purification samples. Briefly, after electrophoresis the gels were washed in 
distilled water before being stained with colloidal Coomassie for approximately 1 hour. 
The gels were de-stained using distilled water for 2-3 hrs. Gels were visualised on the 
GelDoc™ system (Bio-Rad) before being dried onto Whatman paper using the model 
583 gel dryer (Bio-Rad) 
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Table 2.3. Contents of polyacrylamide gels used to separate cell lysates. 
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2.8.2 Western analysis 
Western blotting was performed as previously described (Armstrong et al., 2006). 
Briefly, after transfer, the membranes were placed in 5% blocking solution (5% milk 
(Marvel) or 5% bovine serum albumin (BSA) in Tris-buffered saline (TBS; 20 mM Tris-
HCL, 500 mM NaCl) for 1 hour. Membranes were then washed twice for 10 minutes in 
TBS-Tween (TTBS; TBS, 0.1% tween-20) and then incubated with primary antibody in 
an appropriate diluent (1% milk or 1% BSA in TTBS) for 1 hour at room temperature. 
Membranes were then washed twice for 5 minutes in TTBS and incubated with HRP-
conjugated secondary antibodies (Dako) in diluents for a further 1 hour at room 
temperature. Unbound secondary antibody was removed by two washes in TTBS and 
one wash in TBS for 10 minutes each. Enhanced chemiluminescence (ECL; GE 
Healthcare) was used to detect HRP-conjugated secondary antibodies and signals were 
visualised by exposure to X-ray film (Kodak). Antibodies used within the study are 
described in Table 2.4. 
Where densitometry analysis was required Western blots were scanned and analysed 
using the Quantity one program on the GelDoc™ system (Bio-Rad). 
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Table 2.4. Details of antibodies used in Western blotting studies. 
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2.9 Immunoprecipitation (IP) 
Immunoprecipitation was performed to examine interactions between proteins of 
interest in mammalian cells. Briefly, transfected COS-7 cells or LNCaP cells were grown 
to approximately 60% confluency on 90 mm dishes in serum-containing media prior to 
collection by scraping into PBS. Cells were pelleted by centrifugation and resuspended 
in 1.5 ml IP lysis buffer (50 mM Tris, pH7.5, 150 mM NaCl, 1 mM PMSF, 1 mM DTT, 1% 
NP-40 alternative, 1 mM Na3VO4, 1 Complete Mini EDTA-free protease inhibitor 
cocktail tablet (Roche)). Cells were incubated at 4oC with gentle agitation for 30 
minutes. 
Following lysis, samples were centrifuged for 3 minutes at 13000 rpm to pellet cell 
debris. Resultant supernatants were then separated into a 100 μl input, 1 ml sample 
and 400 μl extract. The input sample was stored at -20oC until after the IP procedure 
was complete and was used to examine expression levels of proteins of interest in the 
whole cell extract (WCE). Samples and extracts were precleared by incubation with 
Protein G Sepharose (PGS; GE Healthcare) for 4 hours at 4oC with gentle agitation and 
centrifuged for 3 minutes at 13000 rpm to remove PGS. 2 μg of specific antibody was 
added to each of the sample tubes, but excluded from the extracts, and incubated 
overnight at 4oC with agitation. An additional antibody-only control containing lysis 
buffer and antibody was also incubated overnight at 4oC. The antibodies used in the IP 
studies are shown in Table 2.5. 
An appropriate amount of PGS was added to samples, extracts and the antibody only 
control, following incubation with antibody, for a further 1 hour at 4oC. The PGS beads 
were then collected by centrifugation for 3 minutes at 13000 rpm and washed with IP 
wash buffer A (PBS, 350 mM NaCl, 0.2% Triton) followed by two washes with IP wash 
buffer B (PBS, 0.2% Triton). All inputs, samples, extracts and antibody-only control 
were resuspended in SDS sample buffer and analysed by SDS-PAGE and Western 
blotting. 
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Table 2.5. Details of antibodies used in Immunoprecipitation studies. 
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2.10 Cytoplasmic/nuclear extraction 
Cytoplasmic/nuclear extracts were generated using the NE-PER nuclear and 
cytoplasmic extraction kit (Pierce) according to the manufacturer’s recommendations. 
Briefly, cells were harvested by trypsinisation and pelleted by centrifugation at 2000 
rpm for 5 minutes. Cell pellets were washed twice in PBS before being resuspended in 
60 μl of cold CER I buffer. Resuspension was assisted by vortexing samples for 15 
seconds and incubating on ice for 10 minutes. 3.3 μl cold CER II buffer was then added 
and samples were vortexed twice for 5 seconds, with a minute incubation on ice 
between vortexing. The cytoplasmic fraction was collected by centrifugation of 
samples at 13000 rpm for 5 minutes and transferring the cytoplasmic fraction 
(supernatant) into chilled eppendorf tubes. The insoluble nuclear pellet was 
resuspended in 30 μl of cold NER buffer, vortexed for 15 seconds and incubated on ice 
for a total of 40 minutes. The samples were vortexed every 10 minutes for 15 seconds 
during this incubation. Finally, nuclear fractions were collected by centrifugation of 
samples at 13000 rpm for 10 minutes and the nuclear supernatant transferred into 
chilled eppendorf tubes. Both cytoplasmic and nuclear samples were resuspended in 
SDS sample buffer and analysed by SDS-PAGE and Western blotting. 
2.11 Luciferase reporter assays 
Cells grown on 24-well plates and subject to siRNA knockdown or plasmid DNA 
transfection were washed twice in PBS and then lysed in 50 μl reporter lysis buffer 
(Promega) at 37oC for 10 minutes.  
Luciferase assays were performed using the Promega luciferase assay system 
(Promega). Briefly, 10 μl of cell lysate was transferred into wells of an opaque, flat-
bottomed 96-well plate. 50 μl of luciferase assay reagent (Promega) was added and 
luminescence read immediately on the Micro Beta Plus liquid scintillation and 
luminescence counter (PerkinElmer). 
β-galactosidase (β-gal) assays were performed in order to normalise the luciferase 
activity data to transfection efficiency in each sample. 10 μl of cell lysate was 
transferred to a 96-well plate before 10 μl of β-gal reagent (2 mM MgCl2, 100 mM β-
mercaptoethanol, 1.33 mg/ml ortho-nitrophenyl-β-D-galactopyranoside (ONPG) and 
100 mM sodium phosphate buffer, pH 7.5) added and incubated at 37oC for 10 
minutes. The reaction, which results in the colorimetric conversion of ONPG from 
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colourless to a yellow colour, was terminated by addition of 50 μl NaHCO3. Optical 
density, which is proportional to the activity of the β-gal enzyme, was assessed by 
reading plates on the Bio-Rad 680 microplate reader using the 415 nm filter. 
For luciferase assays involving LNCaP-7B7 cells, a bicinchoninic acid (BCA) assay 
(Pierce) was used to normalise the luciferase activity readouts to total cellular protein, 
which is equivalent to a reading of approximate cell numbers. BCA solution A was 
added to BCA solution B at a ratio of 50:1 and 10 μl of the mixture was added to 10 μl 
of cell lysate on a 96-well plate. Samples were incubated for 30 minutes at 37oC before 
reading on the plate reader using the 570 nm filter. 
Luciferase assay results were normalised against either β-gal or BCA assay readouts. As 
each luciferase experiment was performed using triplicate samples the average and 
standard deviation of each triplicate was calculated. Three independent repeats of 
each experiment were performed and combined, unless otherwise stated, and 
standard error of the mean calculated for each data-set. 
2.12 Sulphorhodamine B cell proliferation/viability assay 
Cellular proliferation/viability was determined by sulphorhodamine B (SRB) assay 
based on a published protocol by Skehan et al. SRB dye stains cellular proteins and is 
indicative of the cell numbers. 2 x 103 LNCaP cells seeded onto 96-well plates were 
subject to siRNA knockdown by reverse transfection. 96 hours post-knockdown, cells 
were fixed with cold trichloroacetic acid (TCA) at a final concentration of 10% for 1 
hour at 4oC. Cells were washed with water five times to remove residual TCA and 
growth media. Plates were dried at 37oC for 1 hour before addition of 100 μl SRB dye 
(0.4% SRB in 1% acetic acid) for 30 minutes at room temperature. Cells were washed 
five times in 1% acetic acid and air dried. Dye was then solubilised in 10 mM Tris, pH 
10.5 for 30 minutes with gentle agitation. Optical density was measured using the 
plate reader and the 570 nm filter. 
2.13 Flow cytometry 
2.13.1 Cell cycle analysis 
LNCaP cells were subject to knockdown in 6-well plates in serum-containing media for 
48 or 96 hours. Non-adherent cells (potentially apoptotic) contained within the growth 
media were collected into tubes before the adherent cells were trypsinised, collected 
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and added to the non-adherent population. Cell pellets were collected by 
centrifugation at 2000 rpm for 5 minutes and washed twice in PBS. Cells were 
subsequently permeabilised using 5% Triton X-100, stained with 2.5 mg/ml propidium 
iodide (PI) and treated with 100 μg/ml RNase to ensure DNA staining rather than RNA 
staining. Samples were analysed on the FACScan (BD Biosciences) At least 1x104 cells 
were evaluated for each sample.  
2.13.2 Apoptosis detection: cleaved caspase-3 
Apoptosis in response to siRNA knockdown was measured using the FITC-conjugated 
monoclonal active caspase-3 antibody apoptosis kit (BD Biosciences). LNCaP cells were 
subject to knockdown in 6-well plates in serum-containing media and after 48 hours, 
cells were treated with 200 nM doxorubicin or vehicle control for a further 48 hours. 
Both adherent and non-adherent cells were harvested and pelleted. Cell pellets were 
washed twice in PBS before fixation with cytofix/cytoperm™ for 20 minutes on ice. 
Cells were the washed twice with perm/wash™ and stained with FITC-conjugated anti-
activate caspase-3 antibody for 30 minutes in the dark. Cells were washed and 
resuspended in perm/wash™ before analysis on the FACScan. At least 1x104 cells were 
evaluated for each sample. A cells only control without antibody staining was included 
as a negative control in this experiment. 
2.13.3 Flow cytometry data analysis 
CellQuest software was used for data acquisition and data analysis performed on the 
WINMDI and Cychlred software programs. Cells were gated on Forward Scatter vs. Side 
Scatter to exclude cell debris and doublet discrimination was carried out on the FL2-
Width vs. FL2-Area dot-blot to ensure only single cells were examined for cell cycle. 
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3 Chapter 3: Identification and validation of deubiquitinase 
enzymes involved in androgen receptor regulation 
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3.1 Introduction 
Androgen receptor (AR) is the key target of current prostate cancer (CaP) therapies. In 
response to DHT binding the cytoplasmic, inactive AR translocates to the nucleus 
where it stimulates the transcription of androgen-regulated genes to promote 
proliferation and survival (Gelmann, 2002). Use of androgen ablation therapy (AAT), 
which functions by blocking androgen production or competitive inhibition of AR, 
suppresses the action of the AR thereby reducing pro-proliferative effects on prostate 
cells (Petrylak, 2005a). Targeting the AR is initially successful and results in gross 
tumour shrinkage. Unfortunately, in the vast majority of cases, patients relapse after a 
median time period of 18 months after commencing neo-adjuvant therapy, and 
develop tumours that have become androgen-independent, termed castrate-resistant 
CaP (CRCaP) (Feldman and Feldman, 2001). Importantly, AR is expressed, is active and 
remains important to the survival and progression of these malignancies (Feldman and 
Feldman, 2001). Many pathways resulting in androgen-independence have been 
identified, including mutations to the AR itself that lead to aberrant activation of 
activity in minimal or absent circulating androgens (Feldman and Feldman, 2001). The 
T877A mutation of AR, a threonine to alanine substitution at position 877, is one of the 
most commonly identified mutations in patients (Veldscholte et al., 1992). This 
mutation has been shown to alter the ligand binding pocket of AR, therefore allowing 
activity to be stimulated by other steroid hormones, including estrogens and 
progesterone. Furthermore, the anti-androgenic agent flutamide becomes an agonist 
of this variant AR (Sack et al., 2001). 
An additional mechanism of AR activation in CRCaP that has received substantial 
interest in the past decade is the process by which aberrant expression of co-
regulatory proteins can facilitate receptor-mediated transcription and drive cancer 
progression. Indeed numerous studies have shown that AR co-regulators, including 
TIP60, p68 and AIB1 are up-regulated in high grade CaP, suggesting that they may drive 
AR function during progression to CRCaP (Culig et al., 1994; Clark et al., 2008). The p53 
induced protein with a RING H2 domain (PIRH2), is an E3 ligase which also acts as a co-
activator of the AR. PIRH2 interacts with TIP60 leading to the degradation of histone 
deacetylase 1 (HDAC1) that in turn increases AR transcriptional activity (Logan et al., 
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2006). There is a positive correlation between PIRH2 expression and grade of CaP 
tumour, with high grade disease expressing more PIRH2 protein (Logan et al., 2006). 
Ubiquitination is the covalent modification of a substrate protein through attachment 
of a 76 amino acid protein called ubiquitin via a multi-step cascade (Pickart and Eddins, 
2004). The first step in the cascade is activation of the ubiquitin molecule by the E1 
activating enzymes UBE1 and UBE6 (Groettrup et al., 2008), followed by transfer of the 
ubiquitin to the E2 conjugating enzyme, of which there are approximately 30 members 
of this family (van Wijk and Timmers, 2010). Finally, ubiquitin is transferred by an E3 
ubiquitin ligase enzyme to the target lysine within the substrate via the formation of 
an isopeptide bind between the C-terminal glycine residue of the ubiquitin protein and 
the ε-amino group of the substrate lysine, as described in Chapter 1.3 (Pickart and 
Eddins, 2004). Ubiquitination is a tightly regulated process in the normal cell which has 
been shown to be disrupted in many disease states including cancer. For example, 
mutations of the E3 ligase BRCA1 that disrupt catalytic activity have been associated 
with loss of BRCA1 tumour suppressor function (Ruffner et al., 2001) and predispose to 
breast, ovarian and prostate cancers (Futreal et al., 1994; Kirchhoff et al., 2004; Turner 
et al., 2007). 
In addition to PIRH2, a number of other E3 ligases interact with the AR including C-
terminal HSP-interacting protein (CHIP), murine double minute (MDM2) and E6 
associated protein (E6-AP). MDM2, a negative regulator of p53, is over-expressed in a 
large proportion of prostate tumours and has been found to restore sensitivity of the 
LNCaP cell line to AAT (Mu et al., 2008). MDM2 ubiquitinates AR after it becomes 
phosphorylated by AKT resulting in the proteasomal degradation of AR (Lin et al., 
2002b). Subsequently, Gaughan et al., found that MDM2 cooperates with HDAC1 to 
co-repress AR activity and drive AR degradation (Gaughan et al., 2005). CHIP binds AR 
after phosphorylation of the hinge region, inhibiting AR folding and leading to 
degradation of AR (Cardozo et al., 2003; Rees et al., 2006). Conversely, PIRH2 and E6-
AP act as co-activators of AR activity. E6-AP is recruited to the active PSA promoter and 
enhances AR-mediated transcription (Khan et al., 2006). Interestingly, AR co-activation 
appears to be coupled with AR turnover as the same report demonstrated that E6-AP 
depletion enhances AR protein levels (Khan et al., 2006). 
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Deubiquitinase enzymes (DUBs) negatively regulate ubiquitination by removing mono-
ubiquitin and ubiquitin chains from substrates. Amongst other functions, DUBs allow 
for the normal rate of protein turnover and maintain the pools of available ubiquitin by 
processing ubiquitin precursors and recycling ubiquitin from proteins targeted for 
proteasomal degradation (Amerik and Hochstrasser, 2004). Five subfamilies of 
enzymes have been identified based on sequence homology and catalytic mechanism 
(Reyes-Turcu et al., 2009). The first four classes are cysteine hydrolases called 
ubiquitin-specific processing proteases (USP), ubiquitin C-terminal hydrolases (UCH), 
ovarian tumour related proteases (OTU-related) and Josephine domain DUBs (Amerik 
and Hochstrasser, 2004). These four subfamilies differ in sequence and structure but 
do share mechanistic similarities. They contain similar cysteine and histidine rich 
motifs which are important for active site function (Wilkinson, 1997). Interestingly, the 
Josephin domain DUB family contains only one characterised member, ataxin-3 which 
was initially identified as a DUB by it binding to ubiquitin aldehyde, a DUB inhibitor 
(Burnett et al., 2003). The fifth subfamily is the zinc-dependent metalloproteases 
containing the MPN+ domain. The MPN+ domain contains two histidine residues and 
an aspartate residue that bind a zinc ion, important for function (Maytal-Kivity et al., 
2002).  
A number of DUBs have been reported to influence AR activity and prostate cancer. 
Prostate tumours expressing high levels of USP2a also express high levels of MDM2, 
while, reciprocally, low USP2a expression correlates with high expression of p53 target 
genes and pro-apoptotic genes (Priolo et al., 2006). USP2a therefore has a role in 
protecting CaP cells from apoptosis by increasing p53 degradation through MDM2 
stabilisation (Priolo et al., 2006). Another DUB, USP10, was identified in purified 
nuclear extracts of AR-null PC-3 prostate cancer cells in complex with ectopically 
expressed AR bound to DNA. Over-expression of USP10 stimulates ectopically 
expressed AR activity by increasing its binding to both selective and non-selective 
response elements. The authors of this study hypothesise that this DUB edits ubiquitin 
chains modifying them from proteasome-targeting poly ubiquitin chains to mono or 
tri-ubiquitin chains that can be transcriptionally activating (Faus et al., 2005). 
Additionally, USP10 deubiquitinates histone H2A.Z allowing AR regulated genes to be 
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transcribed (Draker et al., 2011) However, as a whole this class of enzymes are not 
widely studied in AR signalling. 
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3.2 Aims 
The interplay between DUB enzymes and AR signalling has not been fully explored. 
Only recently a small number of DUB enzymes have been identified as playing a role in 
this signalling pathway. To investigate the full impact of this class of enzymes on AR 
function, an unbiased siRNA library screening approach was utilised. 
The specific aims of this Chapter are:- 
 To identify DUB enzymes involved in regulating AR transcriptional activity 
 To validate these potential ‘hits’ for both level of knockdown at the mRNA and 
protein level 
 To validate the effect of target knockdown on PSA mRNA and protein 
expression 
 To investigate the role of the identified DUBs on additional AR-target genes 
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3.3  Results 
3.3.1 Identification of deubiquitinase enzymes that modulate AR function in 
LNCaP prostate cancer cells 
Currently, USP10 and USP26 are the only reported DUB enzymes that have been 
directly linked to the AR signalling cascade (Faus et al., 2005; Dirac and Bernards, 
2010). In order to address whether any additional DUB enzymes are involved in AR 
regulation, an unbiased siRNA library screen was utilised targeting 72 DUB enzymes in 
the androgen-dependent LNCaP CaP cell line. This covers 75% of the currently known 
DUBs, those without catalytic activity or with only partial sequences were excluded 
from the investigation. Secretion of the AR regulated protein prostate specific antigen 
(PSA), using a commercially available PSA ELISA was used as a primary read-out for AR 
transcriptional activity. A schematic of the experimental design of the whole screening 
process is illustrated in Figure 3.1. 
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Figure 3.1. Schematic of experimental design of the siRNA screen.  
LNCaP cells were subject to knockdown of DUB targets before 100 nM DHT treatment. ELISA measuring prostate 
specific antigen (PSA) secretion was the primary screen output. Targets selected from the ELISA were further 
examined for PSA expression. Any targets which consistently affected PSA secretion and expression were further 
validated before final target selection. 
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Each DUB was targeted with a pool of three individual siRNA oligonucleotides designed 
against different regions of target mRNA using the Rosetta Algorithm (Sigma-Aldrich) 
to ensure robust target knockdown and reduced off-target effects. Messenger RNAs of 
each target gene were knocked down in LNCaP cells in steroid-depleted media on a 96 
well plate format. After 24 hours knockdown, the cells were treated with 100 nM DHT 
for a further 72 hours. An siRNA oligonucleotide specifically designed not to cause 
knockdown of any cellular target, known as scrambled (SCR), was used as a negative 
control. Given PSA was the main read-out for this experiment, siRNA targeting AR and 
the PSA mRNA were used as positive controls as both would attenuate PSA expression. 
Figure 3.2 shows the results of four independent PSA ELISA experiments. The data is 
represented as fold changed compared to the SCR control which has been set to a 
value of 1. As expected, there was a wide variety of effects on PSA expression; 
knockdown of some targets resulted in increased PSA secretion whilst others 
decreased PSA secretion. Potential targets for the next round of screening were 
selected based on 50% PSA modulation, i.e. those with 1.5-fold up-regulation or 50% 
down-regulation in PSA secretion. The red stars indicate those targets which were 
taken forward for QPCR analysis. This work was performed by Dr Steven Darby, 
Northern Institute for Cancer Research, Newcastle University. 
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Figure 3.2. Effect of DUB knockdown on PSA secretion as measured by ELISA.  
Deubiquitinase enzyme (DUB) targets were depleted in LNCaP cells for 24 hours before DHT was applied to cells for a further 72 hours. Secretion of prostate specific antigen (PSA) protein was 
measured by ELISA. Data is shown as fold change compared to the scrambled siRNA (SCR) control, represented by the blue arrow. SCR siRNA which does not affect gene expression was used as a 
negative control. Androgen receptor (AR) and PSA siRNA knockdown were used as positive controls, represented by red arrows. The red and green line represent a level of PSA secretion -/+ 50% of SCR 
respectively. Targets selected for further investigation are indicated by red stars. Data represents the mean of four independent repeats and error bars show the standard error. This work was 
performed by Dr Steven Darby. 
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To elucidate whether the effect of DUB knockdown was a result of a reduction in PSA 
transcription or due to an effect on PSA secretion, PSA expression was evaluated by 
QPCR. Each DUB selected from the ELISA was depleted as described for the initial 
screen. Figure 3.3 shows the results of four independent QPCR analyses of PSA mRNA 
expression for the eighteen selected targets from the PSA ELISA. Data is again 
represented as fold changed compared to the SCR control.  
To aid selection of targets for further validation, ELISA and QPCR data for each DUB 
knockdown were compared. Some targets, for example, showed a reduction in PSA 
secretion at the protein level but did not show reduction in PSA mRNA expression, 
suggesting that these DUBs have a role in the secretion of PSA only. Targets which 
affected both PSA secretion and expression were thought to represent DUBs that 
potentially affected AR regulated transcriptional events and therefore only these 
targets were selected. The results of the PSA ELISA and QPCR experiments are 
tabulated in Table 3.1. The eight targets that consistently influenced PSA in both the 
ELISA and QPCR were selected for further validation (represented by highlighted 
targets in Table 3.1). This work was performed by Dr Steven Darby. 
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Figure 3.3. Effect of DUB knockdown on PSA mRNA expression.  
Deubiquitinase enzyme (DUB) targets were depleted in LNCaP cells for 24 hours before DHT was applied to cells for a 
further 72 hours. RNA was collected for expression analysis. Data is shown as fold change compared to the 
scrambled siRNA (SCR) and is the mean of four independent repeats. SCR siRNA which does not affect gene 
expression was used as a negative control. Androgen receptor (AR) and prostate specific antigen (PSA) siRNA were 
used as positive controls. Error bars show standard error. This work was performed by Dr Steven Darby. 
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Table 3.1. Comparison of the results of DUB knockdown on PSA secretion and expression from the PSA ELISA and 
QPCR experiments.  
All results are shown as fold change compared to the scrambled siRNA (SCR). Data represents and the mean of four 
independent repeats ± standard error. Targets highlighted in red are those which were selected for further 
validation.  
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3.3.2 Validation of potential targets 
The first two rounds of screening identified eight targets which modulate PSA 
expression by at least 50%. Four of these targets were validated by Dr Steven Darby, 
USP10, USP33, USP37 and USP53, while I validated the remaining four targets which 
were UCHL1, USP12, USP29 and USP50. 
In the initial screening, each DUB target was knocked down with a pool of three 
individual siRNA oligos and investigated only for the effect on PSA expression and 
secretion. Importantly, knockdown of each DUB had not been verified in these early 
experiments and thus it was unknown whether the effects of the siRNAs on PSA 
expression were genuinely via DUB enzyme depletion or an off-target phenomenon. In 
addition, use of a pool of multiple siRNAs directed against one target has been 
reported to increase the likelihood of knockdown, although it has also been suggested 
that the effects of a less efficient siRNA may attenuate the effects of more potent 
oligonucleotides and vice versa (Koller et al., 2006; Dharmacon, 2011). Therefore, to 
validate depletion of the selected targets, individual and pooled siRNAs for each DUB 
were assessed for knockdown and investigated that their effects correlated with 
changes to PSA expression.  
An additional control was also introduced into these validation experiments. Previous 
experiments used only the SCR siRNA as a base-line for effects on PSA. It is not known 
whether introduction of our control SCR siRNA itself may have had an effect on PSA 
secretion and/or expression. In order to address this, a non-transfected (NT) control 
was introduced which comprised of cells that had been subjected to the same 
procedures as the SCR control but without the addition of siRNA. As with previous 
experiments, AR knockdown was used as a positive control. Figure 3.4 shows the effect 
of the NT and SCR controls alongside AR knockdown on both AR and PSA mRNA 
expression. Firstly, it is shown that the NT and SCR control arms show no significant 
difference in either AR or PSA expression (Figure 3.4). As expected, transfection of AR 
siRNA caused almost complete attenuation of AR mRNA expression (Figure 3.4a) and 
reduced PSA expression by approximately 60-fold (Figure 3.4b). 
For the subsequent validation experiments, targets were knocked-down in LNCaP cells, 
with each individual siRNA oligo or the pooled siRNA, in steroid depleted media on a 6-
well plate format. 48 hours post-knockdown, cells were then treated with DHT for a 
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further 48 hours. QPCR analysis was performed to check target knockdown and the 
effect on PSA expression. Results are from a minimum of three independent repeats 
and are represented as fold change compared to the SCR control.  
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Figure 3.4. Effect of knockdown on AR and PSA mRNA expression.  
Androgen receptor (AR) was depleted in LNCaP cells for 48 hours before DHT was applied to cells for a further 48 
hours. RNA was collected for expression analysis. Non-transfected cells (NT) and scrambled siRNA (SCR) were used as 
negative controls. Data is presented as fold change compared to the SCR control. Data is representative of the mean 
of three repeats and error bars show the standard error. A) The effect of AR knockdown on AR expression. No 
significant difference was observed between NT and SCR samples. B) The effect of AR knockdown on Prostate 
specific antigen (PSA) expression. No significant difference was observed between NT and SCR samples. 
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3.3.2.1 UCHL1 
Figure 3.5 shows the results for both the knockdown and PSA expression analysis for 
UCHL1. In the PSA ELISA and initial QPCR analysis UCHL1 showed 60% and 70% 
reduction in PSA secretion and expression, respectively (Figure 3.2; Figure 3.3). Firstly, 
it is important to note that no significant difference is seen in the expression of UCHL1 
or PSA between the NT and SCR controls (Figure 3.5a and b). siRNA oligo A knocked-
down UCHL1 by around 2-fold (Figure 3.5a), but increased PSA expression by 1.8-fold 
(Figure 3.5b). siRNA B had no effect on expression of UCHL1, giving comparable levels 
to the SCR control (Figure 3.5a), but resulted in a 1.3-fold reduction in PSA (Figure 
3.5b). siRNA oligo C and the pooled siRNA both caused an increase in UCHL1 
expression (3 and 1.5-fold, respectively; Figure 3.5a). However, oligo C caused a 1.3-
fold increase in PSA while unexpectedly, the pooled siRNA reduced expression by 1.3-
fold (Figure 3.5b). The level of PSA mRNA reduction seen in these validations with the 
pooled siRNA is much less than in the ELISA and initial QPCR. However, it is fair to 
conclude that any effect seen on PSA in the previous screening steps was not a result 
of UCHL1 knockdown but likely an off-target effect. 
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Figure 3.5. Validation of UCHL1 knockdown on PSA expression.  
UCHL1 was depleted in LNCaP cells for 48 hours prior to DHT stimulation for a further 48 hours. Non-transfected cells 
(NT) and scrambled siRNA (SCR) were used as negative controls. Data is represented as fold change compared to the 
SCR control. Data is representative of the mean of three independent repeats and error bars show the standard 
error. A) The effect of individual UCHL1 siRNA oligos and pooled siRNA on UCHL1 mRNA expression. B) The effect of 
individual UCHL1 siRNA oligos and pooled siRNA for UCHL1 on prostate specific antigen (PSA) mRNA expression. 
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3.3.2.2 USP29 
USP29 showed the most promise in the initial screening reducing PSA secretion and 
mRNA expression by 60% and 90%, respectively (Figure 3.2; Figure 3.3). However, 
further analysis indicated that similarly to UCHL1, each individual siRNA and the pooled 
siRNA had differential effects on target knockdown (Figure 3.6). Oligonucleotides A 
and B showed induction of USP29 expression (9 and 1.4-fold, respectively), oligo C 
showed 5-fold knockdown and the pooled siRNA showed no effect when compared to 
the SCR control (Figure 3.6a). It is important to note that a large amount of variability 
was observed between repeat knockdown validations and therefore the error bars on 
Figure 3.6a, particularly for the oligo A and B data-sets, were substantial. USP29 
showed very low expression in LNCaP cells resulting in 30-35 cycles of PCR being 
required to detect mRNA and therefore a high threshold cycle (Ct) value resulted. High 
Ct values are usually thought to be less accurate and therefore potentially unreliable. 
Interestingly, all siRNA oligos and the pooled siRNA showed reduction of PSA 
expression, to a maximum of 2.8-fold (Figure 3.6b). From these results it was 
concluded that the initial selection of USP29 may be potentially due to an off-target 
effect of siRNA causing reduction in PSA levels and that it could be a false positive. 
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Figure 3.6. Validation of USP29 knockdown on PSA expression.  
USP29 was depleted in LNCaP cells for 48 hours prior to DHT stimulation for a further 48 hours. Non-transfected cells 
(NT) and scrambled siRNA (SCR) were used as negative controls. Data is represented as fold change compared to the 
SCR control. Data is representative of the mean of three independent repeats and error bars show the standard 
error. A) The effect of individual USP29 siRNA oligos and pooled siRNA on USP29 mRNA expression. B) The effect of 
individual USP29 siRNA oligos and pooled siRNA for USP29 on prostate specific antigen (PSA) mRNA expression.  
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3.3.2.3 USP50 
Similar problems were encountered in the analysis of USP50. This target showed 60% 
decrease in PSA in both the ELISA and QPCR data (Figure 3.2; Figure 3.3). Expression of 
this target was also very low; represented by very high Ct values high in the QPCR 
analysis akin to USP29. siRNA oligonucleotides A and B caused induction of USP50 
expression (3 and 6-fold increase, respectively), whereas oligo C and the pooled siRNA 
showed no difference when compared to the SCR control (Figure 3.7a). Individual oligo 
knockdown showed no effect (oligo B, C and pooled) or an increase in PSA expression 
(2-fold maximum with siRNA oligo A). Interestingly, the pooled siRNA showed no effect 
on PSA expression which when compared to the initial QPCR data is disappointing 
(Figure 3.7b; Table 3.2). USP50 was therefore deemed as a potential false positive and 
the study of this enzyme was stopped. 
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Figure 3.7. Validation of USP50 knockdown on PSA expression.  
USP50 was depleted in LNCaP cells for 48 hours prior to DHT stimulation for a further 48 hours. Non-transfected cells 
(NT) and scrambled siRNA (SCR) were used as negative controls. Data is represented as fold change compared to the 
SCR control. Data is representative of the mean of three independent repeats and error bars show the standard 
error. A) The effect of individual USP50 siRNA oligos and pooled siRNA on USP50 mRNA expression. B) The effect of 
individual USP50 siRNA oligos and pooled siRNA for USP50 on prostate specific antigen (PSA) mRNA expression.  
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Table 3.2. Comparison of effects on PSA with knockdown of USP50. 
Knockdown of USP50 had 0.39-fold prostate specific antigen (PSA) secretion and 0.37-fold PSA expression compared 
to the scrambled siRNA (SCR). Data represented the mean of three independent repeats ± standard error in the PSA 
ELISA and initial PSA QPCR. Validation of USP50 knockdown showed no effect on PSA expression compared to the 
SCR control. 
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3.3.2.4 USP12 
Unlike the other targets tested thus far, USP12 levels were markedly depleted by each 
of the individual and pooled siRNAs, ranging from a minimum knockdown of 3-fold 
with oligo A to a maximum knockdown of 9-fold with oligo B (Figure 3.8a). However, it 
is important to note that a slight increase in USP12 expression was seen upon 
treatment of cells with the SCR siRNA compared to the NT control (Figure 3.8a). 
Importantly, depletion of USP12 by each siRNA caused a reduction in PSA expression; 
individual oligos showed an approximate 2-fold decrease in PSA expression while the 
pooled siRNA showed a 3.5-fold decrease (Figure 3.8b). This was in accordance with 
the initial screening data that demonstrated a respective 70% and 50% reduction in 
PSA secretion by ELISA and expression by QPCR (Figure 3.2; Figure 3.3; Table 3.3).  
Given these findings, USP12 was taken through to the next round of investigation, as 
described below.  
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Figure 3.8. Validation of USP12 knockdown on PSA expression.  
USP12 was depleted in LNCaP cells for 48 hours prior to DHT stimulation for a further 48 hours. Non-transfected cells 
(NT) and scrambled siRNA (SCR) were used as negative controls. Data is represented as fold change compared to the 
SCR control. Data is representative of the mean of three independent repeats and error bars show the standard 
error. A) The effect of individual USP12 siRNA oligos and pooled siRNA on USP12 mRNA expression. B) The effect of 
individual USP12 siRNA oligos and pooled siRNA for USP12 on prostate specific antigen (PSA) mRNA expression. 
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Table 3.3. Comparison of effects on PSA with knockdown of USP12. 
Knockdown of USP12 had 0.3-fold prostate specific antigen (PSA) secretion and 0.5-fold PSA expression compared to 
the scrambled siRNA (SCR) control. Data represents the mean of three independent repeats ± standard error in the 
PSA ELISA and initial PSA QPCR. Validation of USP12 knockdown showed 0.3-fold PSA expression compared to the 
SCR control. 
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3.3.3 Effect of USP12 knockdown on the AR-regulated PSA expression over 72 
hours DHT stimulation 
The next stage of validating USP12 as a bona fide AR co-regulator was to investigate 
the effect of USP12 knockdown on PSA expression over an extended time course of 72 
hours DHT treatment. This was to validate that the effect of USP12 knockdown on PSA 
expression was directly as a result of modulating AR transcriptional activity rather than 
a secondary effect.  
USP12 was depleted in LNCaP cells on a 6-well plate format for 48 hours prior to 100 
nm DHT treatment for up to 72 hours. Cells were harvested at 0, 6, 12, 24, 48 and 72 
hours post-treatment and both PSA and USP12 levels measured by QPCR. For each 
experimental replicate SCR siRNA was used as a control and results from at least three 
independent repeats are shown as fold change compared to SCR at the 0 hour time-
point. 
As in the previous validations (Section 3.3.2), the effect of siRNA oligonucleotide 
transfection on PSA expression compared to a non-transfected control was assessed to 
provide evidence of toxicity or off-target effects of the transfection procedure. Figure 
3.9a and b show the expression of PSA and AR in the NT and SCR controls over the 
duration of 72 hours DHT stimulation. As expected, PSA mRNA levels were elevated in 
response to androgen in the NT control which was mirrored in the SCR samples 
indicating minimal effect of the SCR siRNA transfection procedure on AR-mediated 
transcription (Figure 3.9a). Unexpectedly, expression of the AR was slightly reduced in 
the SCR control compared to the NT control (Figure 3.9b). Therefore, although the 
results of target knockdown in the subsequent time-course experiments were 
compared to the SCR control, the NT control was included to allow any effects of the 
SCR siRNA on mRNA expression to be observed. 
Consistent with the previous validation experiments described in Section 3.3.2, and to 
confirm that PSA expression was mediated by the AR, depletion of the receptor was 
included as an additional control to the above experiment. As shown in Figure 3.9a, 
knockdown of AR showed almost complete ablation of PSA expression at all time-
points and this correlated with depleted AR mRNA levels (Figure 3.9b). Interestingly, 
the levels of AR in the SCR control were seen to decrease over the 72 hour time-course 
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(Figure 3.9b), this is a trend that has been observed previously in a study investigating 
the effect of EGF and ErbB2 on AR expression (Cai et al., 2009). 
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Figure 3.9. Effect of AR knockdown on PSA expression over 72 hours DHT stimulation.  
Androgen receptor (AR) was depleted in LNCaP cells for 48 hours before 100 nM DHT treatment was applied for a 
further 72 hours. RNA was collected at 0, 6, 12, 24, 48 and 72 hours post treatment. Non-transfected cells (NT) and 
scrambled siRNA (SCR) were used as negative controls. Results are representative of the mean of four independent 
repeats and are shown as fold change compared to the 0 hours SCR control. Error bars show the standard error. A) 
The effect of AR knockdown on prostate specific antigen (PSA) expression over 72 hours DHT treatment. B) The effect 
of AR knockdown on AR expression over 72 hours DHT treatment. 
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To maximise USP12 depletion, USP12 oligonucleotide B was used in the subsequent 
studies as this demonstrated the most robust knockdown of the deubiquitinase 
enzyme by the individual siRNAs. Importantly, knockdown of USP12 showed reduced 
PSA expression at each time-point post 6 hour DHT treatment (Figure 3.10a). At 6 
hours, knockdown showed little or no difference in PSA expression when compared to 
SCR control, but from this point onwards PSA expression was decreased dramatically 
with upwards of 2-fold reduction observed at 72 hours (Figure 3.10a). Profiling USP12 
mRNA levels over the duration of the experiment showed little difference between the 
NT and SCR controls and approximately 70% knockdown was achieved with USP12 
siRNA at each time-point indicating that the effects seen on PSA levels is a result of 
USP12 depletion (Figure 3.10b). 
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Figure 3.10. Effect of USP12 knockdown on PSA expression over 72 hours DHT stimulation.  
USP12 was depleted in LNCaP cells for 48 hours before 100 nM DHT treatment was applied for a further 72 hours. 
RNA was collected at 0, 6, 12, 24, 48 and 72 hours post treatment. Non-transfected cells (NT) and scrambled siRNA 
(SCR) were used as negative controls. Results are representative of the mean of four independent repeats and are 
shown as fold change compared to the 0 hours SCR control. Error bars represent the standard error. A) The effect of 
USP12 knockdown on prostate specific antigen (PSA) expression over 72 hours DHT treatment. B) The effect of 
USP12 knockdown on USP12 expression over 72 hours DHT treatment. 
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To elucidate whether USP12 was itself an AR-regulated gene, USP12 expression was 
investigated in cells subject to AR depletion. No significant difference in USP12 
expression was apparent between AR knockdown and the NT and SCR controls 
suggesting that USP12 is not an AR-responsive gene. Furthermore, AR expression was 
investigated in cells subject to USP12 knockdown to see if USP12 had any effect on the 
transcription of the AR gene. Again, no significant difference in AR expression was 
observed between USP12 knockdown and the NT and SCR controls suggesting that 
USP12 does not regulate the transcription of AR. 
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Figure 3.11. Effect of AR and USP12 knockdown on USP12 and AR expression over 72 hours DHT stimulation.  
Androgen receptor (AR) and USP12 were depleted in LNCaP cells for 48 hours before 100 nM DHT treatment was 
applied for a further 72 hours. RNA was collected at 0, 6, 12, 24, 48 and 72 hours post treatment. Non-transfected 
cells (NT) and scrambled siRNA (SCR) were used as negative controls. Results are representative of the mean of four 
independent repeats and are shown as fold change compared to the 0 hour SCR control. Error bars represent the 
standard error. A) The effect of AR knockdown on USP12 expression over 72 hours DHT treatment. B) The effect of 
USP12 knockdown on AR expression over 72 hours DHT treatment. 
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To investigate whether the observed effect of USP12 knockdown on mRNA expression 
impacted on PSA protein expression in LNCaP cells, PSA protein levels were assessed 
by Western analysis. Using the same time-course experiment as described above, with 
DHT treatment from 0-72 hours, cell lysates were collected and subject to SDS-PAGE 
and Western blotting for PSA and AR. α-tubulin was used as a loading control. A 
representative series of Western blots from one of three independent experimental 
repeats is show in Figure 3.12. Figure 3.13 shows the densitometry analysis of the 
three experimental repeats and is presented as the mean relative protein expression 
normalised to the respective α-tubulin loading control. Data was analysed for 
statistical significance using 2-way ANOVA, significant data is indicated on the figure 
(Figure 3.13). 
In concordance with the QPCR data, NT and SCR samples were comparable and 
showed a marked increase in PSA protein at 24 hours DHT stimulation that increased 
further at 48 and 72 hour time-points (Figure 3.9; Figure 3.12a and b; Figure 3.13a). In 
contrast, knockdown of USP12 reduced PSA protein at each time-point tested to 
undetectable levels and was comparable to the effect of AR knockdown on PSA levels 
(Figure 3.12c and d; Figure 3.13a) indicating a robust effect on AR function upon USP12 
depletion. Importantly, these findings are consistent with the QPCR data (Figure 3.9; 
Figure 3.10). Interestingly, knockdown of USP12 reduced the total amount of protein in 
each sample, indicated by lower levels of α-tubulin (Figure 3.12d), suggesting that it 
may be involved in regulating the proliferation of LNCaP cells (this point is addressed in 
Section 4.3.5.1). 
Assessment of AR levels in the NT and SCR controls demonstrated an expected 
increase in AR levels in response to DHT stimulation after 6 hours treatment that was 
maintained until 24 hours after treatment; AR levels then returned to basal levels 
(Figure 3.12a and b; Figure 3.13b). AR protein was not detectable in AR knockdown 
samples (Figure 3.12c; Figure 3.13b). Taking into account the reduced α-tubulin levels 
in USP12 knockdown cells, there was minimal effect of USP12 depletion on AR protein 
levels and a similar profile to both NT and SCR controls was observed (Figure 3.12d; 
Figure 3.13). Unfortunately, due to a lack of appropriate antibodies the USP12 protein 
levels could not be assessed (refer to Section 4.3.1.2).  
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Figure 3.12. Effect of USP12 knockdown on PSA and AR protein levels.  
LNCaP cells were subject to siRNA knockdown for 48 hours prior to 72 hours 100 nM DHT stimulation. Cell lysates 
were collected at 0, 6, 12, 24, 48 and 72 hours post-treatment. Western blotting for prostate specific antigen (PSA) 
and androgen receptor (AR) were performed. α -tubulin was used as a loading control. Non-transfected (NT), 
scrambled siRNA (SCR) and AR knockdown were used as negative and positive controls. Western blots are 
representative of three independent experimental repeats. A) The effect of the NT control on PSA and AR protein. B) 
The effect of the SCR control on PSA and AR protein. C) The effect of AR knockdown on PSA and AR protein. AR 
Western blot confirmed AR was knocked down throughout the time course. D) The effect of USP12 knockdown on 
PSA and AR protein. 
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Figure 3.13. Densitometry analysis of the effect of USP12 knockdown on PSA and AR protein levels. 
Western blot data from the time-course experiments was analysed using the Quantity one programme on the 
GelDoc™ system. Data for prostate specific antigen (PSA) and androgen receptor (AR) protein levels were normalised 
to the respective α-tubulin loading control data. Data is presented as the mean relative expression of three 
independent experimental repeats. Error bars represent the standard error. Data was analysed for statistical 
significance using 2-way ANOVA. Each knockdown was compared to the SCR control at each time point, significant 
data is indicated by an asterisk. A) The effect of siRNA knockdown on PSA protein levels over 72 hours DHT 
treatment. B) The effect of siRNA knockdown on AR protein levels over 72 hours DHT treatment. 
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3.3.4 Effect of USP12 knockdown on other AR-regulated gene expression 
To assess whether the effect of USP12 knockdown was limited exclusively to the PSA 
gene, the same sample set was analysed for expression of a number of other AR 
regulated genes; KLK2, a member of the same kallikrein family as PSA, TMPRSS2, 
NKX3.1 and NDRG1. 
All of the AR-regulated genes examined showed characteristic induction with DHT 
treatment in the NT and SCR controls (Figure 3.14) (Ngan et al., 2009).KLK2 showed a 
similar expression pattern to PSA in the NT and SCR control (Figure 3.14a), while 
TMPRSS2, NKX3.1 and NDRG1 demonstrated an increase in expression at 
approximately 20 hours DHT treatment before returning to basal levels at 72 hours 
(Figure 3.14b, c and d). Large error bars were observed due to variation between 
sample sets and taking these into account little difference was observed in mRNA 
expression of the AR-regulated between the NT and SCR controls (Figure 3.14). As 
expected, almost complete loss of androgen-responsiveness was observed for all 
genes upon AR knockdown (Figure 3.14), although the difference in expression was 
minimal at 72 hours for TMPRSS2, NKX3.1 and NDRG1 due to mRNA levels returning to 
basal levels in the SCR controls (Figure 3.14b, c and d). 
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Figure 3.14. Effect of AR knockdown on other androgen receptor regulated gene expression over 72 hours DHT 
stimulation.  
Androgen receptor (AR) was depleted in LNCaP cells for 48 hours before 100 nM DHT treatment was applied for a 
further 72 hours. RNA was collected at 0, 6, 12, 24, 48 and 72 hours post treatment. Non-transfected cells (NT) and 
scrambled siRNA (SCR) were used as negative controls. Results are representative of the mean of four independent 
repeats and are shown as fold change compared to the 0 hours SCR control. Error bars show the standard error. A) 
The effect of AR knockdown on KLK2 expression over 72 hours DHT treatment. B) The effect of AR knockdown on 
TMPRSS2 expression over 72 hours DHT treatment. C) The effect of AR knockdown on NKX3.1 expression over 72 
hours DHT treatment. D) The effect of AR knockdown on NDRG1 expression over 72 hours DHT treatment. 
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The effect of USP12 knockdown on KLK2 expression was consistent with that observed 
for PSA; a decrease in expression throughout the 72 hours, with a maximum of 10-fold 
decrease observed at 24 hours DHT stimulation (Figure 3.15a). TMPRSS2 expression 
was reduced by approximately 3-fold when USP12 was depleted, however similarly to 
AR knockdown, the difference in expression at 72 hours post-treatment was minimal 
(Figure 3.15b). Likewise, NKX3.1 and NDRG1 expression were both reduced following 
USP12 knockdown with between 2 to 5-fold decreases observed over the course of the 
72 hours DHT time-course (Figure 3.15c and d). Consistent, with the TMPRSS2 data-set, 
the difference in expression between the USP12 knockdown and SCR samples for both 
NKX3.1 and NDRG1 was not significant at the 72 hour time-point (Figure 3.15c and d). 
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Figure 3.15. Effect of USP12 knockdown on other androgen receptor regulated gene expression over 72 hours DHT 
stimulation.  
USP12 was depleted in LNCaP cells for 48 hours before 100 nM DHT treatment was applied for a further 72 hours. 
RNA was collected at 0, 6, 12, 24, 48 and 72 hours post treatment. Non-transfected cells (NT) and scrambled siRNA 
(SCR) were used as negative controls. Results are representative of the mean of four independent repeats and are 
shown as fold change compared to the 0 hours SCR control. Error bars show the standard error. A) The effect of 
USP12 knockdown on KLK2 expression over 72 hours DHT treatment. B) The effect of USP12 knockdown on TMPRSS2 
expression over 72 hours DHT treatment. C) The effect of USP12 knockdown on NKX3.1 expression over 72 hours DHT 
treatment. D) The effect of USP12 knockdown on NDRG1 expression over 72 hours DHT treatment. 
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3.4 Discussion 
Ubiquitination of AR acts to regulate both AR activity and stability. The E3 ubiquitin 
ligase PIRH2 acts as a co-activator of AR activity, potentially ubiquitinating AR or other 
components of the AR protein complex, whilst other E3 ligases, such as MDM2, 
ubiquitinates AR promoting its proteasomal degradation (Lin et al., 2002b; Logan et al., 
2006). DUBs provide a means of negatively regulating these ubiquitination signals. The 
aim of this study was to identify DUBs that significantly affect the transcriptional 
activity of AR resulting in altered levels of PSA expression in LNCaP cells. These DUBs 
may prove to be important in the development and progression of prostate cancer and 
hence provide potential targets for therapy. 
Only approximately 80 DUBs had been identified at the planning stage of the siRNA 
screen and of these, several were eliminated based on their lack of catalytic activity or 
incomplete sequence hence 72 DUBs were investigated. siRNA was utilised to 
individually knockdown each DUB in the LNCaP cell line prior to DHT treatment. The 
primary experimental readout was PSA secretion by PSA ELISA. As PSA is an AR-
regulated gene, any effect on AR activity may have a downstream effect on PSA 
expression and secretion. Targets found to modulate PSA secretion by 50% were 
selected for further analysis of PSA expression by QPCR. PSA expression analysis 
allowed discrimination between DUBs that potentially effected AR transcriptional 
activity and those that may have had a role in the secretion of PSA. 
The initial siRNA knockdown data-set from the PSA ELISA revealed that 18 of the 72 
DUB enzymes screened influenced PSA secretion by 50% above or below the SCR 
control value. Subsequent profiling of PSA mRNA levels after knockdown of each of 
these 18 targets by QPCR showed 8 consistently altered PSA expression; these were 
taken forward for further validation. Validation of four of these targets, namely UCHL1, 
USP12, USP29 and USP50 was performed in this Chapter.  
It is a possibility that some of the 54 targets ruled out of the QPCR analysis may have 
had an effect on PSA expression. DUB targets that modulated PSA secretion by 50% 
were selected. However, none of the DUBs that increased PSA secretion reached the 
threshold and the three closest targets were selected for further investigation; one of 
these targets, USP10, was validated (this is discussed in Chapter 5). This flexibility in 
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target selection for those that increased PSA secretion was not applied in those that 
reduced secretion meaning other potential hits may have been missed. 
Little is known about the function of USP29, USP50 or USP12, especially within CaP. 
UCHL1 is an exception with a previous study reporting that it is expressed in the AR-
negative, androgen-independent PC-3 and DU145 cell lines but not in the androgen-
dependent LNCaP (Leiblich et al., 2007). UCHL1 is a widely studied neuronal protein 
with implications in neurodegenerative disorders such as Parkinson’s and Alzheimer’s 
disease (Setsuie and Wada, 2007). Therefore, the authors of the CaP study suggest that 
cell lines expressing UCHL1 may be derived from neuronal lineages (Leiblich et al., 
2007). Interestingly, UCHL1 was found to be expressed in LNCaP cells at the mRNA 
level and at easily detectable quantities (Figure 3.5). Leiblich et al., used PCR to 
confirm UCHL1 expression in PC-3 and DU145 cells, although they used conventional 
gel electrophoresis instead of a quantitative method and this may account for not 
detecting UCHL1 in LNCaP cells. Increasingly, UCHL1 has been associated with a wide 
variety of cancers including lymphoma (Hussain et al., 2010), breast (Wang et al., 
2008), colorectal (Okochi-Takada et al., 2006) and small cell lung carcinoma (Kim et al., 
2009). In a head and neck squamous cell carcinoma cell line study performed by 
Tokumaru et al., the authors postulated that UCHL1 is a tumour suppressor gene as it 
is methylated during tumourigenesis (Tokumaru et al., 2008). Contradictory to this 
notion, however, primary tumour samples within this study were found to over-
express the protein potentiating the conclusion that UCHL1 acts as a tumour 
suppressor gene in normal tissue but is over-expressed in cancer due to oncogenic 
signals (Tokumaru et al., 2008). Li et al., also found that UCHL1 acts as a tumour 
suppressor through its interaction with and promotion of p53 activity, and the same 
study found that UCHL1 was frequently methylated in nasopharyngeal carcinoma (Li et 
al., 2010). More recently, conflicting reports have suggested that UCHL1 actually acts 
as an oncogene (Kim et al., 2009; Hussain et al., 2010). Hussain et al., reported that 
UCHL1 drives the development of lymphoma through down regulation of apoptosis 
and promotion of proliferation through the AKT pathway (Hussain et al., 2010). 
Similarly, UCHL1 was found to stimulate tumour invasion in a lung cancer cell line 
through activation of the Akt pathway (Kim et al., 2009). Disappointingly, UCHL1 could 
not be validated in the context of our screen. PSA ELISA data suggested knockdown of 
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UCHL1 caused a decrease in PSA secretion which was confirmed by QPCR analysis 
(Figure 3.2, Figure 3.3). However, further validation revealed that the pool of three 
siRNA oligonucleotides failed to knockdown UCHL1 and that the decrease in PSA may 
have been an off target effect of the siRNA (Figure 3.5). Importantly, knockdown of 
UCHL1 was only successful using oligonucleotide A, and in this case, PSA mRNA 
expression was increased (Figure 3.5), suggesting this may be the genuine effect of 
UCHL1 knockdown on AR activity. In order to resolve this conflicting result and 
elucidate the true effect of UCHL1 knockdown on PSA expression new siRNA 
oligonucleotides would need to be designed. 
Complete validation of both USP29 and USP50 was also unsuccessful due to both 
targets being expressed at very low levels in LNCaP cells that made determination of 
knockdown difficult. 30-35 cycles of PCR were required to detect USP29 and USP50. Ct 
values of this level would not normally be considered reliable and accurate and could 
account for some of the variability seen between experimental repeats particularly for 
USP29 (Figure 3.6a). Therefore, to determine whether these targets would be worth 
further follow up, the study is limited to analysis of PSA expression only as no informed 
decision on the robustness of USP29 and USP50 knockdown can be made from the 
expression data of each of the DUBs (Figure 3.6a and Figure 3.7a). Importantly, USP29 
knockdown showed consistent reduction in PSA expression with each individual siRNA 
oligo and the greatest effect was observed with the pooled siRNA (Figure 3.6b). 
Therefore, it is possible that knockdown of the already low levels of the enzyme 
reduces AR activity, suggesting an involvement of USP29 in the AR signalling cascade. 
One possible method of validating USP29 knockdown would be at the protein level by 
Western blotting. Several USP29 antibodies are available commercially, however, no 
USP29 antibodies have been successfully used in the literature and verification would 
have to be performed. With hindsight, USP29 could have been brought forward to the 
next steps of validation; even though knockdown could not be accurately determined 
by QPCR, the effect on PSA expression was consistent. However, without thorough 
validation of USP29 knockdown levels, the function of the enzyme in AR regulation 
remains an intriguing possibility. 
Interestingly, USP50 knockdown did not show reduction in PSA expression with the 
pooled siRNA or individual oligos (Figure 3.7b), while both the ELISA and initial QPCR 
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experiments at the on-set of the screening programme demonstrated robust reduction 
in PSA by utilising the same pool of siRNA (Table 3.1). This condition effectively acts as 
an internal control for these experiments and should give similar results to the ELISA. 
The data sets theoretically should not be different as the cell line used was the same, 
although there were differences in passage numbers. As the ELISA and first PSA QPCR 
were performed without knockdown checks there may have been some large scale off-
target effect, although the knockdown validations proved difficult. 
Of the four targets chosen for additional validation, USP12 was the only target that 
was successfully taken forward and shown to be a regulator of AR gene expression. All 
individual siRNA oligos and the pooled siRNA showed robust knockdown of USP12 that 
markedly reduced PSA expression (Figure 3.8) with maximal effect seen with the 
pooled oligonucleotides (approximately 70% reduction). For subsequent DHT time-
course validation experiments, siRNA oligo B was used alone to knockdown USP12 as 
this provided up to 90% depletion of USP12 mRNA and was a simpler and cheaper way 
of achieving robust knockdown of the target and decreases in AR target gene 
expression. Over 72 hours DHT stimulation, USP12 knockdown was shown to reduce 
the expression of all the AR-regulated genes investigated. No effect was seen on AR 
protein levels and so it can be postulated that USP12 regulates the transcriptional 
functions of AR rather than AR protein stability. 
RNA interference screens have been utilised by a number of laboratories to identify 
DUB enzymes that are important in a wide variety of pathways. Many endpoint assays 
have been used throughout the literature. USP39 and USP44 were identified in screens 
performed in looking for defects in mitosis (Stegmeier et al., 2007; van Leuken et al., 
2008). These screens, performed in human osteosarcoma and cervical cancer cell lines 
respectively, used a visual endpoint to select candidate DUBs for further validation by 
observing defects in cells under the microscope. Western blot analysis of downstream 
targets of TGF β signalling was used to identify USP9x as an important regulator in TGF-
β signalling (Dupont et al., 2009). Other screens such as Brummelkamp et al., and 
Kayagaki et al., used luciferase reporter assay-based approaches to look for the effect 
of DUB knockdown on transcriptional activity and identified CYLD as a regulator of 
NFκB, and DUBA as important in type I interferon production, respectively 
(Brummelkamp et al., 2003; Kayagaki et al., 2007). With such a wide selection of 
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endpoint assays, the question remains as to which is the most appropriate for such a 
screen. At first glance, it may appear a protein based-assay would be most favourable 
as ubiquitination is a post-translational modification, and has been implicated in 
protein turnover. However, ubiquitination events themselves have such a broad 
spectrum of consequences that both protein stability and transcriptional activity can 
be affected (Pickart and Eddins, 2004). The study herein aimed to identify DUBs that 
effected AR transcriptional activity by monitoring production of the AR-responsive PSA 
protein in an ELISA. One potential problem with this protein-based read-out approach 
was that DUBs influencing PSA protein stability may have been inadvertently 
identified. It was a necessity, therefore, to include an additional QPCR screening step 
to look directly at PSA mRNA expression.  
A luciferase-based reporter approach may have simplified the identification of DUBs 
involved in AR transcriptional activity. This system would utilise the luciferase reporter 
gene downstream of an AR-responsive promoter, such as the PSA promoter. Upon 
androgen stimulation, the AR binds to the promoter and drives transcription of the 
luciferase gene. Addition of luciferin, a substrate of the luciferase enzyme, then results 
in a measurable emission of light that is proportional to luciferase levels and hence 
reflects AR activity. An LNCaP cell line with a stably transfected androgen-responsive 
luciferase reporter would be a useful tool cell line for this type of experiment, while 
other non-AR-responsive lines have also been engineered to assess mechanisms of 
receptor regulation (Faus et al., 2005; Caliper Life Sciences, 2011). For example, Dirac 
et al., identified USP26 as an important regulator of AR signalling using the 
hepatocellular carcinoma cell line HepG2 (Dirac and Bernards, 2010). This cell line does 
not endogenously express AR but has been shown to become androgen-responsive 
upon over-expression of ectopic AR. Additionally, the plasmid-based luciferase gene 
downstream of an androgen response element (ARE) was transiently introduced into 
this cell line and subsequent luciferase analysis demonstrated USP26 knockdown 
increases AR activity. However, over-expression of USP26 also showed increased AR 
activity in HEK293 cells upon the same reporter; the authors suggesting that this 
discrepancy is due to differences in AR ubiquitination status between cell lines (Dirac 
and Bernards, 2010). Importantly, both the HepG2 and HEK293 cell lines used in this 
study do not endogenously express the AR and are therefore not reliant on this 
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signalling pathway. It is also probable that other important components of the AR 
signalling pathway are missing that may be required for the effect of USP26 on AR in a 
cell line that does endogenously express AR. The data described in this Chapter have 
utilised the LNCaP cell line which both expresses and is dependent upon AR, suggesting 
that any effect seen with knockdown of a DUB on AR signalling is likely to be more 
representative of the true cellular state. As shown in Figure 3.1 and Table 3.1, USP26 
was identified as a DUB that reduced PSA secretion in the ELISA by 60%. Unfortunately, 
analysis of PSA mRNA levels was not consistent with the results of the PSA ELISA; 
demonstrating an increase in PSA expression by 20% over the SCR control. Therefore 
this DUB was not brought forward for further validation. 
Early DUB knockdown screens such as Brummelkamp et al., and Nijman et al., targeted 
50 proteins postulated to contain the conserved DUB catalytic domain (Brummelkamp 
et al., 2003; Nijman et al., 2005a). When our study was initially designed, 79 functional 
DUB enzymes had been identified from previous literature and bioinformatics searches 
(Nicholson et al., 2007). To date, approximately 100 DUB enzymes have been identified 
(Frappier and Verrijzer, 2011), and this highlights how quickly the field of DUB research 
is expanding. We targeted 72 of the 90 known DUBs based on those which were 
thought to have intrinsic DUB activity. However, the recent demonstration that the E3 
ubiquitin ligase Siah2 is repressed by the DUB enzyme USP13 independently of 
deubiquitinase activity indicates that DUB enzymes have additional mechanisms of 
action that are independent of their catalytic activity (Scortegagna et al., 2011). 
Therefore, analysis of the DUBs that lacked the catalytic domain and were excluded 
from the initial screen may provide additional enzymes that regulate AR activity or 
stability. 
siRNA screens have a number of limitations. siRNA by nature is unstable and the 
effects of knockdown can be transient. Some studies have used vector driven short 
hairpin RNA (shRNA) based approaches to alleviate these issues (Nijman et al., 2005a; 
Stegmeier et al., 2007). Luckily, USP12 knockdown proved to be very stable, lasting at 
least 120 hours with siRNA in LNCaP cells. Another problem with siRNA is the 
possibility of off-target effects due to partial homology of the sense strand with other 
cellular mRNA. Newer siRNA technologies have been developed to minimise this by 
chemical modification of the sense strand to prevent its interaction with the RISC 
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complex such as Dharmacon ON-TARGET plus siRNA oligonucleotides. Additionally, 
chemical modification of the anti-sense strand has been shown to increase specificity 
(Dharmacon, 2011). 
USP12 was the only DUB of the four investigated in this Chapter to be fully validated. 
USP12 was first identified close to chromosomal translocation breakpoints in 
leukaemia (Hansen-Hagge et al., 1998). More recently, USP12 was implicated in the 
development of Xenopus laevis, by regulating histone H2A and histone H2B 
ubiquitination that controls transcription of developmentally important genes (Joo et 
al., 2011). To date USP12 has not been associated directly with any disease state. 
USP12 is investigated and discussed in more detail in Chapter 4.  
In conclusion, USP12 has been identified and validated as a DUB that effects AR 
transcriptional activity. Knockdown of USP12 causes a reduction in PSA mRNA 
expression at almost all time-points over the course of 72 hours DHT stimulation. 
Levels of USP12 knockdown are substantial with depleted expression being maintained 
at 30% throughout the 120 hour duration of this experiment. The effect of USP12 
knockdown on AR activity reduces both PSA mRNA and protein levels. Likewise, USP12 
depletion has effects on expression of AR-regulated genes outside of the kallikrein 
family, as similar effects were seen in all the other genes analysed. Validation of USP29 
and USP50 proved problematic but further validation experiments, at the PSA 
expression level, could be used to elucidate whether these are true regulators of AR 
activity. 
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4 Chapter 4: Characterisation of USP12 as a deubiquitinase 
involved in androgen receptor regulation 
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4.1  Introduction 
Deubiquitinase enzymes (DUBs) fall into five specific sub-families based on structure 
and catalytic mechanism (Amerik and Hochstrasser, 2004). The largest and most 
diverse of these families are the ubiquitin-specific processing proteases (USPs) with 58 
USPs having been identified to date (Ventii and Wilkinson, 2008). The USP family are 
defined as cysteine proteases and consist of two conserved domains, the cysteine (Cys) 
box and the histidine (His) box, that contain conserved Cys, His and aspartic acid (asp) 
residues, referred to as the triad residues, and are critical for enzymatic activity 
(Nijman et al., 2005b). Unlike other proteases, structural analysis has revealed that the 
USP enzymes are non-catalytic in the free form, needing ubiquitin binding to induce 
conformational changes to align the triad residues or to remove bulky loops and 
domains that occlude the active site (Amerik and Hochstrasser, 2004). UCHL3 has an 
active site loop that blocks the entry of substrates into the active site, but upon 
recognition of ubiquitin, this loop is restructured into an α-helix and displaced from the 
active site allowing catalysis (Johnston et al., 1997). This is an important regulatory 
mechanism that prevents non-appropriate substrate interactions (Amerik and 
Hochstrasser, 2004). 
4.1.1 USP12 
USP12 is a relatively uncharacterised member of the USP family. Also known as 
ubiquitin hydrolysing enzyme 1 (UBH1), it was first identified by Hansen-Hagge et al., 
whilst sequencing the breakpoints of the t(5;14)(q33-q34;q11) translocation in a 
subset of leukaemia patients (Hansen-Hagge et al., 1998). The predicted primary 
sequence of USP12 was found to be similar to products of the Caenorhabditis elegans 
gene R10E11.3 and the Sacchormyces cerevisiae Ubp9 and Ubp13 genes that are active 
DUB enzymes (Hansen-Hagge et al., 1998), suggesting that USP12 is an additional DUB 
protein. Interestingly, regions of sequence homology between the proteins were 
limited to within the catalytic Cys and His boxes consistent with USP12 being 
potentially catalytically active; although at just 370 amino acids it is the smallest 
member of the USP family of enzymes (Komander et al., 2009a). USP12 is postulated 
to be a nuclear protein due to the presence of two nuclear localisation signals between 
amino acids 74-77 and 96-112 but this has not been confirmed (Hansen-Hagge et al., 
1998). USP12 is evolutionarily conserved within vertebrates; mouse Usp12 shows 
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98.3% amino acid homology to human USP12 (Baek et al., 2002). Interestingly, USP12 
is highly homologous to the 366 amino acid DUB enzyme, USP46 (Cohn et al., 2009). 
Due to the high degree of homology and comparable size of the two proteins, 
distinguishing between them at the protein level is highly difficult, with antibodies 
generated detecting both DUBs (Cohn et al., 2009).  
4.1.1.1 USP12-interacting proteins 
In vitro deubiquitination assays utilising turn-over of the fluorogenic ubiquitin 
conjugated 7-amido-4-methyl-coumarin (AMC) revealed that USP12 possesses very 
little DUB activity (Cohn et al., 2009). Studies have shown that interaction with various 
WD40-repeat containing proteins, such as UAF1 and WDR20, facilitate and enhance 
USP12 enzymatic activity (Cohn et al., 2009; Kee et al., 2010). Cohn et al., firstly 
reported the presence of USP12 in complex with the deubiquitinase regulatory protein 
UAF1, a protein that contains eight WD40-repeats, and showed that USP12 activity 
towards ubiquitin-AMC was markedly increased upon addition of UAF1 in in vitro 
deubiquitination assays. Importantly, loss of any one of the WD40-repeats was 
sufficient to compromise the UAF1-USP12 interaction, implicating the dependency of 
these domains for complex formation (Cohn et al., 2009). Furthermore, addition of 
WDR20, an uncharacterised five WD40-repeat containing protein, was shown to 
further enhance the DUB activity of USP12 in a UAF1-dependent manner; interacting 
with both USP12 and UAF1, but requiring UAF1 to further enhance USP12 activity. In 
contrast to UAF1, however, only the 2nd WD40-repeat of WDR20 was shown to be 
indispensable for USP12 enzymatic activity (Kee et al., 2010). The most recent USP12 
study identified DMWD, WDR26 and WDR77 as low abundance interacting proteins, in 
addition to confirming the interactions with UAF1 and WDR20 (Joo et al., 2011). 
Reciprocal immunoprecipitation (IP) and mass spectrometry analysis identified Akt 
phosphatases PHLPP and PHLPPL as interacting partners of USP12 (Sowa et al., 2009), 
although, Joo et al., did not identify PHLPP or PHLPPL in their study (Sowa et al., 2009; 
Joo et al., 2011). 
4.1.1.2 USP12 and regulation of ubiquitination 
Cohn et al., and Kee et al., both investigated USP12 in the context of Fanconi anaemia 
(FA) (Cohn et al., 2009; Kee et al., 2010). FA is an autosomal recessive disorder 
characterised by defects in DNA repair and chromosome instability leading to 
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hypersensitivity to DNA cross-linking agents and a predisposition to cancer 
(Jacquemont and Taniguchi, 2007). Approximately 13 proteins co-operate in the FA 
DNA repair pathway and mutation or loss of any can lead to FA (Jacquemont and 
Taniguchi, 2007). FANCD2, a DNA repair protein important in the FA pathway, is 
regulated by mono-ubiquitination. Deubiquitination of FANCD2 by the USP1-UAF1 
complex is essential for its DNA repair function. Loss of USP1 leads to an accumulation 
of mono-ubiquitinated FANCD2 and a hypersensitivity of cells to DNA cross-linking 
agents (Jacquemont and Taniguchi, 2007; Cohn et al., 2009). Stable knockdown of 
USP1 and UAF1 in HeLa cells showed an accumulation of mono-ubiquitinated FANCD2 
whilst knockdown of USP12 had no effect (Cohn et al., 2009). As WDR20 specifically 
regulates the activity of USP12-UAF1, Kee et al., hypothesised that depletion of 
WDR20 would also have no effect on FANCD2 mono-ubiquitination status. Transient 
siRNA knockdown of WDR20 in HeLa cells had no effect on FANCD2 ubiquitination 
confirming the author’s hypothesis (Kee et al., 2010). 
Joo et al., provided the first insight into the functional role of USP12 in early embryonic 
development of Xenopus Laevis. Ubiquitination of histones H2A and H2B are markers 
of transcriptional silencing and activation, respectively, although more recent reports 
have suggested that this is context specific and both marks facilitate both outcomes 
(Weake and Workman, 2008; Joo et al., 2011). In this study, USP12 was shown to 
deubiquitinate histones H2A and H2B at certain developmentally important gene 
promoters to regulate expression of these genes. Specifically, upon USP12 depletion, 
ubiquitinated histone H2A levels were decreased whilst ubiquitinated histone H2B 
levels were increased at the promoter region of the mesodermal fate marker gene 
Xbra, resulting in reduced expression of Xbra, suggesting USP12 regulates mesodermal 
cell fate determination in the early Xenopus embryo. The Hox genes, encoding 
transcription factors which control the positional transcription of genes involved in 
determination of the structure and orientation of an organism, are expressed during 
early development and are regulated by histone modifications including ubiquitination 
of histones H2A and H2B (Wang et al., 2004; Zhu et al., 2005; Barber and Rastegar, 
2010). Although USP12 affected histone ubiquitination at the Xbra promoter, the 
authors found no effect of USP12 on Hox gene expression (Joo et al., 2011). Finally, 
both knockdown and over-expression of USP12 caused major physical defects in the 
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Xenopus embryo including an inability of the embryo to undergo complete gastrulation 
or formation of the three germ layers. 
4.1.1.3 USP12 as a potential AR co-regulator 
USP12 was identified using a siRNA library screen in LNCaP cells as discussed in 
Chapter 3. USP12 knockdown consistently reduced PSA mRNA and protein expression 
in addition to down-regulating expression of all other AR regulated genes studied ( 
Figure 3.10 and Figure 3.15). USP12 was shown not to be an AR target gene, as 
androgen-treatment and receptor-depletion failed to affect USP12 gene expression 
(Figure 3.11). Importantly, AR mRNA and protein levels were unaffected by USP12 
knockdown in LNCaP cells (Figure 3.11 and Figure 3.12), strongly suggesting that USP12 
is a co-activator of AR transcriptional activity. 
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4.2 Aims 
The cellular function of USP12 remains poorly characterised and it is currently 
unknown if the enzyme functions as a co-regulator of transcription factor function, 
including the AR. In addition, there is a major knowledge gap in our understanding of 
the potential role of USP12 in prostate cancer (CaP). The data highlighted in Chapter 3 
suggested that this DUB enzyme is an important regulator of AR activity in CaP cells 
and this needs to be further investigated. 
The specific aims of this Chapter are: 
 To further characterise the effect of USP12 on AR transcriptional activity 
including determining whether the deubiquitinase activity of USP12 is required 
for AR co-regulation 
 To investigate whether USP12 knockdown impedes AR movement into the 
nucleus upon DHT stimulation and therefore affecting recruitment of AR to 
target gene promoters 
 To elucidate whether USP12 exerts its effect through a direct interaction with 
AR 
 To investigate whether USP12 knockdown has any phenotypic effects on LNCaP 
cells 
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4.3 Results  
4.3.1 USP12 up-regulates the activity of the AR in a deubiquitinase-dependent 
manner 
4.3.1.1 Effect of USP12 knockdown on AR transcriptional activity 
Analysis of gene expression in Chapter 3 (Figure 3.10 and Figure 3.15) showed that 
knockdown of USP12 had a negative impact on all AR regulated genes studied. To 
confirm that this effect was due to a change in AR transcriptional activity, we exploited 
the LNCaP-7B7 pPSA cell line that contains a stably integrated pPSA luc reporter which, 
like endogenous AR regulated genes, is driven by the active receptor. 
LNCaP-7B7 pPSA cells were subject to siRNA knockdown for 48 hours in steroid-
depleted media in a 24 well plate format, including both SCR and AR siRNAs as 
negative and positive controls, respectively. Cells were treated with DHT for an 
additional 48 hours before they were harvested and luciferase reporter activity 
assayed. Total protein levels, as measured by bicinchoninic acid (BCA) assay, were used 
to normalise the luciferase activity data. Data is represented as mean fold change 
compared to the untreated SCR control of three independent experiments. 
In the SCR control, DHT stimulation caused a dramatic increase in reporter activity 
(94.4-fold, P=0.0034) indicating potent AR activity in this cell line (Figure 4.1, compare 
lanes 1 and 2). As expected, knockdown of AR significantly decreased AR activity in 
DHT-treated, but not un-stimulated LNCaP cells, compared to the SCR control 
(P<0.001). Importantly, knockdown of USP12 also caused a reduction in luciferase 
activity in both DHT-treated and untreated cells. Basal, un-stimulated AR activity was 
reduced to 0.4-fold compared to the SCR control (Figure 4.1, compare lanes 1 and 5), 
and upon addition of DHT, luciferase expression was 45% less than the androgen-
treated SCR control (Figure 4.1, compare lanes 2 and 6). This result was not statistically 
significant (P=0.057) but does support the previous data from Chapter 3.  
In addition, supporting evidence for the effect of USP12 knockdown resulting in 
reduced LNCaP cell proliferation, as represented by reduced α-tubulin levels presented 
in Figure 3.13, the USP12 knockdown reduced the BCA measurements by 
approximately 20% compared to the SCR control in the absence of DHT (Table 4.1). As 
observed in Figure 3.12, α-tubulin levels increased with addition of androgen even 
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with USP12 knockdown, and this is also observed in the BCA measurements as, 
although still reduced, protein levels increased to approximately 10% below the SCR (- 
DHT) control (Table 4.1). AR knockdown also reduced BCA readout in both the 
presence and absence of DHT by approximately 20%, supporting its pro-proliferative 
function and the reduced α-tubulin levels also observed with AR knockdown in Figure 
3.12 (Table 4.1). 
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Figure 4.1. Effect of USP12 knockdown on luciferase reporter activity in the LNCaP-7B7 pPSA cell line. 
LNCaP-7B7 pPSA cells were subject to knockdown in steroid-depleted media for 48 hours prior to 48 hour treatment 
with 100 nM DHT. Scrambled (SCR) and androgen receptor (AR) siRNA were used as negative and positive controls, 
respectively. Data is normalised to the total protein as measured by bicinchoninic acid (BCA) assay and is 
represented as fold change in luciferase reporter activity compared to the untreated SCR control. Data is the mean of 
three independent repeats and error bars show the standard error between the experimental replicates. Data was 
analysed for statistical significance using the Student’s t-test, significant data is indicated by an asterisk. 
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Table 4.1. Effect of USP12 knockdown on total protein levels in the LNCaP-7B7 pPSA cell line.  
Total protein levels were measured by bicinchoninic acid (BCA) assay to allow for normalisation of the luciferase 
reporter assays. Data is the mean of three independent experiments and is represented as fold change compared to 
the scrambled (SCR) – DHT control. Data represents the mean of three independent repeats ± standard error. 
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4.3.1.2 Generation of p3xFLAG-CMV-10™-USP12 mammalian expression vector 
The above result suggested that in the normal cellular context USP12 may be acting as 
a co-activator of AR transcription. In order to confirm this, additional luciferase assays 
using ectopic USP12 expression were undertaken. For these experiments, a USP12 
mammalian expression vector was required to permit production of the enzyme in cell 
line models utilised for luciferase assays, including the osteosarcoma cell line, U2OS 
and the monkey kidney cell line, COS-7. In addition, given that USP12 antibodies are 
unable to detect both the endogenous and ectopic enzyme (see below); a tagged 
version of the enzyme was required to permit immunoprecipitation and Western 
analysis using tag-specific antibodies. 
Initially, the pDEST-FLAG-HA-USP12 vector was purchased from Addgene (Plasmid 
22567) (Sowa et al., 2009), and sequence analysis confirmed that the full USP12 
protein coding sequence was present. However, upon transfection into COS-7 cells, 
Western analysis using both HA and FLAG-specific antibodies was unable to detect HA- 
(Figure 4.2a, lane 3) or FLAG-tagged USP12 protein (predicted size of tagged USP12 is 
52 kDa) (Figure 4.2b, lane 3) suggesting that the purchased vector was possibly out of 
frame. Importantly, HA-tagged ubiquitin and FLAG-tagged AR were specifically 
detected by the respective HA and FLAG antibodies (Figure 4.2a and b, lanes 1 and 2). 
Therefore, a FLAG-tagged USP12 vector was generated using the p3xFLAG-CMV-10™ 
vector backbone (Sigma-Aldrich). 
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Figure 4.2. Anti-HA and anti-FLAG antibodies do not detect ectopically expressed USP12 in COS-7 cells.  
Lysates from Lysates from pDEST-FLAG-HA-USP12-transfected COS-7 cells were analysed by Western blotting with 
anti-HA and anti-FLAG antibodies. HA-tagged ubiquitin and FLAG-tagged androgen receptor (AR) were used as 
positive controls for the HA and FLAG antibodies, respectively. α-tubulin was used as a loading control. 
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Specific forward and reverse primers were designed to amplify USP12 from the pDEST-
FLAG-HA-USP12 vector by PCR, and contained sites for Xba I and Bam HI restriction 
enzymes cleavage. USP12 cDNA was successfully amplified by PCR and sub-cloned into 
the pCR2.1 vector (Invitrogen) (Figure 4.3a and b). Xba I and Bam HI restriction 
enzymes were used to excise the USP12 cDNA from the pCR2.1 vector that was then 
sub-cloned into the p3xFLAG-CMV-10™ vector. Diagnostic digestion of the 
recombinant p3xFLAG-CMV-10™-USP12 vectors was achieved using the Xba I and Bam 
HI enzymes (Figure 4.3c). Finally, the recombinant vector was sequenced to ensure no 
point mutations had been introduced during the cloning process. Restriction maps and 
sequencing details of the vectors generated can be seen in the appendix. 
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Figure 4.3. Cloning of p3xFLAG-CMV-10™-USP12.  
A) USP12 was amplified by PCR from the pDEST FLAG HA USP12 vector (indicated by the product at .10, 000 bp). The 
PCR product was of the correct predicted size of 1100 bp (indicated by the red box). B) The USP12 PCR product was 
ligated into the pCR2.1 vector. Positive transformants were digested with Xba I and Bam HI to release the USP12 
sequence (indicated by the red box). C) The restriction enzyme digested fragment of USP12 was ligated into the 
p3xFLAG-CMV-10™ vector via Xba I and Bam HI restriction sites. Recombinant vectors were assessed by digestion 
with Xba I and Bam HI (indicated by the red box). 
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To test that p3xFLAG-CMV-10™-USP12 construct expressed the FLAG tagged USP12 
protein, it was transiently transfected into COS-7 cells for 48 hours prior to Western 
blot and QPCR analyses to detect the fusion protein product at the protein and RNA 
level, respectively. 
Figure 4.4a shows detection of the 52 kDa FLAG-tagged USP12 by an anti-FLAG 
antibody in the p3xFLAG-CMV-10™-USP12 transfected cells, but not in the mock-
transfected experimental arm (Figure 4.4a, lane 2). Additionally, QPCR analysis of 
USP12 expression showed that 2200-fold more USP12 mRNA was present in the over-
expression sample compared to the non-transfected (NT) control (Figure 4.4b), 
confirming that over-expression of the DUB enzyme is achievable in transient 
transfection experiments that can be verified by Western and QPCR analyses. In order 
to verify protein expression, a range of commercially available anti-USP12 antibodies 
were tested. Unfortunately, none of the antibodies tested detected either endogenous 
or ectopic USP12 (Figure 4.5), hence Western blotting incorporating the anti-FLAG 
antibody was used in all subsequent experiments to detect USP12 over-expression.  
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Figure 4.4. Validation of p3xFLAG-CMV-10™-USP12 over-expression in COS-7 cells.  
COS-7 cells were either non-transfected or transfected with either 1 μg p3xFLAG-CMV-10™-USP12 for 48 hours in 
serum-containing media. A) Cell lysates were analysed by Western blotting for expression of FLAG-tagged USP12 
with anti-FLAG antibodies. α-tubulin was used as a loading control. B) RNA was collected and QPCR analysis for 
USP12 expression performed. 
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Figure 4.5. Anti-USP12 antibodies do not detect endogenous or ectopically-expressed USP12 protein in COS-7 
cells. 
 Lysates from mock or p3xFLAG-CMV-10™-USP12 transfected COS-7 cells were analysed by Western blotting with 
four commercially available anti-USP12 antibodies. Antibodies A and B corresponds to ab89870 (Abcam) and 
SAB1408437 (Sigma-Aldrich), while antibodies C and D are both from Santa Cruz (sc-82072  and sc-82073, 
respectively). α-tubulin was used as a loading control. 
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4.3.1.3 Effect of USP12 over-expression on AR transcriptional activity 
Given that USP12 knockdown reduces PSA protein levels in LNCaP cells as measured by 
ELISA, and reduces both PSA mRNA in LNCaP cells and luciferase expression in the 
LNCaP-7B7 pPSA cells, it was important to assess whether USP12 acted as a co-
activator of AR transcriptional activity in luciferase-based reporter experiments. To this 
end, mammalian expression vectors for AR and USP12, together with an androgen-
responsive luciferase reporter, ARE3, were transiently transfected into COS-7 cells, and 
72 hours later, luciferase activity was assessed. The ARE3 reporter contains a triplicate 
repeat of a consensus androgen response element (ARE) upstream of the luciferase 
gene. Therefore, consistent with the PSA reporter, upon DHT stimulation, the AR binds 
to the synthetic ARE and drives transcription of the luciferase gene. A constitutively 
expressed β-galactosidase (β-gal) reporter was also included in the transfection to act 
as an internal experimental control to measure transfection efficiency. USP12 was 
transfected at increasing quantities between 25-100 ng, represented as +, ++ and +++, 
respectively (Figure 4.6a).  
COS-7 cells were transfected with 100ng of both ARE3 and β-gal  and 50ng of AR in 
serum-containing media. FLAG-tagged USP was transfected at increasing quantities as 
described above. Media was replaced 24 hours post-transfection with steroid-depleted 
media supplemented with (+ DHT) or without (- DHT) 100 nM DHT for an additional 48 
hours. Luciferase activity was assayed and normalised against β-gal activity. Data 
shows the mean of 3 independent experimental repeats and is represented as fold 
change compared to AR only control without DHT treatment (Figure 4.6a). Data was 
analysed for statistical significance using the Student’s t-test, significant data are 
indicated on the figure. 
As expected, stimulation of AR with DHT caused a 5.3-fold increase in luciferase 
activity (P=0.032), which is similar to that reported by other members of the Solid 
Tumour Target Discovery Group (Gaughan et al., 2011) (Figure 4.6a, compare lanes 1 
and 2). Importantly, co-transfection of USP12 increased AR-mediated transcription to 
7.2-fold and 10.2-fold with 25 ng and 50 ng respectively; although a further increase in 
the amount of USP12 to 100 ng did not follow this trend (Figure 4.6a). Unfortunately, 
none of the changes observed with increasing amounts of USP12 were statistically 
significant.  
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Western blot analysis revealed that ectopic AR was expressed in each of the samples 
(Figure 4.6b, upper panel). FLAG-tagged USP12 was not present in the AR only samples 
as expected (Figure 4.6b, middle panel, lanes 1 and 2) but was detected at increasing 
levels with increasing amounts of FLAG-tagged USP12 (Figure 4.6b, middle panel, lanes 
3–8).  
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Figure 4.6. Effect of USP12 over-expression on AR transcriptional activity.  
COS-7 cells were transiently transfected with 50 ng androgen receptor (AR), 100 ng of an AR-responsive ARE3 
luciferase reporter and 100ng of a β-gal reporter. Increasing amounts of p3xFLAG-CMV-10™-USP12 were also 
introduced; 25 ng (+), 50ng (++) and 100ng (+++). 24 hours after transfection cells were grown in steroid-depleted 
media supplemented with (+ DHT) or without (- DHT) 100 nM DHT for a further 48 hours. A) Luciferase reporter 
activity was measured and normalised against β-gal activity. Data is represented as fold change compared to the AR 
only - DHT control. Data is a mean of three independent repeats and error bars represent the standard error of the 
mean of the three replicates. Data was analysed for statistical significance using the Student’s t-test, significant data 
is indicated by an asterisk. B) Luciferase assay samples were analysed by Western blotting with anti-AR and -FLAG 
antibodies to ensure over-expression of ectopically expressed proteins. α-tubulin was used as a loading control. 
Western blots are representative of three independent experimental repeats. 
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4.3.1.4 Effect of USP12C48A mutant on AR transcriptional activity 
An important knowledge gap that remains to be addressed is whether the 
deubiquitinase activity of USP12 is required for AR co-activation. To address this, site-
directed mutagenesis of the p3xFLAG-CMV-10™-USP12 vector was employed to 
convert the catalytic cysteine (Cys) residue at position 48 to an alanine residue C48A 
mutation) using the primers and methodology described in Table 2.2. Cys48 was 
reported previously to be important for the deubiquitinase function of USP12 and that 
mutation of this residue resulted in loss of catalytic activity (Cohn et al., 2009). 
Sequencing of the vector confirmed that the C48A mutation had been introduced, 
generating the vector p3xFLAG-CMV-10™-USP12C48A. 
To assess whether the deubiquitinase activity was required for co-activation of AR 
transcriptional activity, wild-type and mutant USP12 vectors were transiently 
transfected into COS-7 cells as above with an AR mammalian expression vector and 
both ARE3 and β-gal reporters. 50 ng of either wild-type or mutant USP12 vectors 
were used in this experiment as AR co-activation by the wild-type DUB enzyme is 
maximal at this amount (Figure 4.6), hence potential differences between co-activation 
ability of the wild-type versus deubiquitinase-dead mutant would be more 
pronounced. Data was analysed for statistical significance using the Student’s t-test, 
significant data are indicated on the figure. 
In keeping with experiments in Figure 4.6, AR activity was induced by addition of DHT, 
although the absolute fold induction (13.1-fold) was markedly larger than the previous 
experiment which may be due to a lower total amount of transfected DNA into the 
cells (Figure 4.7, compare lanes 1 and 2). Androgen-dependent AR activation was 
further increased, albeit non-significantly, to 20.7-fold by co-transfection of wild-type 
USP12, confirming the previous data (Figure 4.7, lane 4). Interestingly, ectopic 
expression of the USP12C48A mutant potentiated a 15.1-fold increase in AR activity over 
that of AR alone, but this increase was not as great as with wild type USP12. The 
difference between AR co-activation by wild type USP12 and USP12C48A was not 
significant, however it does suggest that USP12 deubiquitinase activity is at least in 
part required for AR co-activation (Figure 4.7, compare lanes 4 and 6). 
Western blot analysis revealed that ectopic AR was again expressed in each of the 
samples (Figure 3.7b, upper panel). FLAG-tagged USP12 was detected only in the 
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samples with FLAG-tagged wild-type or mutant USP12 over-expression although at a 
lower level than previously observed (Figure 4.7b). 
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Figure 4.7. Effect of the USP12C48A mutant on AR transcriptional activity.  
COS-7 cells were transfected with 50 ng androgen receptor (AR), 100 ng of both ARE3 luciferase and β-gal reporters. 
50ng of wild type (WT) or mutant (C48A) USP12 expression vectors were also introduced. 24 hours after transfection, 
media was replaced with steroid-depleted media supplemented with (+ DHT) or without (- DHT) 100 nM DHT for a 
further 48 hours. A) Luciferase reporter activity was measured and normalised against β-gal activity. Data is 
represented as fold change compared to the AR only - DHT control. Data is a mean of three independent repeats and 
error bars represent the standard error of the mean of the three replicates. Data was analysed for statistical 
significance using the Student’s t-test, significant data is indicated by an asterisk. B) Luciferase assay samples were 
analysed by Western blotting with anti-AR and -FLAG antibodies to ensure over-expression of ectopically expressed 
proteins. α-tubulin was used as a loading control. Western blots are representative of three independent 
experimental repeats.  
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4.3.2 The effect of USP12 knockdown on AR nuclear translocation 
One potential mechanism for USP12-mediated AR co-activation is enhancement of 
nuclear import of the receptor. To address whether USP12 facilitates ligand-induced 
AR nuclear shuttling, cytoplasmic-nuclear extractions were performed in LNCaP cells 
depleted of USP12 by siRNA and AR cellular distribution analysed by Western blotting. 
LNCaP cells were transiently transfected with either SCR or USP12 siRNA for 48 hours 
in steroid-depleted media prior to 100 nM DHT stimulation over a time-course of 0-8 
hours. Cells were harvested, cytoplasmic-nuclear extractions performed and both 
fractions analysed by Western blotting using antibodies raised against AR, and both 
PARP1 and α-tubulin as nuclear and cytoplasmic controls, respectively. Figure 4.8 
shows representative Western blots from two individual experimental repeats. Figure 
3.9 shows the densitometry analysis of the two experimental repeats and is presented 
as the mean relative protein expression normalised to the respective loading control. 
Data was analysed for statistical significance using 2-way ANOVA, however no data 
points were found to be significant. 
As expected, in the SCR control LNCaP cells, nuclear translocation of the AR occurred 
within 30 minutes of DHT stimulation and increased markedly by 8 hour ligand 
treatment, while cytoplasmic levels of receptor were unchanged (Figure 4.8a and b, 
upper panel). The dramatic fluctuation of AR levels in the nuclear fraction of the SCR 
control between 1 and 2 hours DHT treatment can be accounted for, in part, by 
unequal loading shown by the PARP-1 loading control (Figure 4.8b, lower panel, 
compare lane 3 with lanes 4 and 5), further repeats of this experiment and more equal 
loading of the Western blots would rectify this.  
The reduction in cytoplasmic AR in the USP12-depleted LNCaP cells over the duration 
of the DHT time-course, can be accounted for by reduced total protein loading as 
evidenced by lower α-tubulin levels, particularly at the 4 and 8 hour time-points 
(Figure 4.8c, upper and middle panels). Comparing nuclear AR levels between SCR and 
USP12 knockdown samples indicated an increased level of the receptor in un-
stimulated USP12-depleted cells that increased further after 30 minutes androgen 
treatment (Figure 4.8b and d, upper panels, lane 1 and 2). In addition, in contrast to 
the control, nuclear AR levels after 8 hour DHT treatment in the USP12-depleted cells 
was markedly lower, suggesting a potential role of the deubiquitinase in nuclear export 
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of the receptor, or stabilising active AR in the nucleus (Figure 4.8d, upper panel, lane 
6). Importantly, no cytoplasmic contamination was observed in the nuclear fraction 
nor was any nuclear contamination observed in the cytoplasmic fraction (Figure 4.8, 
middle and lower panels). 
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Figure 4.8 Effect of USP12 knockdown on AR translocation to the nucleus upon DHT stimulation.  
LNCaP cells were subject to knockdown of USP12 for 48 hours in steroid-depleted media. Scrambled (SCR) siRNA was 
used as a negative control.100 nM DHT was applied to cells for up to 8 hours. Cells were harvested and cytoplasmic 
and nuclear extractions performed. AR movement was analysed by Western blotting with anti-AR antibodies. α-
tubulin and PARP-1 were used as cytoplasmic and nuclear controls. Western blots are representative of two 
independent experimental repeats. A) The effect of SCR siRNA on cytoplasmic AR protein levels over 8 hours DHT 
treatment. B) The effect of SCR siRNA on nuclear AR protein levels over 8 hours DHT treatment. C) The effect of 
USP12 knockdown on cytoplasmic AR protein levels over 8 hours DHT treatment. D) The effect of USP12 knockdown 
on nuclear AR protein levels over 8 hours DHT treatment. 
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Figure 4.9. Densitometry analysis of the effect of USP12 knockdown on AR translocation to the nucleus upon DHT 
stimulation. 
Western blot data from the cytoplasmic and nuclear extraction experiments was analysed using the Quantity one 
programme on the GelDoc™ system. Data for androgen receptor (AR) protein levels were normalised to the 
respective loading control data, α-tubulin in the cytoplasmic samples and PARP1 in the nuclear samples. Data is 
presented as the mean relative expression of two independent experimental repeats. Error bars represent the 
standard error. A) The effect of USP12 knockdown on cytoplasmic AR protein levels over 8 hours DHT treatment. B) 
The effect of USP12 knockdown on nuclear AR protein levels over 8 hours DHT treatment. 
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4.3.3 USP12 knockdown reduces AR recruitment to target gene promoters 
USP12 has been linked directly to transcription by its function in histone 
deubiquitination. Transcription of developmentally important genes in Xenopus laevis 
was affected by USP12 deubiquitination of histones H2A and H2B (Joo et al., 2011). 
Furthermore, given that many AR co-regulators, such as SET9, p300 and TIP60, also 
affect histone post-translational modifications and regulate AR association at target 
gene promoters (Gaughan et al., 2002; Gaughan et al., 2005; Chmelar et al., 2007; 
Gaughan et al., 2011), it was hypothesised that given that USP12 depletion reduced 
AR-target gene expression, USP12 may facilitate AR association with its target gene 
promoter elements. To assess whether USP12 knockdown affects AR recruitment to 
androgen-responsive genes, chromatin immunoprecipitation (ChIP) was performed 
using an anti-AR antibody in LNCaP cells subject to SCR or USP12 knockdown for 72 
hours in steroid depleted media prior to 120 minute DHT stimulation. SCR siRNA was 
used as a negative control. Cells were fixed, lysed and subjected to ChIP as described in 
Chapter 2.7. Resultant DNA was subject to QPCR using primers specific to the AREs 
within the proximal promoter (ARE I) and enhancer (ARE III) of the PSA cis-regulatory 
elements. Results are the mean of three independent repeats of the entire ChIP 
procedure, including triplicate PCR reactions per sample, per ChIP, and are 
represented as percentage of input. Data was analysed for statistical significance using 
the Student’s t-test, significant data are indicated on the figure. This work was 
performed by Dr Luke Gaughan. 
Figure 4.10a displays the result for AR recruitment to ARE I of the proximal PSA 
promoter. As expected, AR was absent at ARE I without DHT treatment in the SCR 
control, and in response to hormone, showed an approximate 5-fold increase in 
promoter association (Figure 4.10a, compare lanes 1 and 2), although this was not 
statistically significant possibly due to intra-experimental variation. Upon USP12 
depletion, there was a slight increase in AR association to the inactive PSA promoter 
(Figure 4.10a, compare lanes 1 and 3), but this is not statistically significant, while DHT 
treatment failed to facilitate AR promoter binding to ARE I, although, again this was 
not statistically significant, suggesting USP12 may not be important for regulating 
receptor recruitment to the proximal PSA promoter (Figure 4.10a, compare lanes 2 and 
4). 
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Figure 4.10b shows the recruitment of AR to ARE III of the PSA promoter. As reported 
previously DHT-stimulated AR recruitment to the enhancer was greater than observed 
at the proximal ARE I region (Shang et al., 2002; Gaughan et al., 2011), with an 
approximate 6.5-fold increase over IgG background levels compared to 2.5-fold, 
respectively (compare Figure 4.10a lane2 with Figure 4.10b lane 2). AR association at 
the ARE III element was 5.9-fold greater in the androgen-stimulated SCR control than 
those without stimulation, which was statistically significant (P=0.0495) (Figure 4.10b, 
compare lanes 1 and 2). Importantly, consistent with data from ARE I, USP12 
knockdown reduced androgen-stimulated AR recruitment to ARE III by approximately 
60%, indicating that USP12 may potentiate AR-promoter association at androgen-
responsive genes, although this decrease was not significant (Figure 4.10b, compare 
lanes 2 and 4). Given that total AR levels do not change in response to USP12 
knockdown, the effect of depletion of the deubiquitinase on receptor-chromatin 
association is not a consequence of reduced AR protein levels. However, to provide a 
more robust validation for the effects of USP12 knockdown in AR-target gene 
association, it would be necessary to assess AR recruitment to additional androgen-
responsive genes, such as KLK2 and TMPRSS2. 
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Figure 4.10. Effect of USP12 knockdown on AR recruitment to androgen-response elements upstream of the PSA 
gene.  
LNCaP cells were subjected to USP12 knockdown for 72 hours in steroid-depleted media. 10 nM DHT was applied for 
120 minutes before cells were harvested and ChIP for AR or control IgG performed. Scrambled (SCR) siRNA was used 
as a negative control. Data is represented as percentage of input and is the mean of three independent experimental 
repeats. Error bars show the standard error of the mean of the three replicates. Data was analysed for statistical 
significance using the Student’s t-test, significant data is indicated by an asterisk. A) The effect of USP12 knockdown 
on recruitment of AR to the AREI of the PSA promoter. B) The effect of USP12 knockdown on recruitment of AR to the 
AREIII of the PSA enhancer. This work was performed by Dr Luke Gaughan. 
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4.3.4 USP12 interacts with the AR 
The above data suggest a role for USP12 in AR gene transcription as a receptor co-
activator. It is intriguing to speculate that USP12 and the AR interact in CaP cells, given 
that USP12 impacts on AR-mediated transcription and chromatin association. 
Presently, there is no evidence to suggest that USP12 interacts with any members of 
the steroid hormone receptor family thus providing a novel angle of study that may 
strengthen our hypothesis that USP12 is a genuine co-regulator of the AR. 
To address this, FLAG-tagged USP12 and AR were over-expressed in COS-7 cells in 
serum-containing media for 48 hours prior to lysis and immunoprecipitation with 
either AR or FLAG antibodies. 10% of the total cell lysate was taken as an input to 
verify that the ectopically expressed proteins were indeed over-expressed. The 
‘sample’ underwent the entire IP procedure and was incubated with anti-AR antibodies 
whilst the ‘extract’ acted as a control for non-specific interactions between proteins in 
the cell lysate and the protein-G sepharose, and thus did not receive antibody. 
Resultant IP samples were analysed by SDS-PAGE and Western blotting using anti-AR 
and anti-FLAG antibodies. 
As shown in Figure 4.11, the input sample confirmed over-expression of both AR and 
FLAG-tagged USP12, as detected by AR and FLAG antibodies, respectively (Figure 4.11, 
upper and lower panels, lane 1). IP using the anti-AR antibody successfully immuno-
precipitated the receptor (Figure 4.11, lower panel, lane 2) and immuno-blotting with 
an anti-FLAG antibody revealed the presence of FLAG-tagged USP12 exclusively in the 
AR immuno-complex, indicating that the receptor and USP12 interact (Figure 4.11, 
upper panel, lane 2). Importantly, no non-specific protein or antibody binding was 
observed in the extract or antibody only controls, respectively (Figure 4.11, upper and 
lower panels, lanes 3 and 4). To confirm this finding in a more physiological setting, it 
would be beneficial to repeat this experiment using endogenously expressed AR and 
USP12. However, due to difficulties with the currently available USP12 antibodies for 
Western analysis, as described in Figure 4.5, this is currently unachievable. 
  
148 
 
 
 
 
 
 
 
 
 
Figure 4.11. USP12 interacts with AR in COS-7 cells.  
COS-7 cells were transfected with androgen receptor (AR) and FLAG-tagged USP12 mammalian expression vectors 
for 48 hours in serum-containing media. Cells were harvested and immunoprecipitation (IP) performed using an anti-
AR antibody. Inputs (IN) were taken before IP to ensure that both proteins were over-expressed. Samples (S) were 
incubated with anti-AR antibodies before incubation with PGS, while extract (EX) samples were incubated with PGS 
only. The antibody only control (ab) contained only lysis buffer mock immuno-precipitated with anti-AR antibodies. 
Western blots  of the resultant AR immuno-complexes and input samples using anti-AR and anti-FLAG antibodies are 
representative of three independent experimental repeats. 
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4.3.5 Phenotypic effects of USP12 knockdown in LNCaP cells 
4.3.5.1 Effect of USP12 knockdown on LNCaP cell proliferation/viability 
In Figure 3.12 a reduction in the total amount of protein present after USP12 
knockdown in LNCaP cells, as demonstrated by an α-tubulin Western blot was shown, 
suggesting that the proliferation and/or viability of LNCaP cells is potentially reduced 
upon USP12 depletion. Given that USP12 facilitates AR activity in LNCaP cells, as 
demonstrated in Figure 4.1, and that the AR is pro-proliferative, it was hypothesised 
that USP12 may have a role in driving CaP cell proliferation or protecting CaP cells from 
apoptosis. To investigate this, sulphorhodamine B (SRB) cell proliferation assays were 
employed in LNCaP cells previously subjected to SCR or USP12 siRNA knockdown for 96 
hours in serum-containing media prior to SRB staining. Additionally, AR siRNA 
knockdown was included as a positive control for effects on androgen-dependent cell 
proliferation/viability. Data presented in Figure 4.12 is the mean of three independent 
repeats and is represented as fold change compared to the SCR control. Data was 
analysed for statistical significance using the Student’s t-test, significant data are 
indicated on the figure. 
As shown in Figure 4.12, AR knockdown significantly reduced LNCaP cell 
proliferation/viability by approximately 30% compared to SCR control (P=0.0011), and 
is consistent with previous studies (Yang et al., 2005). USP12 knockdown resulted in an 
approximate 40% reduction in LNCaP cells proliferation/viability compared to the SCR 
control, albeit failing to reach significance due to some variability in experimental 
repeats (Figure 4.12). Therefore, USP12, potentially via the AR signalling cascade, 
regulates the growth rate and/or the cell death of LNCaP cells. Further investigation of 
the effect of combined AR and USP12 knockdown would elucidate whether the affect 
seen with USP12 knockdown are due to the direct effect on AR transcriptional activity. 
Furthermore, analysis of the effect of USP12 depletion on both AR positive and 
negative cell lines would strengthen the hypothesis that USP12 knockdown causes a 
reduction in cell proliferation and viability due to its effect on AR signalling. 
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Figure 4.12. Effect of USP12 knockdown on LNCaP cell proliferation/viability.  
LNCaP cells were subjected to USP12 and androgen receptor (AR) knockdown for a total of 96 hours in serum-
containing media and cell proliferation/viability was compared to scrambled siRNA (SCR) control. Data is 
represented as mean fold change compared to the SCR control of three independent experimental repeats. Error 
bars represent the standard error between the three replicates. Data was analysed for statistical significance using 
the Student’s t-test, significant data is indicated by an asterisk. 
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4.3.5.2 Effect of USP12 knockdown on LNCaP cell cycle 
Due to the effects of USP12 knockdown observed in the SRB assays, the phenotypic 
effect of USP12 knockdown on cell cycle profile was assessed. LNCaP cells were subject 
to USP12 depletion for 48 hours in serum-containing media prior to propidium iodide 
(PI) staining and flow cytometry analysis. Data represents the mean of three 
independent repeats and each cell cycle phase is expressed as a percentage of the 
total number of cells analysed. SCR siRNA was used as a negative control. 
The cell cycle profiles for each siRNA are shown in Figure 4.13.  A graphical overview of 
the cell cycle profiles and the effect of USP12 knockdown on the individual phases of 
the cell cycle are shown in Figure 4.14 and Figure 4.15 respectively. The percentage of 
cells in each phase of the cell cycle is summarised in Table 4.2. Data in Figure 4.15 was 
analysed for statistical significance using the Student’s t-test, significant data are 
indicated on the figure. 
The SCR control, representing the ‘normal’ LNCaP cell cycle, demonstrated that the 
largest proportion of cells was in G1 with 70.43% of the population; 6.55% were in 
subG1; 10.36% were in S-phase and 12.66% were in G2/M phase of the cell cycle 
(Figure 4.13a; Table 4.2). As expected, AR knockdown caused significant G1 arrest 
(P=0.026) with reductions in both S and G2/M phases (P=0.0014, 0.0054, respectively), 
in-line with previously published data (Kokontis et al., 1998; Feng et al., 2011) (Figure 
4.13b; Figure 4.15b, c and d, lane 2). USP12 knockdown however, had no effect on G1 
phase but did have a significant reductive effect on both S and G2/M phases similar to 
AR knockdown (P=0.0035, 0.0137 respectively), (Figure 4.13c; Figure 4.15c and d, lane 
3), these data were consistent with the effects of USP12 depletion in the SRB assays 
(Figure 4.12). Interestingly, knockdown of the USP12 enzyme caused an accumulation 
of cells in the subG1 phase of the cell cycle, and although this affect was not significant 
it suggests that USP12 knockdown causes some degree of apoptosis (Figure 4.15a, lane 
3).  
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Figure 4.13. Effect of USP12 knockdown on the cell cycle in LNCaP cells. 
LNCaP cells were subjected to USP12 depletion in serum-containing media for 48 hours. Scrambled (SCR) and 
androgen receptor (AR) siRNA were used as negative and positive controls respectively. Cells were harvested and 
stained with propidium iodide (PI) before flow cytometry analysis. Cell cycle profiles are representative of three 
independent experimental repeats. Markers indicate the individual phases of the cell cycle; subG1 (M1), G1 (M2), S 
(G3) and G2/M (M4).A) The effect of SCR siRNA on the cell cycle of LNCaP cells. B) The effect of AR siRNA on the cell 
cycle of LNCaP cells. C) The effect of USP12 siRNA on the cell cycle of LNCaP cells.  
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Figure 4.14. Overall profile of the effect of USP12 knockdown on the cell cycle of LNCaP cells.  
Graphical representation of the cell cycle profiles from the flow cytometry analysis. Data represents the mean of 
three independent repeats and is expressed as percentage of cells in each cell cycle phase. 
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Figure 4.15. Effect of USP12 knockdown on individual phases of the cell cycle in LNCaP cells.  
Data from the flow cytometry analysis was analysed as individual cell cycle phases. Data is from three independent 
repeats and is represented as percentage of cells in each phase. Error bars show the standard error between each 
experimental replicate. Data was analysed for statistical significance using the Student’s t-test, significant data is 
indicated by an asterisk. A) The percentage of cells in the SubG1 population. B) The percentage of cells in the G1 
population. C) The percentage of cells in the S population. D) The percentage of cells in the G2/M population. 
 
 
Table 4.2 Effect of USP12 knockdown on the individual phases of the cell cycle phase in LNCaP cells.  
Numerical representation of the percentages of cells in each cell cycle phase as determined by flow cytometry 
analysis. Data is presented as the mean of three independent repeats ± standard error.  
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4.3.5.3 Effect of USP12 knockdown on LNCaP cell apoptosis 
The increase in subG1 of the LNCaP cell cycle with USP12 knockdown suggested an 
increase in cell death that prompted further investigation. To do this, a flow 
cytometry-based approach to assess the specific apoptosis marker cleaved caspase-3 
was utilised. 
LNCaP cells were subjected to 96 hours of USP12 knockdown in serum-containing 
media. SCR siRNA was again used as a negative control. After 48 hours knockdown, 
cells were treated with 200 nM doxorubicin for a further 48 hours. At this doxorubicin 
concentration, up to 50% of the cell population are expected to enter apoptosis 
(Shaheen et al., 2011). Therefore in cells subjected to SCR siRNA, treatment with 
doxorubicin acts as a positive control. Data was analysed for statistical significance 
using the Student’s t-test, significant data are indicated on the figure. 
As shown in Figure 4.16, the SCR control population contained approximately 8.89% 
apoptotic cells which increased significantly upon treatment with doxorubicin to 
47.93% (P=0.0019) (Figure 4.16, compare lanes 1 and 2). AR knockdown marginally 
increased the percentage of apoptotic cells to 11.79% which agrees with the cell cycle 
data (Figure 4.16, compare lanes 1 and 3). Following doxorubicin treatment, the 
percentage of apoptotic cells increased significantly increased in the AR knockdown 
cells to 34.47% (P=0.0051) (Figure 4.16, compare lanes 3 and 4). AR knockdown 
appeared to protect LNCaP cells from the effects of doxorubicin compared to the SCR 
control treated with doxorubicin, although this result was not significant (Figure 4.16, 
compare lanes 2 and 4).  
Consistent with the subG1 cell cycle analysis, USP12 knockdown, although not causing 
as dramatic an affect as the SCR + doxorubicin control, did significantly increase the 
apoptotic population to 17.28% (P=0.0408) (Figure 4.16, compare lanes 1 and 5). 
Interestingly, USP12 knockdown combined with doxorubicin treatment had a dramatic 
effect on apoptosis increasing the percentage of cells to 82.43% (P<0.0001) (Figure 
4.16, compare lanes 5 and 6). This increase was approximately 9-fold above the SCR 
control (P= 0.0005) (Figure 4.16, compare lanes 1 and 6) and nearly 2-fold above the 
SCR control treated with doxorubicin (Figure 4.16, compare lanes 2 and 6). 
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Figure 4.16. Effect of USP12 knockdown on apoptosis in LNCaP cells. 
 LNCaP cells were subjected to USP12 and androgen receptor (AR) depletion in serum-containing media for a total of 
96 hours. Scrambled (SCR) siRNA was used as a negative control. Following 48 hours knockdown, cells were 
subjected to treatment with 200 nM doxorubicin (DoxR) for a further 48 hours. Cells were harvested and stained 
with fluorescent anti-cleaved caspase-3 antibodies before undergoing flow cytometry analysis. Data is the mean of 
three independent repeats and is represented as the percentage of total analysed cells with cleaved caspase 3. Error 
bars represent the standard error. Data was analysed for statistical significance using the Student’s t-test, significant 
data is indicated by an asterisk. 
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Considering that the cell cycle data was obtained after 48 hours of USP12 knockdown 
and the apoptosis data was collected after 96 hours knockdown, additional cell cycle 
analysis of LNCaP cells after 96 hours USP12 depletion was performed to make it 
consistent with the caspase-3 experiments. Unfortunately, due to time constraints, 
data is restricted to one experimental repeat and hence would need to be repeated in 
order to draw statistically relevant conclusions from the data. Table 4.3 shows a 
summary of the percentage of cells in each phase if the cell cycle.  
Firstly, the data demonstrated that 96 hours knockdown increases the percentage of 
cells in subG1 in all experimental arms when compared to 48 hours knockdown (Figure 
4.18 and Figure 4.14; Table 4.4). As shown in Figure 4.18, doxorubicin treatment for 48 
hours increased the population of SCR cells in the subG1 phase of the cell cycle from 
9.14% in untreated cells to 22.24% which agrees, in part with the caspase-3 data 
(Figure 4.18, compare lanes 1 and 2). Longer knockdown of AR increased the 
percentage of cells in subG1 from 6.77% after 48 hours to 14.77% post-96 hours AR 
depletion at the expense of cells in the G1 phase of the cell cycle (Figure 4.18, lane 3; 
Table 4.4). Treatment of these cells with doxorubicin again increased the subG1 
population (Figure 4.18, compare lanes 3 and 4). Remarkably, USP12 knockdown had 
the greatest effect on the subG1 cell population as evidenced by an increase from 
9.14% in the SCR control to 54.26% (Figure 4.18, compare lanes 1 and 5) and this was 
increased further to 88.08% in USP12 knockdown cells treated with doxorubicin 
(Figure 4.18, compare lane 5 and 6).  
USP12 depletion caused the greatest increase in LNCaP apoptosis between the 48 and 
96 hour experiments (Table 4.4). This large increase could be due to a prolonged effect 
of USP12 depletion on AR function or simply due to toxicity of prolonged depletion, 
although a total of 120 hours knockdown was utilised in the validation time-course 
experiments and was achieved with minimal toxic effects (Figure 3.10and Figure 3.15). 
Importantly, PI staining only provides an approximate representation of apoptotic cells 
as necrotic and senescent cells are also detected as part of the subG1 population, 
therefore an increase in these other populations may have caused the dis-proportional 
increase in cells detected. Caspase-3 flow cytometry analysis is a more robust and 
specific assay, allowing definite identification of apoptotic LNCaP cells. Therefore, 
158 
 
further repeats of the PI flow cytometry would assist in strengthening the evidence for 
an effect of USP12 knockdown on LNCaP apoptosis. 
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Figure 4.17. Effect of 96 hours USP12 knockdown on the cell cycle in LNCaP cells. 
LNCaP cells were subjected to USP12 and androgen receptor (AR) depletion in serum-containing media for a total of 
96 hours. Scrambled (SCR) siRNA was used as a negative control. Following 48 hours knockdown, cells were 
subjected to treatment with 200 nM doxorubicin (DoxR) for a further 48 hours. Cells were harvested and stained 
with PI before flow cytometry analysis. Cell cycle profiles are representative of three independent experimental 
repeats. Markers indicate the individual phases of the cell cycle; subG1 (M1), G1 (M2), S (G3) and G2/M (M4). A) The 
effect of SCR siRNA with (+DoxR) and without (-DoxR) doxorubicin treatment on the cell cycle of LNCaP cells. B) The 
effect of AR siRNA with (+DoxR) and without (-DoxR) doxorubicin treatment on the cell cycle of LNCaP cells. C) The 
effect of USP12 siRNA with (+DoxR) and without (-DoxR) doxorubicin treatment on the cell cycle of LNCaP cells. 
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Figure 4.18. Overall profile of the effect of 96 hours USP12 knockdown on the cell cycle of LNCaP cells.  
Graphical representation of the cell cycle profiles from the flow cytometry analysis. Data represents the mean of 
three independent repeats and is expressed as percentage of cells in each cell cycle phase. 
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Table 4.3. Effect of 96 hours USP12 knockdown on the individual phases of the cell cycle phase in LNCaP cells. 
 Numerical representation of the percentages of cells in each cell cycle phase as determined by flow cytometry. Data 
is from one experimental repeat. 
 
 
Table 4.4. Comparison of the effect of48 and 96 hours USP12 knockdown on subG1 population in LNCaP cells.  
The percentage of LNCaP cells in the subG1 population as measured by flow cytometry for both 48 hours and 96 
hours siRNA knockdown experiments. 
  
162 
 
In an attempt to confirm these data, Western blot analysis of another marker of 
apoptosis, cleaved PARP-1, was performed on lysates of LNCaP cells treated as 
described above. Figure 4.19 shows the results a Western blot for cleaved PARP-1 and 
α-tubulin as a loading control. Due to time constraints this data is from one 
experimental repeat and would require further repeats. 
A proportion of cleaved PARP-1 was present in the SCR control without doxorubicin 
treatment, consistent with the cleaved caspase-3 data (Figure 4.19, upper panel, lane 
1). Cleaved PARP-1 levels only marginally increased upon doxorubicin treatment, 
although the level of α-tubulin was greatly diminished in this sample, suggesting a 
large proportion of the cells had undergone cell death (Figure 4.19, upper and lower 
panels, compare lane 1 and 2). In contrast to AR knockdown, that showed no change in 
cleaved PARP-1 levels (Figure 4.19, upper panel, compare lanes 1 and 3), USP12 
depletion caused an increase in cleaved PARP-1 that is likely to be more enhanced with 
equalised protein loading (Figure 4.19, upper and lower panels, compare lanes 1 and 
4). Unfortunately, AR and USP12 knockdown samples treated with doxorubicin failed 
to yield a protein band within the loading control suggesting that a greater proportion 
of cells had undergone apoptosis than in the SCR + doxorubicin control (data not 
shown).  
In conclusion taking all of the flow cytometry, caspase-3 and cleaved PARP-1 analyses 
together, USP12 knockdown increases LNCaP cell apoptosis suggesting it may 
constitute a potential target for CaP therapy. Additionally, combination of USP12 
knockdown and chemotherapeutic agents may provide a further means of treatment 
in CaP although this requires more extensive investigation.  
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Figure 4.19. Effect of USP12 knockdown on levels of the apoptosis marker cleaved PARP-1 in LNCaP cells.  
LNCaP cells were subjected to USP12 and androgen receptor (AR) depletion in serum-containing media for a total of 
96 hours. Scrambled (SCR) siRNA was used as a negative control. Following 48 hours knockdown, cells were 
subjected to treatment with 200 nM doxorubicin (DoxR) for a further 48 hours. Cell lysates were collected and 
analysed by Western blot using anti-cleaved PARP-1 and α-tubulin antibodies. Data is from one experimental 
repeat.  
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4.4 Discussion 
USP12 was identified by the Solid Tumour Target Discovery Group, Newcastle 
University, as a regulator of AR activity using an siRNA library screen to investigate the 
effect of DUB enzyme knockdown on AR function in LNCaP cells. Depletion of USP12 
reduced the mRNA expression of all AR-regulated genes studied, including PSA, 
TMPRSS2 and KLK2 (Figure 3.10 and Figure 3.15), without affecting AR levels. It was 
therefore hypothesised that USP12 acts as a co-activator of AR transcriptional activity. 
To investigate this further, luciferase-based reporter assays in multiple cell lines was 
employed, including the LNCaP-7B7 pPSA luciferase cell line that contains an 
integrated AR-responsive PSA promoter upstream from the luciferase gene thus 
providing an informative read-out for receptor activity. Knockdown of USP12 in the 
LNCaP-7B7 pPSA luc cell line confirmed that depletion of USP12 did indeed have a 
negative effect on AR transcriptional activity (Figure 4.1), consistent with the role of 
USP12 as an AR co-activator. In support of this notion, increased amounts of 
ectopically expressed USP12 enhanced AR function in COS-7 cells upon the androgen-
responsive ARE3 luciferase reporter (Figure 4.6); although it was noted that at higher 
amounts of USP12 (100 ng) no AR co-activation was observed. This effect was possibly 
due to overloading of the system with ectopically expressed plasmids that may have 
caused transcriptional “squelching” or may have interfered with the normal 
stoichiometry of the USP12 or AR protein complexes. 
Recently USP13 was reported to regulate the stability of the E3 ligase Siah2 though a 
non-catalytically-dependent mechanism (Scortegagna et al., 2011). This is not the case 
for the majority of DUB enzymes, however, with most requiring the catalytic triad 
residues of histidine, cysteine and aspartic acid to carry out their function. USP2a, for 
example, requires its DUB activity to protect fatty acid synthase (FAS) from 
degradation. Similarly, conversion of cysteine 221 to alanine in USP21 to alanine 
generates an enzymatically dead DUB that no longer inhibits TNFα-mediated NFκB 
activation in luciferase reporter assays (Xu et al., 2010). It was therefore important to 
assess if mutation of the catalytic cysteine at position 48 in USP12 was important for 
co-activation of the AR. Due to the conserved nature of the USP catalytic triad residues 
and their surrounding sequence, the catalytic Cys48 residue of USP12 at position 48 
provided an ideal candidate for mutation to produce a deubiquitinase-dead USP12 
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enzyme. In addition, mutation of Cys48 had previously been shown to cause loss of 
USP12 deubiquitinase activity towards the synthetic ubiquitin-AMC substrate (Cohn et 
al., 2009). Importantly, in luciferase-based AR reporter experiments, the USP12C48A 
mutant dampened the AR co-activation capacity of USP12 to near basal levels, 
although there was considerable variation in the data-set as evidenced by large error 
bars in each experimental arm (Figure 4.7). Additional repeats, and utilising other 
androgen-dependent reporters in similar experiments, will be important to confirm 
the requirement of the catalytic activity of USP12 in stimulating AR activity. 
To further investigate the function of USP12 on AR-regulated transcription, it was 
important to assess whether USP12 facilitated movement of the receptor into the 
nucleus upon DHT stimulation and hence increase the transcriptional response. 
Overall, no dramatic effect of USP12 depletion on AR movement was observed other 
than the surprising observation that more AR appeared to be present in the nucleus 
before DHT stimulation, and that nuclear AR levels declined at 6 and 8 hours DHT 
treatment compared to SCR controls (Figure 4.8). Interestingly, MDM2-mediated 
mono-ubiquitination of p53 has been shown to cause nuclear export of p53 (Li et al., 
2003). An in-frame fusion of ubiquitin to p53 in H1299 p53-null lung carcinoma cells 
was shown to be sufficient to drive nuclear export and MDM2 was shown to be critical 
in this process (Li et al., 2003). Similarly, mono-ubiquitination of the human DCN1-like 
protein (DCNL1) was also shown to be sufficient for its nuclear export by over-
expression of a DCNL1-ubiquitin fusion protein (Wu et al., 2011). The outcome of these 
studies could be extrapolated to suggest that depletion of USP12 from LNCaP cells 
could allow ubiquitination of AR leading to its nuclear export, although further studies 
would have to be performed in order to confirm this. Furthermore, mono-
ubiquitination of AR has not been studied in cell lines and it would be interesting to 
generate an AR-ubiquitin fusion protein to observe the effects on cellular localisation 
and see if the effects of USP12 knockdown are replicated. 
To address the question of whether AR-chromatin association is regulated by USP12, 
and hence may be a reason for enhanced AR-mediated transcription, ChIP experiments 
were performed in LNCaP cells after USP12 depletion (Figure 4.10). It was observed 
that knockdown of USP12 reduced the recruitment of AR to both AREs within the 
proximal promoter (ARE I) and the distal enhancer (ARE III) of the PSA gene, with the 
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greatest effect being observed for ARE III. Other AR co-activators including Ku70 and 
Ku80 have been shown to be important for AR transcriptional activity with both 
proteins being recruited to AR responsive promoters but without affecting nuclear 
translocation of AR due to their nuclear functionality (Mayeur et al., 2005). To support 
this, USP12 has also been postulated to be a nuclear protein due to the presence of 
nuclear localisation signals within its coding sequence (Hansen-Hagge et al., 1998). 
Unfortunately, due to the lack of effective USP12 antibodies and failure to optimise 
the use of anti-FLAG antibodies for immuno-fluorescence this could not be confirmed, 
but remains an important point to be addressed in the future. Interestingly, the USP10 
protein affects the function of p53 in the nucleus, although it was found to localise 
mainly to the cytoplasm with only a small fraction translocating to the nucleus upon 
DNA damage (Yuan et al., 2010). This may also be the case for USP12, with certain 
stimuli such as androgen treatment causing movement. Equally, production of USP12 
antibodies would help to elucidate if the enzyme itself is recruited to AR responsive 
promoters. 
Interplay between multiple post-translational modifications on histones, including 
acetylation, methylation and ubiquitination, provides a dynamic code for gene 
transcription. Deubiquitination of histone H2A has an impact on hyper-acetylation of 
histones in nucleosomes as well as leading to phosphorylation of the linker histone H1. 
This phosphorylation event results in dissociation of histone H1, which is generally an 
indicator of transcriptional activation (Zhu et al., 2007a). Interestingly, in a few cases 
H1 dissociation is involved in transcriptional repression and histone H2A 
deubiquitination also shares this dual role in transcriptional regulation (Zhu et al., 
2007a). Nakagawa et al., reported that histone H2A deubiquitination by USP21 
promoted di- and tri-methylation of histone H3 lysine 4 (H3K4), possibly through 
increasing substrate specificity of the involved methylases or access to the methyl 
target, leading to intiation of transcription (Nakagawa et al., 2008). Conversely, 
ubiquitination of histone H2A K119 coupled with methylation of both K9 and K27 of 
histone H3, have been implicated in the silencing of early developmental genes and 
inactivation of the X chromosome (Shilatifard, 2006). Dover et al., identified the 
ubiquitin conjugating E2 enzyme Rad6 as a gene involved in the methylation of histone 
H3K4 by SET1 in S. cerevisiae (Dover et al., 2002). Rad6 is involved in mono-
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ubiquitination of histone H2B K123 mediated by the E3 ubiquitin ligase Bre1. 
Mutations affecting the interaction and transfer of ubiquitin between Rad6 and Bre1 
resulted in loss of methylation of histone H3K4 (Wood et al., 2003). Joo et al., 
described USP12 as a histone H2A and H2B specific DUB and showed that knockdown 
of USP12 promoted the retention of ubiquitinated histone H2B, whilst histone H2A 
ubiquitination was lost, at the promoter region of the Xbra gene thereby reducing 
expression in Xenopus (Joo et al., 2011). USP12 may also target histones in the LNCaP 
cell line; depletion of USP12 shows a reduction in AR-regulated gene expression that is 
similar to the effect of USP12 knockdown on Xbra expression. ChIP studies to 
investigate the levels of ubiquitinated histones H2A and H2B in the promoter and 
coding regions of AR-target genes such as PSA, KLK2 and TMPRSS2 using commercially 
available antibodies specific to ubiquitinated histone H2A and H2B would help to 
unravel this. Moreover, many histone modifiers have been shown to interact with and 
affect the function of the AR, independently of their histone-directed activity. This is 
true for the histone methyltransferase SET9 which is responsible for histone H3K4 
mono-methylation as well as direct methylation of the AR at lysine 632 within the 
hinge region (Gaughan et al., 2011). It would be interesting to investigate whether the 
effect of USP12 on AR could be accounted for by modification of an ubiquitinated 
histone or whether both histone modification and direct deubiquitination of AR is 
required. 
IP data obtained from over-expression of FLAG-tagged USP12 and AR demonstrated an 
interaction between the two proteins, although the proportion of USP12 that was 
found to interact with the AR was relatively low when compared to the level of over-
expression (Figure 4.11). Use of another experimental system, such as the mammalian 
two-hybrid assays could further confirm these data in the absence of a suitable USP12 
antibody to detect endogenous proteins. 
Analysis of the phenotypic effects of USP12 knockdown revealed that under normal 
conditions, USP12 may act to promote LNCaP cell proliferation whilst inhibiting 
apoptosis (Figure 4.12; Figure 4.14; Figure 4.16). This is comparable to other AR co-
regulators such as hPIRH2 and SET9; depletion of hPIRH2 by siRNA resulted in 
decreased LNCaP proliferation and knockdown of SET9 resulted in both decreased 
proliferation and increased apoptosis in LNCaP cells (Logan et al., 2006; Gaughan et al., 
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2011). Many DUBs have been linked to apoptosis including USP14, USP7 and CYLD 
(Ramakrishna et al., 2011; Vucic et al., 2011). USP2a protects prostate cancer cells 
from apoptosis through stabilisation of FAS and interaction with the p53 pathway via 
MDM2 (Graner et al., 2004). Although not conclusively proven, the Akt phosphatase 
PHLPP has been identified by mass spectrometry to interact with USP12; connecting it 
directly with a pathway involved in both cell proliferation and apoptosis (Sowa et al., 
2009). This phosphatase is responsible for de-phosphorylation of Akt resulting in 
suppression of growth and promotion of apoptosis (Gao et al., 2005a). Investigation of 
this alleged relationship may reveal the mechanism by which USP12 protects cells from 
apoptosis. Pilot studies investigating the levels of phosphorylated Akt in LNCaP cells 
subjected to SCR or USP12 knockdown for 48 hours in steroid-depleted media prior to 
treatment with insulin-like growth factor-1 (IGF-1), which is known to induce 
phosphorylation of Akt, were performed but unfortunately due to time constraints 
could not be fully optimised. Preliminary results, however, indicated that knockdown 
of USP12 led to a reduced level of serine 473 phosphorylated Akt whilst total Akt and 
α-tubulin levels remained unaffected (data not shown). Reduced Akt phosphorylation 
would theoretically result in an increase in apoptosis and a decrease in cell 
proliferation, therefore this result would conform promisingly to the LNCaP 
proliferation and flow cytometry data. Further experimental repeats would be 
required and investigation to confirm and characterise USP12 and PHLPP interaction 
may attach a further cellular role to USP12. 
In conclusion, USP12 has been shown to consistently co-activate AR transcriptional 
activity. Acting in a potentially nuclear location, USP12 affects the recruitment of AR to 
AREs in target genes. Knockdown of USP12 not only dampens the expression of AR-
regulated genes but also promotes apoptosis and growth arrest in prostate cancer 
cells. Therefore, USP12 could prove to be a prospective therapeutic target. 
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5 Chapter 5: Characterisation of USP10 as a deubiquitinase 
involved in androgen receptor regulation 
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5.1 Introduction 
USP10 is a member of the ubiquitin-specific processing protease (USP) family of 
deubiquitinating enzymes that contains an ataxin-2C domain, a region of homology 
with the carboxyl-terminus of the ataxin-2 protein with no known function, and a USP 
domain, containing the catalytically important residues required for deubiquitinase 
activity (Komander et al., 2009a). USP10 was first described as an interacting partner 
of the Ras-GTPase activating protein, G3BP and has subsequently been linked to 
regulating the function of many other proteins involved in an array of cellular 
processes, as described below. 
5.1.1 USP10 and the endo-membrane system 
One of the most characterised cellular functions of USP10 is in regulation of vesicular 
and endosomal transport. The endo-membrane system consists of the endoplasmic 
reticulum (ER), the Golgi apparatus and lysosomes. Vesicles allow transport of proteins 
between the organelles. Endosomes are a specific type of vesicle that forms at the 
plasma membrane to internalise membrane proteins such as cell surface receptors. 
These endosomes are then transported to the Golgi where the internalised proteins 
are either recycled back to the plasma membrane, by recycling endosomes, or 
targeted to the lysosome for degradation (Lee et al., 2004; Hsu et al., 2009). 
Furthermore, proteins destined for the cell membrane can be transported from the ER 
to the Golgi by vesicles (Lee et al., 2004). 
5.1.1.1 USP10 and Ras-GAP SH3 binding protein 
The COPII complex is a coat protein which is incorporated into vesicles transported 
between the ER and the Golgi, allowing transport of membrane proteins which are 
assembled in the ER (Lee et al., 2004). A study in yeast identified that Ubp3p, a DUB 
similar to USP10, deubiquitinated the COPII component Sec23p, protecting it from 
degradation. Furthermore, Bre5p was found to positively regulate the deubiquitinase 
activity of Ubp3p towards Sec23p (Cohen et al., 2003) (Figure 5.1). Interestingly, a 
yeast two-hybrid study using a of human lymphocyte cDNA library identified Ras-GAP 
SH3 binding protein (G3BP), a homologue of Bre5p, as an interacting partner of USP10 
suggesting that this interaction between Ubp3p and Bre5p is evolutionarily conserved 
and that USP10 may have a role in transport of proteins between the ER and the Golgi. 
However, unlike Bre5p, G3BP negatively regulates the deubiquitinase activity of USP10 
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towards substrates (Soncini et al., 2001) (Figure 5.1). Further study of the Ubp3p-
Bre3p complex identified that β’-COP, a component of the COPI vesicular coat protein, 
was also a substrate. USP10 was subsequently observed to interact with the 
mammalian homologue of β’-COP, implicating it further in vesicle transport (Cohen et 
al., 2003) (Figure 5.1). 
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Figure 5.1. USP10 and Ras-GAP SH3 binding protein. 
Ubp3p, a yeast deubiquitinase enzyme (DUB) of USP10,deubiquitinates the Sec23p and β’-COP components of the 
COPII complex leading stabilisation of the complex. Bre5p positively regulates Ubp3p. In mammalian cells, USP10 
deubiquitinates β’-COP. Ras-GAP SH3 binding protein (G3PB), a mammalian homologue of Bre5p, negatively 
regulates USP10. 
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5.1.1.2 USP10 and CFTR 
The cystic fibrosis transmembrane conductance regulator (CFTR) is a cyclic-AMP 
regulated chloride channel that is regulated by endocytosis, lysosomal degradation 
and endosomal recycling (Bomberger et al., 2010). Mutations in CFTR cause cystic 
fibrosis, a genetic disease that is characterised by cysts of the pancreas as well as 
breathing difficulties caused by excess mucus in the lungs (Boucher, 2004). 
CFTR that has been internalised into endosomes is deubiquitinated by USP10, 
promoting its recycling back to the plasma membrane and preventing its degradation 
by the lysosome (Bomberger et al., 2009; Bomberger et al., 2010) (Figure 5.2). A 
further study by Bomberger et al., found that the bacterium Pseudomonas aeruginosa 
secretes a toxin which stabilises the inhibitory effect of G3BP upon USP10, therefore 
preventing CFTR deubiquitination by USP10 and causing increased lysosomal 
degradation of CFTR (Bomberger et al., 2011) (Figure 5.2). P. aeruginosa is an 
opportunistic bacterial infection which affects patients with chronic lung diseases 
including cystic fibrosis. The above studies not only provided evidence of USP10s role 
in endosomal sorting of CFTR, but highlighted a specific insight for the role of USP10 in 
human disease.  
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Figure 5.2. USP10 and CFTR. 
USP10 deubiquitinates CFTR enabling recycling of the receptor to the cell membrane. Toxins secreted from P. 
aeruginosa during infection increase the negative effect of Ras-GAP SH3 binding protein (G3BP) towards USP10 
causing ubiquitinated CFTR to be degraded by the lysosome. 
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5.1.1.3 USP10 and sorting nexin 3 
USP10 gene expression is regulated by the anti-diuretic hormone vasopressin. 
Vasopressin regulates sodium homeostasis by promoting translocation of water and 
sodium channels to the plasma membrane of cells in the kidney. USP10 was found to 
increase the cell surface expression of epithelial sodium channels (ENaC) when co-
transfected into 293T cells, although ENaC was not found to be a substrate for USP10 
(Boulkroun et al., 2008). The endocytic adaptor protein, sorting nexin 3 (SNX3), was 
identified in a yeast two-hybrid screen, as a direct substrate of USP10 and 
deubiquitination of SNX3 led to its stabilisation. Furthermore, over-expression of SNX3 
increased the cell surface expression of ENaC in a USP10-dependent manner due to 
increased endocytic transport of the channel to the plasma membrane (Boulkroun et 
al., 2008). 
5.1.2 USP10 and p53-MDM2 network regulation 
The tumour suppressor gene p53 is often termed the ‘guardian of the genome’ as it 
regulates numerous cellular pathways involved in maintaining DNA integrity during 
cellular and genotoxic stress (Brooks and Gu, 2006). MDM2 triggers nuclear export and 
proteasomal degradation of p53 by direct ubiquitination (Li et al., 2003). In unstressed 
cells, p53 activity is maintained at low levels by MDM2-mediated ubiquitination, 
triggering nuclear export and proteasomal degradation (Vucic et al., 2011) (Figure 5.3). 
However, in cells experiencing stress, such as DNA damage, p53 is stabilised leading to 
increased transcription of p53-target genes that potentiate cell cycle arrest, repression 
of growth or apoptosis (Vucic et al., 2011). Phosphorylation of p53, by kinases involved 
in cell cycle checkpoints or up-regulated by genotoxic stress, allows co-activator 
proteins such as p300 and PCAF to bind p53 and enhance transcriptional activity (Vucic 
et al., 2011) (Figure 5.3). Moreover, this modification disrupts the ability of MDM2 to 
bind and ubiquitinate p53 leading to its enhanced stability (Vucic et al., 2011). MDM2 
is itself regulated by auto-ubiquitination and degradation (Brooks and Gu, 2006) 
(Figure 5.3).  
With regards to a role of deubiquitinase enzymes in the regulation of this cascade, 
USP7 was shown to regulate the ubiquitination of both MDM2 and p53 (Figure 5.3). Li 
et al., reported that USP7 was a novel interacting partner of p53, identified by mass 
spectrometry, that directly deubiquitinated and stabilise p53, resulting in p53-
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dependent cell growth inhibition and apoptosis. Conversely, over-expression of 
deubiquitinase-dead USP7 resulted in accumulation of ubiquitinated p53 (Li et al., 
2002a). In contrast to this study, Cummins et al., reported that USP7 depletion 
stabilised p53 due to an increase in ubiquitination and degradation of MDM2 
(Cummins and Vogelstein, 2004). Importantly, cellular and genotoxic stress regulates 
the substrate specificity of USP7 (Vucic et al., 2011). In unstressed cells, USP7 
deubiquitinates MDM2 leading to increased p53 ubiquitination, whilst preferential 
deubiquitination and stabilisation of p53 in response to DNA damage increases p53 
transcriptional activity and assists p53-mediated DNA repair, cell cycle arrest and 
apoptosis (Li et al., 2002a; Meulmeester et al., 2005; Vucic et al., 2011). Furthermore, 
Ataxia telangiectasia mutated (ATM), a kinase activated during cellular response to 
DNA damage, was found to lower the affinity of USP7 for MDM2, thereby leading to its 
increased degradation (Meulmeester et al., 2005). 
Importantly, and in keeping with the focus of this Chapter, USP10 has been found to 
play a role in the p53-MDM2 network by counteracting MDM2-mediated 
ubiquitination of p53 and hence facilitating p53 activity in response to genotoxic 
stress. USP10, a mainly cytoplasmic protein, was found to interact directly with p53 by 
immunoprecipitation. Depletion of USP10 resulted in a reduction of p53 protein, but 
did not affect mRNA expression suggesting USP10 had a role in the stability of p53. 
Subsequent use of the proteasomal inhibitor MG132 confirmed that USP10 regulated 
p53 stability in a proteasome-dependent manner. MDM2-mediated ubiquitination and 
nuclear export of p53 was rescued by USP10 with mutation of the catalytic cysteine 
residue of USP10 abrogating its ability to reverse this ubiquitination in vitro. Although 
MDM2 expression was decreased in response to USP10 depletion in p53-proficient 
cells, this effect was due to a decrease in p53 protein levels as knockdown of USP10 in 
p53-deficient cells did not yield the same result. Furthermore, unlike USP7, USP10 did 
not directly interact with MDM2. Reversal of MDM2-mediated ubiquitination of p53 by 
USP10 resulted in increased p53 transcriptional activity leading to increased expression 
of p53-target genes p21 and Bax and increased p53-induced apoptosis (Yuan et al., 
2010) (Figure 5.3). 
As p53 activity is up-regulated in response to genotoxic stress, Yuan et al hypothesised 
that USP10 may play a key role in p53 regulation during DNA damage response. 
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Expression of USP10 was stimulated and protein levels in the nucleus increased in 
response to ionising radiation. Phosphorylation events, at threonine 42 and serine 337, 
mediated by ATM were found to be important for translocation of USP10 into the 
nucleus where it deubiquitinated and stabilised p53. Inhibition of ATM blocked nuclear 
translocation of USP10 and mutation of Thr42 and Ser337 led to defective p53 
stabilisation and reduced p53-target gene expression (Yuan et al., 2010) (Figure 5.3).  
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Figure 5.3. USP10 and p53-MDM2 network regulation. 
The activity of p53 is maintained at low levels by MDM2 under normal cellular conditions. MDM2-mediated 
ubiquitination of p53 leads to degradation. In cells experiencing stress p53 is stabilised by deubiquitination via USP7 
and phosphorylation. USP10 deubiquitinates p53 in an ATM-mediated phosphorylation-dependent manner. 
Stabilised p53 interacts with co-activator proteins leading to increased transcriptional activity.MDM2 is regulated by 
auto-ubiquitination which is counter-acted by USP7. 
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5.1.3 USP10, MDM2 and AR regulation 
Both USP10 and MDM2 have been shown to function as AR co-regulators. USP10 was 
identified in a study by Faus et al., to be in complex with DNA-bound AR in nuclear 
extracts of a PC-3, AR-null, cell line stably over-expressing AR. This result was 
confirmed using radio-labelled in vitro translated AR and recombinant GST-tagged 
USP10 in GST pull-down experiments, where AR was only observed in USP10 
containing samples compared to GST-tag only controls. The cellular localisation of 
USP10 was found to be both cytoplasmic and nuclear in the PC-3/AR cells and USP10 
increased AR transcriptional activity upon two luciferase reporters, containing four 
copies of either the ARE-1 or ARE-2 of the murine androgen-responsive Pem gene. 
Moreover, the effect of USP10 on AR activity was found to be deubiquitinase-
dependent as mutation of the catalytic cysteine of USP10, Cys424, showed almost 
basal levels of AR activity towards the ARE-1 reporter. Similarly, depletion of USP10 
with siRNA in PC-3/AR cells stably expressing a MMTV luciferase reporter construct 
showed basal levels of AR activity (Faus et al., 2005). 
Most recently, Draker et al., have linked USP10 to AR transcriptional activity through 
association with and regulation of mono-ubiquitinated histone H2A.Z. Cell-free in vitro 
deubiquitination assays and the observation that levels of ubiquitinated histone H2A.Z 
decreased in 293T cells over-expressing USP10 suggested that USP10 directly 
deubiquitinated histone H2A.Z. Furthermore, depletion of USP10 by stable shRNA 
expression in LNCaP cells increased the levels of ubiquitinated histone H2A.Z at the 
promoter regions of both the PSA and KLK2 genes suggesting that this mark is retained 
upon knockdown and providing additional evidence that USP10 is responsible for 
deubiquitination of this histone variant. Deubiquitination of histone H2A.Z increased 
expression of both PSA and KLK2 genes in LNCaP cells and PC-3/AR luciferase 
experiments using an ARE3 luciferase reporter, similar to that used in the current 
study, confirming USP10 is a potential co-activator of AR transcriptional activity 
(Draker et al., 2011). Interestingly, immuno-fluorescence and cytoplasmic-nuclear 
extraction in LNCaP cell confirmed that USP10 resides in both the nuclear and 
cytoplasmic compartments in concordance with Faus et al. 
Consistent with the role of MDM2 as an E3 ubiquitin ligase, the enzyme has been 
shown to repress AR transcriptional activity by causing ubiquitin-dependent 
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degradation of the receptor (Lin et al., 2002b; Gaughan et al., 2005). The initial 
demonstration that MDM2 was an E3 ligase of the AR came on the back of some 
earlier observations that the Akt pathway actively reduced receptor protein levels (Lin 
et al., 2001). Akt was found to directly phosphorylate serine residues 210 and 790 of 
the receptor, as well as key residues in MDM2, that was required to drive interaction 
between AR and the E3 ligase. Upon binding, MDM2 catalysed poly-ubiquitination of 
the AR that facilitated degradation of the AR; a process blocked by the proteasomal 
inhibitor MG132, implicating a role for the proteasome in receptor turnover (Lin et al., 
2002b). Interestingly, MDM2 is found in complex with AR at the PSA promoter 
suggesting that transcription and degradation of the receptor is coupled allowing tight 
regulation of AR transcriptional activity (Gaughan et al., 2005). 
5.1.4 USP10 and disease 
A quantitative real-time gene array study conducted In the aggressive brain tumour 
glioblastoma multiforme identified USP10, in conjunction with thymidylate synthetase 
and survivin, as being significantly over-expressed in patients who die of the disease 
(DOD) compared to those with long term survival (LTS) over 36 months post-surgery 
(Grunda et al., 2006). This study, however, analysed only a small number of tissue 
samples, 8 LTS and 13 DOD patients, and the 96 genes included on the array were 
selected based on their known involvement in cancer-related pathways such as 
apoptosis, tumour progression and patient survival. Immuno-histochemical staining of 
paraffin-embedded glioblastoma tissue for USP10 confirmed over-expression of the 
protein in DOD tissue compared to LTS tissue. Unfortunately, this study did not 
elucidate the molecular role for USP10 in glioblastoma but the authors suggested that 
further study into proteins involved in the ubiquitin-proteasome system may provide 
further prognostic indicators of survival in this disease (Grunda et al., 2006). 
Intriguingly, expression profiling of 6 infiltrating ductal breast carcinoma samples, to 
identify proteins associated with the ubiquitin proteasomal pathway and 
ubiquitination, identified USP10 as one of ten ubiquitin pathway associated genes, 
including four USPs, to be over-expressed by more than three-fold in carcinoma 
compared to normal breast tissue (Deng et al., 2007). 2D gel electrophoresis and mass 
spectrometry analysis did not detect USP10 as an over-expressed protein in the breast 
cancer samples, as a threshold of 4-fold over-expression compared to normal breast 
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tissue was applied; therefore USP10 was not investigated by immuno-histochemistry. 
The authors speculate that the four over-expressed USPs identified, may aberrantly 
regulate the rate of protein turn-over thereby preventing protein degradation in 
cancer and that these, along with the five proteasome subunits and E3 ubiquitin ligase 
E6-AP, potentially provide therapeutic targets in infiltrating ductal carcinoma (Deng et 
al., 2007). 
In a study investigating the role of USP10 as a regulator of MDM2-mediated 
ubiquitination and degradation of p53, USP10 deubiquitination of p53 increased p53 
function and inhibited cell proliferation of the p53-wild type colorectal carcinoma cell 
HCT116 (Yuan et al., 2010). The authors suggested that USP10 may act as a tumour-
suppressor and in renal cell carcinoma (RCC), a cancer that rarely harbours p53 
mutations; down-regulation of USP10 may act as a mechanism for down-regulating 
p53. USP10 was confirmed to be down-regulated in p53-wild type RCC cell lines and 
the level of p53 protein was also found to be lower. 90% of clear cell carcinoma, 50% 
of chromophobe and 20% of papillary RCC tissues on tissue microarrays containing a 
total of approximately 230 RCC cases showed negative staining for both USP10 and 
p53. Interestingly, all cell lines and samples with p53 mutation showed up-regulation 
of both USP10 and p53 protein. Furthermore, reconstitution of USP10 expression in 
the USP10 down-regulated RCC cell lines Caki-1 and Caki-2 restored p53 protein levels, 
increased expression of p53-target genes p21 and Bax and inhibited cell proliferation 
and colony forming efficiency (Yuan et al., 2010). 
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5.2 Aims 
USP10 was identified as a potential AR co-regulator by the Solid Tumour Target 
Discovery Group, using a siRNA library screen containing 72 DUB targets in LNCaP cells. 
USP10 knockdown was shown to consistently up-regulate PSA secretion, as measured 
by ELISA, and PSA mRNA expression that is in contrast to recently published work 
describing the DUB as a co-activator of the AR (Faus et al., 2005; Draker et al., 2011). 
The specific aims of this Chapter are: 
 To validate the effect of USP10 knockdown on PSA mRNA and protein 
expression 
 To further characterise the effect of USP10 on AR transcriptional activity 
 To elucidate if USP10 and AR interact directly 
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5.3 Results 
5.3.1 Effect of USP10 knockdown on AR-regulated PSA gene expression over 
72 hours DHT stimulation 
USP10 was initially identified in the Solid Tumour Target Discovery Laboratory, 
Newcastle University, as a potential AR co-regulator using an in-house DUB siRNA 
library in androgen-dependent LNCaP cells to address the effect of DUB depletion on 
AR activity (Figure 3.2). Individual DUB enzymes were depleted in LNCaP cells for 24 
hours in steroid-depleted media prior to 100 nM DHT treatment for 72 hours and PSA 
secretion analysed by ELISA. As described in Chapter 3.3.1, the criteria for target 
selection was based on 50% modulation of PSA secretion in response to knockdown, 
and although none of the targets caused an increase in PSA secretion over the 50% 
threshold, USP10, USP8 and USP38 all increased PSA secretion by 40% above the SCR 
control and hence were selected for further validation experiments. 
Knockdown of these targets was then investigated for effect on PSA mRNA expression. 
USP10 was the only target to consistently increase PSA mRNA levels upon knockdown 
and was therefore selected for further validation (Figure 3.3). 
As described in Chapter 3.3.2 each target was initially depleted using a pool of three 
siRNA oligonucleotides and none of the knockdowns were confirmed during the initial 
QPCR analysis to validate the PSA ELISA data. Therefore, to demonstrate that the 
effect of USP10 depletion on PSA expression was a consequence of DUB knockdown, 
USP10 levels were analysed using individual USP10 oligonucleotides. LNCaP cells were 
subjected to USP10 depletion by each siRNA oligo individually and SCR siRNA was used 
as a negative control. This work was performed by Dr Steven Darby.  
Figure 5.4 shows the mean of three experimental repeats for USP10 expression and 
indicates that siRNA oligo B gave the best knockdown; this was subsequently used as 
the sole siRNA in the further validation steps (Figure 5.4). Unfortunately, no PSA 
expression data was obtained for this validation experiment and the pooled siRNA was 
not included as a comparison. 
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Figure 5.4. Validation of USP10 knockdown in LNCaP cells.  
USP10 was depleted in LNCaP cells for 48 hours prior to 100 nM DHT stimulation for a further 48 hours. Scrambled 
siRNA (SCR) was used as a negative control. Data shows the effect of individual USP10 siRNA oligos on USP10 mRNA 
expression. Data is represented as fold change compared to the SCR control. Data is representative of the mean of 
three independent repeats and error bars show the standard error. This work was performed by Dr Steven Darby. 
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As with the initial validation experiments in Chapter 3.3.3, the next step of the 
investigation was to study the effect of USP10 knockdown on PSA mRNA expression 
over a time course of 72 hours DHT treatment. USP10 was depleted in LNCaP cells for 
48 hours before 100 nM DHT was applied and cells harvested for RNA extraction at 0, 
12, 48 and 72 hours post-DHT treatment. QPCR was used to analyse both PSA and 
USP10 knockdown and scrambled (SCR) siRNA was used as a control. Given that this 
experiment was performed at the very early stages of target validation, the work was 
performed by Dr Steven Darby who had performed the initial PSA ELISA screen. Figure 
5.5 shows a representative data-set of three independent repeats, and the data is 
presented as relative expression compared to HPRT1 house-keeping gene expression. 
As shown in Figure 5.5a, knockdown of USP10 showed an increase in PSA expression at 
all time-points in the absence of DHT stimulation, PSA expression was 5.9-fold above 
the SCR control, suggesting a role for USP10 in regulating the basal activity of the AR. 
As expected, ligand treatment enhanced PSA expression in the SCR control by 
approximately 10-fold at 10 hours that remained at this level for the duration of the 
experiment. Remarkably, USP10 depletion steadily enhanced PSA expression in the 
presence of hormone to a maximum level of 48.7-fold above SCR control at 72 hours. 
Interestingly, this is a much greater level than observed at the same time point for the 
initial PSA QPCR (Figure 3.3) and may be attributed to better knockdown achieved with 
a single siRNA. USP10 expression was reduced by at least 80% in response to 
knockdown throughout the 72 hour time-course experiment (Figure 5.5b, compare the 
purple and red lines). 
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Figure 5.5. Effect of USP10 knockdown on PSA expression over 72 hours DHT stimulation.  
USP10 was depleted by siRNA in LNCaP cells for 48 hours before 100 nM DHT treatment was applied for a further 72 
hours. RNA was collected at 0, 12, 48 and 72 hours post treatment. Scrambled siRNA (SCR) was used as a negative 
control. Results are from one repeat and are representative of three independent repeats. Data is shown as relative 
expression compared to the HPRT1 house-keeping gene and error bars show the standard deviation between 
experimental triplicates. A) The effect of USP10 knockdown on prostate specific antigen (PSA) expression over 72 
hours DHT treatment. B) The effect of USP10 knockdown on USP10 expression over 72 hours DHT treatment. This 
work was performed by Dr Steven Darby.  
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To confirm that the effect on PSA was also apparent at the protein level, Western blot 
analysis of PSA was performed. Furthermore, to address whether the effect of USP10 
depletion on PSA expression could be attributed to a change in AR protein, receptor 
levels were measured by Western analysis. A time-course experiment was set up as 
described above and cell lysates were collected at each time point. SDS-PAGE and 
Western blotting for PSA, AR and USP10 to confirm protein knockdown was 
performed. α-tubulin was used as a loading control. Figure 5.7 shows the densitometry 
analysis of the three experimental repeats and is presented as the mean relative 
protein expression normalised to the respective α-tubulin loading control. Data was 
analysed for statistical significance using 2-way ANOVA, significant data is indicated on 
the figure (Figure 5.7). 
Consistent with Chapter 3.3.3, no significant difference was observed between the 
non-transfected (NT) and SCR controls for each protein analysed indicating that there 
are no discernible off-target or transfection-related affects during each of the 
experiments. As expected, PSA and AR protein levels both increased in response to 
DHT stimulation in the NT and SCR controls, while USP10 levels remain largely 
unchanged over the course of the experiment (Figure 5.6a and b). Consistent with PSA 
being an androgen-responsive gene, AR knockdown, as confirmed by anti-AR Western 
blotting, reduced PSA expression but had no effect on USP10 levels (Figure 5.6c). 
As shown in Figure 5.6d, knockdown of USP10 showed a similar effect on PSA protein 
levels to the SCR control within the first 24 hours DHT treatment in that there was a 
small increase in PSA protein compared to the un-treated control. However, at 48 and 
72 hour time-points, PSA protein levels were massively elevated in the USP10 depleted 
samples compared to the SCR controls suggesting a role for USP10 in AR-mediated 
transcription. This notion was further strengthened by demonstrating that AR levels in 
the USP10 depleted samples mimic those in the NT and SCR controls suggesting 
changes to PSA expression is not a result of increased AR protein (Figure 5.6d). USP10 
Western analysis confirmed depletion of the DUB enzyme (Figure 5.6d). 
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Figure 5.6. Effect of USP10 knockdown on PSA and AR protein levels.  
LNCaP cells were subject to siRNA knockdown for 48 hours prior to 72 hours 100 nM DHT stimulation. Cell lysates 
were collected at 0, 6, 12, 24, 48 and 72 hours post-treatment. Western blotting for prostate specific antigen (PSA), 
androgen receptor (AR) and USP10 were performed. α -tubulin was used as a loading control. Non-transfected (NT), 
scrambled siRNA (SCR) and AR knockdown were used as negative and positive controls. Western blots are 
representative of three independent experimental repeats. A) The effect of the NT control on PSA and AR protein 
levels. B) The effect of the SCR control on PSA and AR protein levels. C) The effect of AR knockdown on PSA and AR 
protein levels. AR Western blot confirmed AR was depleted throughout the time course. D) The effect of USP10 
knockdown on PSA and AR protein levels. Western blot for USP10 confirmed USP10 was depleted throughout the 
time course. 
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Figure 5.7. Densitometry analysis of the effect of USP10 knockdown on PSA and AR protein levels. 
Western blot data from the time-course experiments was analysed using the Quantity one programme on the 
GelDoc™ system. Data for prostate specific antigen (PSA) and androgen receptor (AR) protein levels were normalised 
to the respective α-tubulin loading control data. Data is presented as the mean relative expression of three 
independent experimental repeats. Error bars represent the standard error. Data was analysed for statistical 
significance using 2-way ANOVA. Each knockdown was compared to the SCR control at each time point, significant 
data is indicated by an asterisk. A) The effect of siRNA knockdown on PSA protein levels over 72 hours DHT 
treatment. B) The effect of siRNA knockdown on AR protein levels over 72 hours DHT treatment. C) The effect of 
USP10 knockdown on USP10 protein levels over 72 hours DHT treatment.  
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5.3.2 Effect of USP10 knockdown on other AR-regulated gene expression 
To assess whether USP10 knockdown also had a similar effect on four other AR-
regulated genes studied in Chapter 3.3.4, KLK2, TMPRSS2, NKX3.1 and NDRG1 mRNA 
expression was analysed using the same sample set as above (Figure 5.5). Figure 5.8 
shows a representative data-set of three independent repeats, and the data is 
presented as relative expression compared to HPRT1 house-keeping gene expression. 
This work was performed by Dr Steven Darby. 
As expected, all of the androgen-responsive genes showed characteristic induction in 
expression in response to DHT treatment (Figure 5.8, red line) (Ngan et al., 2009). 
KLK2, TMPRSS2 and NDRG1 showed similar expression profiles to those observed 
previously (Figure 3.14a, b and c, red line), however in all cases, the peak of expression 
was delayed, for example, KLK2 and TMPRSS2 showed maximal expression at 
approximately 55 hours DHT treatment (Figure 5.8a and b, red line) whereas previous 
experiments showed expression to peak at approximately 20 hours post-androgen 
treatment (Figure 3.14a and b, red line). Unlike the other androgen-responsive genes, 
the expression profile of NKX3.1 was markedly different to that observed previously, as 
expression did not reach a maximum level before returning to basal levels (Compare 
Figure 3.14c and Figure 5.8c, red line). 
Unlike USP12 knockdown, that reduced transcription of each of the AR-target genes, 
depletion of USP10 did not have the same effect on all of the tested AR-regulated 
genes. KLK2 and TMPRSS2 expression were enhanced with USP10 knockdown and 
were consistent with PSA expression (Figure 5.8a and b, purple line). NKX3.1 
expression, on the other hand, was reduced in cells depleted of USP10 compared to 
the SCR control during the first 24 hour of the time-course. Expression of this AR target 
gene then increased to higher levels than the SCR control at 48 hours post-DHT 
treatment which then decreased and returned to the same level of expression as the 
SCR control at 72 hours (Figure 5.8c, compare red and purple lines). USP10 knockdown 
appeared to delay the expression of NDRG1 in response to DHT, with an increase in 
expression observed after approximately 24 hours DHT treatment compared with 
approximately 12 hours in the SCR control (Figure 5.8d, compare red and purple lines). 
Overall the expression of NDRG1 was lower in response to USP10 depletion compared 
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to the SCR control, however, unlike the SCR control where expression returned to 
basal levels, NDRG1 expression continued to increase (Figure 5.8d, purple line). 
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Figure 5.8. Effect of USP10 depletion on AR regulated gene expression over 72 hours DHT stimulation.  
USP10 was depleted in LNCaP cells for 48 hours before 100 nM DHT treatment was applied for a further 72 hours. 
RNA was collected at 0, 6, 12, 24, 48 and 72 hours post treatment. Scrambled siRNA (SCR) was used as a negative 
control. Results are from one repeat and are representative of three independent repeats. Data is shown as relative 
expression compared to the HPRT1 house-keeping gene and error bars show the standard deviation between 
experimental triplicates. A) The effect of USP10 knockdown on KLK2 expression over 72 hours DHT treatment. B) The 
effect of USP10 knockdown on TMPRSS2 expression over 72 hours DHT treatment. C) The effect of USP10 knockdown 
on NKX3.1 expression over 72 hours DHT treatment. D) The effect of USP10 knockdown on NDRG1 expression over 
72 hours DHT treatment. This work was performed by Dr Steven Darby. 
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5.3.3 USP10 down-regulates the transcriptional activity of the AR 
The above data showed that, at least for a subset of AR regulated genes, USP10 
knockdown caused an up regulation of expression. This suggested, therefore, that 
USP10 may be acting as a transcriptional co-repressor of the AR in LNCaP cells. To 
investigate this further, an androgen-responsive luciferase reporter system was 
utilised to interrogate whether USP10 acts as a repressor of AR transcriptional activity 
and whether any effect could be amplified with increasing amounts of USP10. 
To this end, COS-7 cells were transfected with 100ng of both ARE3 and β-gal and 50ng 
of AR in serum-containing media. USP10 was transfected at increasing quantities 
between 25-100 ng (represented as +, + and +++). Media was replaced 24 hours post-
transfection with steroid-depleted media supplemented with (+ DHT) or without (- 
DHT) 100 nM DHT for an additional 48 hours. The average and standard error of the 
mean was calculated for each triplicate. Only assays that showed greater than 3-fold 
AR induction with DHT stimulation were deemed to have been successful; this was 
applied to all luciferase reporter assays. Data shown is from three independent repeats 
and is represented as fold change compared to the un-stimulated AR only control. 
Data was analysed for statistical significance using the Student’s t-test, significant data 
are indicated on the figure. 
As expected, AR activity was significantly increased by approximately 6-fold upon 
treatment with DHT (P=0.0017) (Figure 5.9, compare lanes 1 and 2). Co-transfection of 
25 ng of USP10 (+) had no effect on DHT-stimulated AR activity, while 50 ng (++) and 
100 ng (+++) of USP10 slightly reduced AR-mediated luciferase activity (Figure 5.9, 
compare lanes 6 and 8 with lane 2), although this effect was not statistically significant 
(P=0.4745 and P=0.266, respectively). 
Western blot analysis revealed that ectopic AR was again expressed in each of the 
samples (Figure 5.9b, upper panel). Interestingly, there appeared to be increased AR in 
the samples containing 50 ng and 100 ng USP10 which were not treated with DHT 
(Figure 5.9b, Upper panel, lanes 5 and 7). USP10 was detected in each of the samples 
with ectopic expression (Figure 5.9b, middle panel, lanes 3-8). Low levels of 
endogenous USP10 were observed in the AR only controls (Figure 5.9b, middle panel, 
lanes 1 and 2). 
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Figure 5.9. Effect of USP10 on AR transcriptional activity in COS-7 cells.  
COS-7 cells were transfected with 50 ng androgen receptor (AR), 100 ng of both an AR responsive ARE3 luciferase 
reporter and a β-gal reporter and increasing amounts of USP10; 25 ng (+), 50ng (++) and 100ng (+++). 24 hours 
after transfection, cells were grown in steroid-depleted media supplemented with (+ DHT) or without (- DHT) 100 nM 
DHT for a further 48 hours. A) Luciferase reporter activity was measured and normalised against β-gal activity. Data 
is represented as fold change compared to the AR only - DHT control. Data is a mean of three independent repeats 
and error bars represent the standard error of the mean of the three replicates. Data was analysed for statistical 
significance using the Student’s t-test, significant data is indicated by an asterisk. B) Luciferase assay samples were 
analysed by Western blotting with anti-AR and -FLAG antibodies to ensure over-expression of ectopically expressed 
proteins. α-tubulin was used as a loading control. Western blots are representative of three independent 
experimental repeats..  
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In contrast to our findings above, the study conducted by Faus et al., demonstrated 
that exogenous over-expression of USP10 (75 ng) stimulated AR transcriptional activity 
in luciferase reporter-based assays utilising two reporter constructs containing four 
copies of either the ARE-1 or ARE-2 of the androgen responsive murine Pem gene 
promoter. These findings were confirmed by knockdown of USP10 in a PC-3 cell line 
stably over-expressing both AR and an MMTV luciferase construct; depletion of USP10 
resulted in decreased luciferase activity. Furthermore, Draker et al., confirmed that 
both knockdown of USP10 increased AR transcriptional activity in experiments utilising 
an ARE3 luciferase reporter, supporting the notion that USP10 is a transcriptional co-
activator of the AR. However, these experiments were performed in the AR null PC-3 
cell lines that had been stably transfected with AR, suggesting the observed disparity 
between data-sets may be a consequence of variability in the cell background. It was 
therefore pertinent to ask whether transiently expressing AR and USP10 in PC-3 cells 
would reproduce the results described in the Faus et al., and Draker et al., studies 
(Faus et al., 2005; Draker et al., 2011). 
PC-3 cells were transfected with 100ng of both ARE3 and β-gal and 50ng of AR in 
serum-containing media. USP10 was transfected at increasing quantities between 25-
100 ng (represented as +, + and +++). Media was replaced 24 hours post-transfection 
with steroid-depleted media supplemented with (+ DHT) or without (- DHT) 100 nM 
DHT for an additional 48 hours. As the data shown in Figure 5.10 is from only two 
repeats it should be further repeated to draw firm conclusions, particularly when 
considering the variability between the experimental replicates. Data was analysed for 
statistical significance using the Student’s t-test, however no data points were found to 
be significant. 
AR activity was induced 15.5-fold upon DHT stimulation that was markedly higher than 
that observed in COS-7 cells (Figure 5.9 and Figure 5.10). Increasing amounts of USP10 
showed a marginal decrease in AR activity; 25 ng of USP10 had little effect compared 
to the AR only control reducing induction to approximately 15-fold whilst 50 ng of 
USP10 reduced induction to approximately 11-fold (Figure 5.10, compare lanes 4 and 6 
with lane 2). 100 ng USP10 did not have any additional effect over 50 ng with induction 
remaining at 11-fold (Figure 5.10, compare lane 8 with lane 6). Although none of these 
results reached statistical significance these results support our previous findings and 
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are contradictory to both the Faus et al., and Draker et al., reports. Further 
experimental repeats would be necessary in order to obtain statistically relevant 
results. AR and USP10 over-expression was confirmed by Western blot analysis (Figure 
5.10b). 
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Figure 5.10. Effect of USP10 on AR transcriptional activity in PC-3 cells.  
PC-3 cells were transfected with 50 ng androgen receptor (AR), 100 ng of both ARE3 luciferase and β-gal reporters 
and increasing amounts of USP10; 25 ng (+), 50ng (++) and 100ng (+++). 24 hours after transfection, cells were 
grown in steroid-depleted media supplemented with (+ DHT) or without (- DHT) 100 nM DHT for a further 48 hours. 
A) Luciferase reporter activity was measured and normalised against β-gal activity. Data is represented as fold 
change compared to the AR only - DHT control. Data is a mean of two independent repeats and error bars represent 
the standard error of the mean of the two replicates. Data was analysed for statistical significance using the 
Student’s t-test, however no data points were significant.  B) Luciferase assay samples were analysed by Western 
blotting with anti-AR and -USP10 antibodies to ensure over-expression of ectopically expressed proteins. α-tubulin 
was used as a loading control. Western blots are representative of three independent experimental repeats. 
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5.3.4 USP10 does not directly interact with the AR in LNCaP cells 
The data thus far has revealed that USP10 acts to repress endogenous AR activity in 
the LNCaP cell line, and does not act as a receptor co-activator in luciferase-based 
reporter experiments in COS-7 and PC-3 cells as previously documented (Faus et al., 
2005; Draker et al., 2011). Faus et al., also provided evidence that there is a direct 
association between both proteins in PC-3 cells ectopically expressing AR and USP10. 
USP10 was identified firstly as an AR interacting protein in DNA response element bait 
experiments. Nuclear extracts of the PC-3/AR cell line treated with synthetic androgen 
R1881 were incubated with a biotin-tagged ARE-2 of the androgen responsive gene 
Pem. The interacting proteins were then purified by streptavidin affinity 
chromatography, separated by 2D gel electrophoresis and identified by mass 
spectrometry (Faus et al., 2005). Furthermore, radio-labelled AR generated using the 
rabbit reticulocyte lysate transcription/translation system was found to interact with 
GST-tagged USP10 in vitro (Faus et al., 2005). These experiments however were 
performed in the stably transfected PC-3/AR cell line or in a cell free environment 
providing no evidence of an endogenous interaction between USP10 and AR in an AR-
positive cell line. As USP10 depletion in LNCaP cells showed an effect on AR 
transcriptional activity it suggested that USP10 may exert its effects on the 
endogenous receptor through a direct interaction therefore immunoprecipitation 
studies were performed to elucidate this. 
LNCaP cells were cultured in serum-containing media for 48 hours prior to 
immunoprecipitation using both anti-AR or USP10 antibodies and Western analysis 
using the same immuno-globulins. Extract and antibody only controls were also 
included as described in Chapter 2.9. 
Firstly, input samples, that represent a sample of the whole cell extract, confirmed 
expression of both AR and USP10 in LNCaP cells (Figure 5.11a and b, lane 1). However, 
although anti-AR and USP10 antibodies were able to immuno-precipitate AR and 
USP10, respectively (Figure 5.11a and b, lower panels lane 2), probing the immuno-
precipitates with reciprocal antibodies failed to detect an association between USP10 
and the receptor (Figure 5.11a and b, upper panels lane 2). These results, therefore, 
suggest that endogenous AR and USP10 do not interact within LNCaP cells however 
studies of the interaction between the endogenous proteins in other cell lines would 
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be required to draw any firm conclusions. In addition, ectopic expression of both AR 
and USP10 in PC-3 cells would provide a logical next step in the investigation as 
although the luciferase reporter data in PC-3 cells contradicted the previous studies 
(Faus et al., 2005; Draker et al., 2011), the fact that USP10 impacted on AR activity may 
suggest an interaction between the two proteins. 
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Figure 5.11. AR and USP10 do not interact in LNCaP cells.  
LNCaP cells grown in serum-containing media were subject to immunoprecipitation. Inputs (IN) were taken before IP 
to ensure endogenous expression of both androgen receptor (AR) and USP10. Samples (S) were incubated with anti-
AR or anti-USP10 antibodies before incubation with Protein G sepharose (PGS). Extract (EX) samples were incubated 
with PGS but where not exposed to antibodies. The antibody only control (ab) contained only lysis buffer mock 
immuno-precipitated with anti-AR or anti-USP10 antibodies. Western blots are representative of three independent 
experimental repeats. A) Representative Western blots for AR IP, using anti-USP10 (upper panel) and anti-AR (lower 
panel) antibodies. B) Representative Western blots for USP10 IP using anti-AR (upper panel) and anti-USP10 (lower 
panel) antibodies. 
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5.3.5 Effect of USP10 and MDM2 on AR transcriptional activity 
5.3.5.1 Effect of MDM2 on AR transcriptional activity 
As described above, a number of E3 ubiquitin ligases involved in ubiquitination of p53 
are also linked to the regulation and ubiquitination of the AR, including MDM2 (Lin et 
al., 2002b; Gaughan et al., 2005). MDM2 promotes proteasomal degradation of the 
AR, potentially via catalysis of lysine-48 linked poly-ubiquitin chains, ultimately 
reducing activity of the receptor (Lin et al., 2002b; Gaughan et al., 2005). Furthermore, 
a recent study associated USP10 with both MDM2 and p53 showing that MDM2-
mediated nuclear export and subsequent degradation of p53 could be reversed by 
USP10 (Yuan et al., 2010). Considering that USP10 acts to reduce AR activity in LNCaP 
cells (Figure 5.5 and Figure 5.6) coupled to what is already known about the role of 
MDM2 in receptor regulation, it was hypothesised that unlike p53, USP10 may 
cooperate with MDM2 to enhance repression of AR activity. 
To this end, luciferase assays were performed to firstly confirm that MDM2 has a 
repressive effect on the AR as reported previously (Lin et al., 2002b; Gaughan et al., 
2005). COS-7 cells were transfected with 100ng of both ARE3 luciferase and β-gal 
reporters together with 50 ng of AR and either 50 ng or 100ng of MDM2 (represented 
as + and ++ respectively) for 24 hours in serum-containing media prior to replacement 
with steroid-depleted media supplemented with (+ DHT) or without (- DHT) 100 nM 
DHT for a further 48 hours. Luciferase activity was assayed and normalised against β-
gal activity. Data was analysed for statistical significance using the Student’s t-test, 
however no data points were found to be significant. 
As expected and consistent with data in Figure 5.9, AR activity was increased 
approximately 6-fold in response to DHT treatment (Figure 5.12, compare lanes 1 and 
2). However, unlike the literature, co-transfection of cells with MDM2 caused no 
change in androgen-dependent AR activity compared to the control; 6.7-fold and 5.9-
fold above the un-treated AR control with 50 ng and 100 ng MDM2, respectively 
(Figure 5.12, compare lanes 4 and 6 with lane 2). Inclusion of MDM2 overall caused no 
significant change in AR activity compared to the AR only control with DHT treatment 
(P=0.7979 and P=9899 for 50 ng and 100 ng MDM2, respectively). Unfortunately, a 
large amount of variation between individual repeats resulted in large error bars; 
however, it is important to note that no singular repeat resulted in MDM2-mediated 
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reduction of AR activity compared to the AR only control but a variable amount of AR 
induction with androgen stimulation was observed. 
Western blot analysis showed over-expression of AR in each of the samples (Figure 
5.12b, upper panel). Unfortunately, due to problems with the anti-MDM2 antibodies 
analysis of MDM2 over-expression was not possible. 
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Figure 5.12. Effect of MDM2 on AR transcriptional activity in COS-7 cells.  
COS-7 cells were transfected with 100 ng of both ARE3 luciferase and β-gal reporters together with 50 ng androgen 
receptor (AR) and increasing amounts of MDM2 expression vectors; 50 ng (+) and 100ng (++). 24 hours after 
transfection, media was replaced with steroid-depleted media supplemented with (+ DHT) or without (- DHT) 100 
nM DHT and incubated for a further 48 hours. A) Luciferase reporter activity was measured and normalised against 
β-gal activity. Data is represented as fold change compared to the AR only - DHT control. Data is the mean of three 
independent repeats and error bars represent the standard error of the three replicates. Data was analysed for 
statistical significance using the Student’s t-test, however no data points were significant. B) Luciferase assay 
samples were analysed by Western blotting with an anti-AR antibody to ensure over-expression of ectopically 
expressed AR. α-tubulin was used as a loading control. Western blots are representative of three independent 
experimental repeats.. 
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The intriguing result obtained in Figure 5.12 may have been due to number of 
differences between this experimental design and that of the previous Gaughan et al., 
study including the use of a different luciferase reporter and a different AR construct, 
pcDNA3-AR (Gaughan et al., 2005).  
In an attempt to overcome these differences, the same androgen-responsive luciferase 
reporter containing approximately 700 base pairs of the PSA promoter upstream of the 
luciferase gene, pPSA-luc, was used. COS-7 cells were transfected with 100ng of both 
pPSA-luc and β-gal reporters together with 50 ng of AR and either 50 ng or 100 ng of 
MDM2 (represented as + and ++ respectively) for 24 hours in serum-containing media 
prior to replacement with steroid-depleted media supplemented with (+ DHT) or 
without (- DHT) 100 nM DHT for a further 48 hours. Luciferase activity was assayed and 
normalised against β-gal activity. Figure 5.13 shows a representative experiment of 
three independent repeats.  
Employing the pPSA-luc reporter in COS-7 cells was unsuccessful as there was no 
androgenic stimulation of the receptor in cells expressing the AR treated with 100 nM 
DHT (Figure 5.13, compare lanes 1 and 2). AR over-expression was confirmed by 
Western blotting as shown in Figure 5.13b. 
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Figure 5.13. Effect of DHT treatment and MDM2 on the pPSA-luc reporter in COS-7 cells.  
COS-7 cells were transfected with 100 ng of both pPSA-luc and β-gal reporters together with 50 ng androgen 
receptor (AR) and increasing amounts of MDM2 expression vectors; 50 ng (+) and 100ng (++). 24 hours after 
transfection, media was replaced with steroid-depleted media supplemented with (+ DHT) or without (- DHT) 100 
nM DHT and incubated for a further 48 hours. A) Luciferase reporter activity was measured and normalised against 
β-gal activity. Data is represented as fold change compared to the AR only - DHT control. Data is from one repeat 
and is representative of three independent repeats. B) Luciferase assay samples were analysed by Western blotting 
with an anti-AR antibody to ensure over-expression of ectopically expressed AR. α-tubulin was used as a loading 
control. 
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To further address this issue, and to provide evidence that MDM2 reduces AR-
mediated transcription, the ARE3 luciferase reporter experiments were repeated in the 
human osteosarcoma cell line U2OS as this cell line is relatively easy to transfect with 
plasmid DNA, and has been used to interrogate the activity of numerous co-regulators 
on ectopically-expressed AR (Gaughan et al., 2011). 
U2OS cells were transfected as described above for 24 hours in serum-containing 
media prior to growth in steroid-depleted media supplemented with (+ DHT) or 
without (- DHT) 100 nM DHT for a further 48 hours. Results are collated from three 
independent repeats and are represented as the mean fold change compared to the 
AR control without DHT treatment. Data was analysed for statistical significance using 
the Student’s t-test, however no data points were found to be significant. 
Similarly to COS-7 cells using the ARE3 reporter, AR transcriptional activity was induced 
upon DHT treatment in U2OS cells approximately 4-fold (Figure 5.14, compare lanes 1 
and 2). However, in contrast to the COS-7 cells, 50 ng (+) and 100 ng (++) MDM2 
repressed AR transcriptional activity upon DHT stimulation by 50% (Figure 5.14, 
compare lanes 4 and 6 with lane 1). AR over-expression was again confirmed by 
Western blot analysis (Figure 5.14b, upper panel). 
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Figure 5.14. Effect of MDM2 on AR transcriptional activity in U2OS cells.  
U2OS cells were transfected with 100 ng of both ARE3 luciferase and β-gal reporters together with 50 ng androgen 
receptor (AR) and increasing amounts of MDM2 expression vectors; 50 ng (+)and 100ng (++). 24 hours after 
transfection, cells grown in steroid-depleted media supplemented with (+ DHT) or without (- DHT) 100 nM DHT for a 
further 48 hours. A) Luciferase reporter activity was measured and normalised against β-gal activity. Data is 
represented as fold change compared to the AR only - DHT control. Data is the mean of three independent repeats 
and error bars represent the standard error of the three replicates. Data was analysed for statistical significance 
using the Student’s t-test, however no data points were significant. B) Luciferase assay samples were analysed by 
Western blotting with an anti-AR antibody to ensure over-expression of ectopically expressed AR. α-tubulin was used 
as a loading control. Western blots are representative of three independent experimental repeats. 
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Given that USP10 only marginally reduced AR activity in COS-7 cells (Figure 5.9), but 
MDM2 repressed AR transcriptional activity robustly in the U2OS cell line, it was 
important to investigate the effect of USP10 on AR-mediated transcription in U2OS 
cells. 
To this end, U2OS cells were transfected as described in Figure 5.9 and results are 
derived from three independent experimental repeats and are again represented as 
the mean fold change compared to the AR only control without DHT treatment. Data 
was analysed for statistical significance using the Student’s t-test, however no data 
points were found to be significant. 
As expected, AR activity in U2OS cells was induced upon DHT stimulation by 
approximately 5.5-fold (Figure 5.15, compare lanes 1 and 2). Importantly, USP10 over-
expression had a much greater repressive effect on AR activity in U2OS cells compared 
to COS-7, with a maximal 50% reduction in AR induction observed with 25 ng of USP10 
(Figure 5.15, compare lanes 2 and 4) that steadily declined with increasing amounts of 
the DUB enzyme (Figure 5.15, compare lanes 6 and 8 with lane 4). This result, in 
conjunction with the USP10 depletion data in LNCaP cells and luciferase reporter data 
in COS-7 and PC-3 cells suggests a role for USP10 as co-repressor of the AR. Once again 
Western blot analysis confirmed over-expression of both AR and USP10 (Figure 5.15b). 
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Figure 5.15. Effect of USP10 on AR transcriptional activity in U2OS cells.  
U2OS cells were transfected with 100 ng of both ARE3 luciferase and β-gal reporters together with 50 ng androgen 
receptor (AR) and increasing amounts of USP10; 25 ng (+), 50ng (++) and 100ng (+++). 24 hours after transfection, 
cells were grown in steroid-depleted media supplemented with (+ DHT) or without (- DHT) 100 nM DHT for a further 
48 hours. A) Luciferase reporter activity was measured and normalised against β-gal activity. Data is represented as 
fold change compared to the AR only - DHT control. Data is the mean of three independent repeats and error bars 
represent the standard error of the mean of the three replicates. Data was analysed for statistical significance using 
the Student’s t-test, however no data points were significant. B) Luciferase assay samples were analysed by Western 
blotting with anti-AR and -USP10 antibodies to ensure over-expression of ectopically expressed proteins. α-tubulin 
was used as a loading control. Western blots are representative of three independent experimental repeats. 
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5.3.5.2 Effect of MDM2 and USP10 combination on AR transcriptional activity 
MDM2 is regulated by auto-ubiquitination and degradation. It was therefore 
hypothesised that potential deubiquitination of MDM2 by USP10 would protect it from 
degradation and therefore enable enhanced activity towards AR. Therefore, once the 
effects of MDM2 and USP10 on AR function had been established in U2OS cells, it was 
pertinent to assess whether a combination of the two enzymes would further enhance 
repression of AR activity suggesting a possible role for USP10 as an MDM2 DUB. 
U2OS cells were transfected with 100ng of both ARE3 and β-gal reporters together 
with 50 ng AR, 100 ng MDM2 and  50ng USP10 mammalian expression vectors for 24 
hours in serum-containing media prior to growth in steroid-depleted media 
supplemented with (+ DHT) or without (- DHT) 100 nM DHT for an additional 48 hours. 
The amounts of MDM2 (100 ng) and USP10 (50 ng) were chosen based on their ability 
to repress AR activity separately (Figure 5.14 and Figure 5.15). Data is represented as 
fold change compared to AR only without DHT treatment. The data presented is from 
only one experimental repeat and would therefore require repeating in order to 
substantiate the results of this experiment. 
In accordance with the previous data, MDM2 did indeed repress DHT-stimulated AR 
activity; reducing it from 8.3-fold in the AR only control to 3.4-fold (Figure 5.16, 
compare lanes 2 and 4). Unfortunately, and inconsistent with data in Figure 5.15, 
USP10 failed to markedly effect AR activity (Figure 5.16, compare lanes 2 and 6), which 
meant that the entire experiment designed to test potential co-operativity between 
the two AR co-regulators had failed. Although disappointing, this experiment has the 
potential to demonstrate interplay between MDM2 and USP10 within the AR signalling 
cascade and warrants further exploration. 
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Figure 5.16. Effect of MDM2 and USP10 combination on AR transcriptional activity in U2OS cells. 
U2OS cells were transfected with 50 ng androgen receptor (AR), 100 ng of both ARE3 luciferase and β-gal reporters, 
as well as 100 ng MDM2 or 50 ng USP10 or a combination of both. 24 hours after transfection, cells were grown in 
steroid-depleted media supplemented with (+ DHT) or without (- DHT) 100 nM DHT for a further 48 hours. Luciferase 
reporter activity was measured and normalised against β-gal activity. Data is from one experiment and is 
represented as fold change compared to the AR only - DHT control. 
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5.4 Discussion  
USP10 has been reported to be a direct AR interacting protein that causes an increase 
in AR transcriptional activity in addition to direct deubiquitination of ubiquitinated 
histone H2A.Z, influencing AR-regulated gene transcription (Faus et al., 2005; Draker et 
al., 2011). Validation of targets isolated from the siRNA library screen of DUB enzymes 
in LNCaP cells conducted in the Solid Tumour Target Discovery Group, identified USP10 
as a potential regulator of AR transcriptional activity. However, in contrast to the 
previous studies knockdown of USP10 increased mRNA expression and protein level of 
PSA as well as other AR-target genes, including KLK2, TMPRSS2 and NDRG1. 
Over-expression of USP10 in COS-7 cells revealed that it has a subtle repressive effect 
on AR transcriptional activity upon the ARE3 luciferase reporter, although this was not 
statistically significant. However, subsequent extrapolation from these experiments 
into the U2OS cell line model demonstrated a robust attenuation of AR-mediated 
transcription using the ARE3 luciferase reporter. 
The disparity between these findings, both from the USP10 depletion experiments in 
LNCaP cells and the reporter studies in U2OS cells, and those of the Faus et al., and 
Draker et al., reports, that indicate the DUB as an AR co-activator is intriguing and 
suggests a potential cell-type and transcriptional assay dependency on the function of 
USP10 in the AR signalling cascade. The first paper identifying USP10 as a regulator of 
AR activity utilised a PC-3 cell variant, termed PC-3/AR that stably expressed AR. 
Although it is known that PC-3 cells become responsive to androgens upon over-
expression of AR (Kokontis et al., 1991), they may have lost other factors involved in 
the AR signalling cascade and therefore may not function identically to an AR-positive 
cell line. Faus et al., demonstrated that USP10 over-expression in PC-3/AR cells 
increased AR activity upon the murine Pem gene ARE-1 and ARE-2 reporters and that 
the DUB interacted directly with the receptor both in mass spectrometry analysis of 
PC-3/AR nuclear extracts and in cell-free experiments. In contrast, the data presented 
in Figure 5.11 failed to show an endogenous interaction between USP10 and AR in 
LNCaP cells, suggesting either that the interaction in this cell line is transient and thus 
difficult to detect by immunoprecipitation, or that the observation by Faus et al., is a 
potential artefact of protein over-expression in a non-androgenic cell line; further 
studies of the endogenous interaction within other cell lines would be required to 
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elucidate this. In addition, the luciferase assays performed in PC-3 cells using a 
triplicate consensus ARE reporter construct (Figure 5.10) failed to demonstrate an 
effect of USP10 over-expression on AR-mediated transcription, again questioning the 
role of USP10 as a co-activator of the receptor. 
PC-3 cells were originally isolated from a bone metastasis of a grade IV prostatic 
adenocarcinoma (Kaighn et al., 1979). Analysis of gene expression between LNCaP cells 
and PC-3 cells has identified nearly 2200 differentially expressed genes; PC-3 cells 
down-regulate prostate specific genes and up-regulate genes required for angiogenesis 
and invasion (Dozmorov et al., 2009). Furthermore, many studies have shown that 
over-expression of AR in PC-3 results in repression of androgen-induced proliferation 
and invasion, contrary to data from AR positive cell lines where AR is a driver of 
proliferation and metastasis (Niu et al., 2008; Yuan et al., 2010). Although over-
expression of AR in PC-3 cells allows for transcription of known AR regulated genes, 
these cells do not behave identically to their AR-positive counterparts (Dozmorov et 
al., 2009), and therefore USP10 may not behave as it would in AR-positive LNCaP cells. 
Additional AR co-factors may be missing from this cell line, and interestingly, p53, a 
known target of USP10, is not expressed in PC-3 (Skjoth and Issinger, 2006). The AR 
and p53 positive LNCaP cell line was utilised throughout the study, including all of the 
initial validation experiments which is a more physiologically relevant and robust 
model system to interrogate the function of component proteins of the AR signalling 
cascade. 
USP10 was most recently shown to directly deubiquitinate the histone variant H2A.Z, 
resulting in reduction of ubiquitinated histone H2A.Z at AREs of AR regulated gene 
promoters, including PSA, and therefore causing increased transcription of AR-
regulated genes (Draker et al., 2011). These data was consistent with a previous study 
reporting that mono-ubiquitination of H2A.Z was linked to silencing of gene 
transcription (Sarcinella et al., 2007) and suggested that deubiquitination could 
antagonise the repressive effect of H2A.Z modification. Firstly, Draker et al showed 
that USP10 over-expression decreased the levels of ubiquitinated H2A.Z in HEK293 cell 
lysates and confirmed ubiquitinated histone H2A.Z as a substrate of USP10 by use of 
an in vitro deubiquitination assay. Furthermore, immuno-fluorescence and 
cytoplasmic-nuclear extraction in LNCaP cells were used to demonstrate that USP10 
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localised to both the cytoplasm and the nucleus. Histone H2A.Z was present at the 
promoters of the PSA and KLK2 genes in LNCaP cells and the levels of ubiquitinated 
histone were increased upon stable USP10 depletion suggesting retention of this 
histone modification after USP10 knockdown. PC-3/AR cells over-expressing an ARE3 
luciferase reporter were utilised to prove that over-expression of USP10 was linked to 
transcriptional activation by AR and that knockdown of USP10 led to a reduction in 
reporter activity. This result was confirmed by decreased mRNA expression of PSA and 
KLK2 in LNCaP cells in response to stable USP10 knockdown (Draker et al., 2011). The 
level of USP10 knockdown achieved by stable shRNA depletion of USP10 in LNCaP 
cells, assessed by detection of USP10 Western blotting, was approximately 80% 
(Draker et al., 2011); this was in contrast to the USP10 protein levels shown in Figure 
5.6c, which were undetectable by Western blotting following siRNA knockdown. Due 
to the differences in knockdown methodologies and use of the stably transfected PC-
3/AR cell lines highlighted in the previous paragraph, it is intriguing to speculate that if 
these experiments were repeated in LNCaP cells using an shRNA knockdown approach, 
that the effect of USP10 on AR activity and H2A.Z ubiquitination status may not be the 
same. It is worth noting, however, that USP10 could be acting at an epigenetic level in 
addition to directly within the signalling cascade to affect AR transcriptional activity.  
From the literature, it is known that USP10 counteracts MDM2-mediated 
ubiquitination of p53 and hence facilitates p53 function in response to DNA damage 
(Yuan et al., 2010). Due to the link between MDM2 and the AR, it was hypothesised 
that USP10 and MDM2 function co-operatively within the AR signalling system to 
regulate receptor activity. It has been shown previously that MDM2-mediated 
ubiquitination of the AR causes receptor degradation and transcriptional repression 
(Lin et al., 2002b; Gaughan et al., 2005). However, this was not observed in the first 
luciferase experiments in COS-7 cells. This discrepancy may have been due to the use 
of the ARE3 reporter in these experiments compared to the pPSA luc reporter 
construct employed in the Gaughan et al., study. As such, in contrast to this earlier 
study, it was found that MDM2 in COS-7 cells failed to affect AR transcriptional 
activation upon the synthetic ARE3 luciferase reporter (Figure 5.12), while attempts 
with the pPSA-luc reporter were unsuccessful due to very high background reporter 
activity resulting in no androgen-induced activation of the AR. It was therefore 
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important to repeat the luciferase experiments in the osteosarcoma cell line U2OS as it 
is a human cell line that has high transfection efficiency and thus lends itself to this 
kind of study. In this cell line, MDM2 was found to repress AR transcriptional activity 
upon the ARE3 reporter by upwards of 50% (Figure 5.14) indicating a cell line 
dependency for the function of MDM2 upon the AR using the ARE3 reporter. The 
differences between the responses of the two cell lines could be due to: (1) species 
specific differences as COS-7 are a monkey cell line and U2OS are a human cell line; (2) 
differences in expression of other proteins involved in the ubiquitination or turnover 
process of the receptor; or (3) the fact that the reporter is a synthetic ARE rather than 
an endogenous one, hence repeating these experiments with the pPSA luc reporter in 
U2OS cells would be an important extrapolation to the study. 
The next step in the investigation was to assess potential interplay between 
transcriptional repression of AR by MDM2 and USP10. It was hypothesised that a 
combination of the two enzymes, both shown to repress AR activity (Gaughan et al., 
2005), would enhance the repressive effect on the AR signalling cascade. 
Unfortunately, this experiment failed, in part, due to the failure of USP10 to down-
regulate AR activity and hence the combination effect of USP10 and MDM2 could not 
be addressed (Figure 5.16). However, this experiment is from only one experiment and 
should be repeated to further address the hypothesis. One important question from 
this experiment is why did USP10 not repress AR activity given that it was shown in 
Figure 5.15 to repress receptor function by 50%? Although difficult to predict, and 
given that it was only a single experiment, it could be due to the increased levels of 
plasmid DNA being over-expressed in this system that resulted in transcriptional 
squelching. However, it is worth noting that MDM2 functioned as expected so this may 
negate this argument. Obviously, repeats of this experiment are necessary. 
In conclusion, USP10 has been identified as a transcriptional co-repressor of AR in 
contrast to previously published work in this area (Faus et al., 2005; Draker et al., 
2011). USP10 knockdown increases the expression of the majority of AR regulated 
genes investigated. Over-expression of USP10 in three cell lines suggested that it has a 
repressive effect on AR signalling. However, further studies interrogating the potential 
interplay between USP10 and MDM2 would be a fascinating extension to the 
investigation. In addition, assessment of both USP10 and MDM2 catalytic mutants 
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individually and together on AR activity would be interesting to explore. The link 
between MDM2 and Akt warrants investigating in this system as it may promote 
additional effects of MDM2 and potentially USP10. Further investigation of USP10 
recruitment to AR regulated promoter and reinvestigation of its role in histone 
deubiquitination in AR positive cell lines may be vital in solving the conflicts between 
the data presented above and previous reports (Faus et al., 2005; Draker et al., 2011). 
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6 Chapter 6: Generation of recombinant GST-tagged AR C-
terminal domain proteins and USP10 as tools for in vitro 
assays 
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6.1 Introduction 
6.1.1 Post-translational modification of the Androgen receptor 
Post-translational modifications of nuclear hormone receptors by phosphorylation, 
acetylation, methylation, SUMOylation and ubiquitination can dramatically alter their 
functionality and stability (Anbalagan et al., 2012). The AR contains 23 reported 
residues that are the target of modification (Gioeli and Paschal, 2012), these are 
summarised in Figure 6.1. 
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Figure 6.1. The sites of AR post-translational modification.  
Post-translational modification of the AR occurs within each of the domains; the N-terminal domain (NTD), DBD-
binding domain (DBD), the hinge and the ligand-binding domain (LBD). The AR is modified by phosphorylation, 
acetylation, methylation, SUMOylation and ubiquitination. Adapted from (Gioeli and Paschal, 2012). 
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Phosphorylation of the AR at the serine, threonine and tyrosine residues can affect 
multiple aspects of AR activity including transcriptional activity, cellular localisation 
and stability (Gioeli and Paschal, 2012). The majority of phosphorylation sites are 
clustered in the N-terminal transactivation domain (NTD) of the AR, although at least 
one phosphorylation site is found in each of the other receptor domains, including the 
DBA-binding domain (DBD) and ligand-binding domain (LBD) (Gioeli and Paschal, 
2012). Phosphorylation of many sites is found to increase in the presence of androgen 
and several sites are phosphorylated in response to epidermal growth factor (EGF) 
treatment (Yang et al., 2007). Akt, MAPK and members of the stress kinase family are 
found to influence AR phosphorylation (Lin et al., 2001; Lin et al., 2003; Gioeli et al., 
2006; Ponguta et al., 2008). Phosphorylation of S213 and S791 is induced by EGF- and 
insulin-like growth factor (IGF)-mediated activation of Akt (Lin et al., 2001; Lin et al., 
2003). Phosphorylation of these sites was found to have a differential effect on AR 
transcriptional activity depending on the passage number of the LNCaP cells 
investigated; low passage number LNCaP cells showed repression of AR activity upon 
phosphorylation by Akt whereas high passage number LNCaP cells showed increased 
transcriptional activity (Lin et al., 2003).  
The sites of acetylation are found clustered within the conserved KLKK/RXKK motif of 
the hinge region of the AR (Faus and Haendler, 2006). Mutation of K630, K632 or K633 
sites is found to impair recruitment of co-activator proteins and promote recruitment 
of the N-CoR co-repressor therefore inhibiting AR activation (Faus and Haendler, 
2006). Acetylation of AR is mediated by p/CAF, p300 and Tip60 (Fu et al., 2000; Fu et 
al., 2002; Gaughan et al., 2002). Over-expression of AR K630Q, a mutant in which the 
lysine at position 630 is mutated to a glutamate and mimics constitutive acetylation, in 
CaP cells is found to increase cell growth and reduce apoptosis (Gioeli and Paschal, 
2012). SET9, a methyltransferase, has also been reported to methylate the AR at K630 
and K632 of the KLKK motif (Gaughan et al., 2011). Methylation by SET9 up-regulates 
AR activity by enhancing the interaction of the N- and C-terminal domains of the AR 
(Gaughan et al., 2011).  
SUMOylation is the conjugation of a small ubiquitin-like protein, SUMO, to the lysines 
of a target protein in a process similar to ubiquitination (Hay, 2006). Two SUMOylation 
sites have been reported within the NTD, K386 and K520 (Poukka et al., 2000). 
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SUMOylation is androgen-induced and mediated by the SUMO E3 ligase Ubc9 (Poukka 
et al., 1999). SUMOylation is generally repressive for AR activity; SUMOylation is 
dependent for recruitment of the Co-repressor Daxx (Lin et al., 2004). 
Until recently the ubiquitination sites of the AR were unknown despite several E3 
ligases being implicated in the regulation of AR activity and stability. Xu et al., reported 
ubiquitination of the AR by the novel E3 ligase RNF6 (Xu et al., 2009). Importantly, this 
study was the first to report the exact location of ubiquitination sites within the AR. In 
vitro ubiquitination assays and proteomic analysis revealed that RNF6-mediated 
ubiquitination occurred at K845 and K847 of the AR LBD (Xu et al., 2009). These poly-
ubiquitination events promoted AR-mediated transcription of target genes through 
promotion of ARA54, an AR co-activator, recruitment (Xu et al., 2009). Interestingly, 
K845 ubiquitination was found to act as a prerequisite for the efficient ubiquitination 
of K847; mutation of K845 to arginine abolished RNF6-mediated ubiquitination and 
activation of AR activity whilst mutation of K847 only partially reduced ubiquitination 
and did not affect AR activity (Xu et al., 2009). Furthermore, examination of a panel of 
ubiquitin mutants able to form only one type of poly-ubiquitin linkage revealed that 
RNF6 preferentially formed K6- and K27-linked chains (Xu et al., 2009).  
Alternative ubiquitination sites have currently not been identified; however it is 
possible that additional target sites exist not just within the LBD but also within other 
AR domains. With this mind, in vitro ubiquitination assays provide a possible means to 
preliminarily identify novel ubiquitination sites with the AR by profiling each of the AR 
domains with all of the currently known AR-associated E3 ligases. Additionally, these 
experiments in combination with ubiquitin mutants would allow identification of the 
specific poly-ubiquitin chain types formed by the specific E3 ligases on the AR. 
6.1.2 Deubiquitinase enzymes and the Androgen receptor 
Ubiquitination of the AR can be counteracted by DUB enzymes. USP10 and USP26 
directly influence the ubiquitination status of the AR (Faus et al., 2005; Dirac and 
Bernards, 2010). Data from the Faus et al., and Draker et al., studies shows that USP10 
regulates the ubiquitination both the AR and histone H2A.Z via a direct interaction 
with both proteins leading to stimulation of transcription of AR target genes (Faus et 
al., 2005; Draker et al., 2011). USP26 is found to directly interact with the AR and is co-
localised to the nucleus in an androgen-dependent manner (Dirac and Bernards, 2010). 
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Unlike USP10 however, USP26 was found to both inhibit and activate AR activity 
depending on the cell background investigated (Dirac and Bernards, 2010). Despite 
both enzymes being implicated directly in the deubiquitination of AR neither has been 
evaluated for their ubiquitin chain specificity or ubiquitination site specificity. 
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6.2 Aims 
In order to build a complete picture of the function of ubiquitination in the context of 
the AR we need to examine the relationships between AR-associated E3 ligases and 
their DUB counterparts including analysis of the specific ubiquitin chains they target. In 
vitro assays provide a tool to test hypothesised ubiquitination events in a cell-free 
environment before more robust characterisation studies are undertaken. To develop 
this methodology further recombinant AR substrate proteins and enzymes were 
required. 
The specific aims of this Chapter are: 
 To generate a series of AR C-terminal domain expression vectors designed to 
produce GST-tagged recombinant protein in bacterial cells and utilise GST 
affinity chromatography as a mean to purify these proteins 
 To study the specific sites of androgen receptor ubiquitination via in vitro 
ubiquitination assays 
 To employ GST affinity chromatography to purify enzymatically active 
recombinant GST-tagged USP10 
 To investigate the enzymatic activity of recombinant GST-tagged USP10 against 
specific lysine-linked poly-ubiquitin chains in vitro 
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6.3 Materials and methods 
6.3.1 Generation of pGEX-6P-1-AR-DBD, pGEX-6P-1-AR-DBD-Hinge and pGEX-
6P-1-AR-DBD-Hinge-LBD 
6.3.1.1 Agarose gel electrophoresis 
All products of PCR, digestion, gel extraction and plasmid preparations were analysed 
by agarose gel electrophoresis on 1% agarose gels (1% agarose in Tris acetate EDTA 
(TAE) buffer). Samples were mixed with DNA sample buffer (30% sucrose, 100 mM 
EDTA pH8, 0.05% bromophenol blue) before loading alongside Hyperladder I, II or IV 
DNA marker (Bioline). Samples were run at 100 V for approximately 30 minutes and 
gels were stained with ethidium bromide and visualised using the GelDoc™ DNA 
analysis equipment (Bio-Rad).  
6.3.1.2 PCR 
To amplify the different domains of the AR, 100 ng of pYFP-AR was used as a template 
in a PCR reaction containing 1 nM of each primer (Table 6.1), 1 x reaction buffer 
(containing MgCl2), 0.2 mM dNTPs and 1.5 units of Taq polymerase (Bioline) in a total 
volume of 10 μl. PCR reactions were performed on the PCR express thermal cycler 
HBX110 (Thermo Hybaid). 
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Table 6.1. Sequence of PCR primers used in the amplification of the AR C-terminal domains. 
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6.3.1.3 Diagnostic digestion and vector ligation 
Resultant AR amplicons were cut from an agarose gel, DNA extracted using the 
QIAquick spin gel extraction kit (as described by the manufacturer, Qiagen) and ligated 
into the pCR2.1 vector using the TA cloning kit according to the manufacturer’s 
recommendations (Invitrogen). Briefly, ligation reactions were set up containing 25 ng 
of vector and approximately 10 ng of the desired AR amplicon with 4 units of T4 DNA 
ligase on a total volume of 10 μl. Ligation reactions were incubated at 14 oC overnight 
and were transformed into chemically competent E.coli as described in Section 2.2.4. 
Transformants were selected by blue/white selection on ampicillin and bromo-chloro-
indolyl-galactopyranoside (X-gal)-containing LB agar plates. 
Small-scale plasmid preparations (minipreps) of colonies containing potentially 
recombinant pCR2.1-AR C-terminal domain vectors were performed using the 
GenElute plasmid miniprep kit (as described by the manufacturer, Sigma-Aldrich) and 
resultant plasmid DNA digested with the appropriate restriction enzymes (Fermentas) 
i.e. Bam HI and Eco RI for the AR-DBD and DBD-hinge and Bam HI and Xho I for DBD-
hinge-LBD for 1 hour at 37 oC. Released inserts were size-verified by agarose gel 
electrophoresis prior to sub-cloning into the pGEX-6P-1 vector (GE healthcare) 
following the same ligation protocol. Recombinant pGEX-6P-1-AR C-terminal domain 
vectors were identified by diagnostic restriction enzyme digestion as described above 
and subsequently transformed into XA90 or BL21 strains of competent E.coli using the 
protocol described in section 2.2.4. Once again, recombinant vectors were identified 
by diagnostic digestion and subsequently subject to large-scale plasmid preparation 
(maxiprep) using an endotoxin-free plasmid maxiprep kit (Qiagen). Resultant plasmids 
were sequenced by Cogenics (UK). 
6.3.2 Protein purification  
6.3.2.1 Small scale protein induction 
A positive XA90 or BL21 colony from specific pGEX-6P-1-AR recombinants were 
inoculated into 10 ml of LB media containing 50 μg/ml ampicillin and grown overnight. 
This colony was also streaked onto a fresh ampicillin-containing LB agar plate and 
incubated over-night at 37 oC.  
227 
 
500 μl of over-night culture was added to fresh LB media with 50 μg/ml ampicillin and 
grown for a further 3 hours at 37 oC before 9 μl of 1 M isopropyl B-D-1-
thiogalactopyranoside (IPTG) was added to induce protein production. 1 ml samples 
were collected at the point of induction and each hour after induction for a total of 4 
hours as shown in Figure 6.2. These samples were pelleted by centrifugation and the 
pellets resuspended in 150 μl of water before sonication for 3 x 5 min using the 
Bioruptor system (Diagenode). 150 μl of SDS sample buffer was added and the samples 
separated by gel electrophoresis on 15% poly-acrylamide gels as described in section 
2.8.1 and stained with Coomassie as described below. 
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Figure 6.2. Schematic of small-scale protein induction.  
XA90 or BL21 E. coli cells transformed with pGEX-6P-1 vectors and cultured overnight at 37 
o
C. 500 μl of culture was 
inoculated into 9.5 ml fresh media and grown for 3 hours before stimulation of protein production by addition of 
IPTG. Samples were collected at the points shown for analysis by SDS-PAGE and Coomassie staining. 
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6.3.2.2 Large scale protein induction 
A positive colony was picked from XA90 or BL21 plates and inoculated into 10 ml of LB 
media containing 50 μg/ml ampicillin and grown overnight at 37 oC. 5 ml of over-night 
culture was added to 500 ml fresh LB media with 50 μg/ml ampicillin. 1 ml samples 
were collected each hour and the optical density at 600 nm measured using the 
SmartSpec Plus spectrophotometer (Bio-Rad) until 0.5 was achieved.   
500 μl of 1 M IPTG was added to induce protein production and the culture incubated 
for a further 4 hrs. 1 ml samples were collected at the point of induction and after 4 
hour incubation as shown in Figure 6.3. These samples were pelleted by centrifugation 
and resuspended in 150 μl of water and 150 μl of SDS sample buffer added.  
After 4 hours of protein induction, bacterial cells were pelleted using the Avanti J-26 
XP centrifuge (Beckman Coulter) and the pellets resuspended in 40 ml ice cold PBS 
before being stored at -20 oC.  
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Figure 6.3. Schematic of large-scale protein induction. 
XA90 or BL21 E. coli cells transformed with pGEX-6P-1 vectors were cultured overnight at 37 
o
C. 5 ml of culture was 
inoculated into 500 ml fresh media and grown until an optical density (O.D) 600 of 0.5 was achieved. Protein 
production was stimulated by addition of IPTG. Cultures were grown for a further 4 hours before cells were pelleted 
and resuspended in 40 ml PBS. Samples were collected at the points shown for analysis by SDS-PAGE and Coomassie 
staining. 
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6.3.2.3 GST affinity chromatography 
Bacterial cell resuspensions produced from large-scale protein inductions (40 ml) were 
thawed on day of purification and the following added; 1 ml PBS containing 4 protease 
inhibitor tablets and 200 μl 1 M Phenylmethylsulfonyl fluoride (PMSF). The cultures 
were sonicated for 6 x 15 sec with 1 min intervals using the Soniprep 150 plus 
sonicator (MSE), centrifuged and the supernatant passed through Mira cloth 
(Calbiochem) to remove any cellular debris. The filtered sample was then loaded onto 
a column containing 2.5 ml glutathione sepharose (GE healthcare) and incubated for 5 
minutes.  
The initial flow through from the column was collected. Subsequently, the column 
washed twice with 20 ml ice cold PBS and the washes were also collected. The GST-
tagged protein was then eluted using 15 ml of elution buffer (10 mM reduced 
glutathione, Tris pH 8.0) and collected in approximately 1 ml fractions. Fractions were 
then pooled together and subject to buffer exchange by dialysis overnight at 4 oC. 
Dialysis buffer A (50 mM NaCl and 50 mM HEPES pH8.0) was used for all non-
enzymatically active substrate proteins whilst dialysis buffer B (50 mM NaCl, 50 mM 
HEPES pH8.0, 5mM DTT and 15% glycerol) was used for all recombinant enzymes. 
Fractions were stored at -80 oC. The process is summarised in Figure 6.4. 
150 μl samples were collected at each step of the purification process and 150 μl SDS 
sample buffer added. These samples and those collected from the large scale induction 
were separated by SDS-PAGE.  
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Figure 6.4.  Schematic of the GST affinity chromatography protocol. 
Protease inhibitors and PMSF were added to bacterial resuspensions from the large-scale protein induction process before samples were sonicated and filtered. Samples were loaded onto freshly 
prepared glutathione sepharose columns and incubated for 5 minutes. The sample flow through was collected and the column was washed twice with PBD. Proteins were eluted into approximately 1 
ml fractions by addition of elution buffer to the column. Samples were collected at the points shown for analysis by SDS-PAGE and Coomassie staining. 
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6.3.3 In vitro ubiquitination assay 
In vitro ubiquitination assay reagents were purchased from Boston Biochem (Boston, 
MA) with the exception of GST-tagged AR C-terminal domain proteins that were 
generated in-house (see Section 6.4.1.2). To investigate ubiquitination of the AR C-
terminal domains by MDM2, in vitro ubiquitination assays containing 2 μl reaction 
buffer, 100 nM UBE1 (E1 enzyme), 5 μM UbcH5a (E2 enzyme), 1 μM MDM2 (E3 ligase), 
200 μM K7R ubiquitin, 3.5 μl AR substrate and 10 mM ATP in a total volume of 20 μl 
were set up. Reactions were incubated at 37 oC for 4 hours before termination by 
addition of 1 μl E1 stop buffer. SDS sample buffer with 1% β-mercaptoethanol was 
added to all samples before analysis by SDS-PAGE, Coomassie staining and Western 
blot.  
6.3.3.1 In vitro deubiquitination assay 
To investigate the enzymatic activity of recombinant GST-tagged USP10 in vitro 
deubiquitination assays were set-up containing 2 μl reaction buffer, 50 ng/μl penta-
ubiquitin (either K48- or K63 linked) and 0-5 μl of GST-tagged USP10 in a total volume 
of 20 μl. Reactions were incubated at 37 oC for up to 4 hours and terminated by 
addition of SDS sample buffer containing 1% β-mercaptoethanol. Samples were 
analysed by SDS-PAGE and Western blotting.  
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6.4 Results 
6.4.1 Generation and purification of recombinant GST-tagged AR C-terminal 
domain proteins 
6.4.1.1 Generation of pGEX-6P-1-AR C-terminal domain bacterial expression 
vectors 
To increase our understanding of AR ubiquitination an in vitro ubiquitination assay 
approach would be utilised. This cell-free methodology allows investigation of 
different E3 ligases in their ability to ubiquitinate the AR as well as enabling the exact 
sites of ubiquitination to be identified by subsequent mass spectrometry analysis.  
In order to generate a series of recombinant AR substrate proteins for in vitro 
ubiquitination assays a series of AR expression vectors were generated. These vectors 
encompassed the domains of the AR C-terminal namely the DNA-binding domain 
(DBD), the hinge region and the ligand-binding domain (LBD). Specific forward and 
reverse primers were designed to amplify the AR-DBD, AR-DBD-Hinge and AR-DBD-
Hinge-LBD from the pYFP-AR vector by PCR. These primers contained specific sites for 
restriction enzyme cleavage; Bam HI and Eco RI sites for the AR-DBD and DBD-Hinge 
and Bam HI and Xho I for the DBD-Hinge-LBD. Figure 6.5 shows a schematic 
representation of the AR domains amplified. 
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Figure 6.5. Schematic of the AR C-terminal domains amplified by PCR. 
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AR-DBD, DBD-Hinge and DBD-Hinge-LBD cDNA was successfully amplified by PCR 
(Figure 6.6). Amplification of the AR-DBD and DBD-Hinge was performed by Miss 
Lynsey Rogerson. Figure 6.6a shows the products of these PCR reactions after gel 
extraction. The DBD is approximately 300 bp whilst the DBD-Hinge is approximately 
500 bp. Figure 6.6b shows the result of PCR of the AR-DBD-Hinge-LBD.  An amplicon of 
approximately 1100 bp is seen in the PCR reaction containing template whilst no 
amplification was see in the no template control. 
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Figure 6.6. AR C-terminal domain amplicons were amplified from pYFP-AR. 
A) Androgen receptor (AR)-DBD and AR-DBD-Hinge were amplified by PCR from the pYFP-AR vector before gel 
extraction. These products were of the correct predicted size of approximately 300 bp and 500 bp (indicated by the 
red boxes). This work was performed by Miss Lynsey Rogerson. B) AR-DBD-Hinge-LBD was amplified by PCR from the 
pYFP-AR vector. This product was of the correct predicted size of approximately 1100 bp (indicated by the red box). 
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Each AR C-terminal domain amplicon was successfully ligated into the pCR2.1 vector 
(Invitrogen) and subsequently excised using the appropriate restriction enzymes 
(Figure 6.7a). The amplicons were then sub-cloned into the pGEX-6P-1 vector. 
Diagnostic digestion of the recombinant pGEX-6P1-1-AR-DBD, pGEX-6P-1-AR-DBD-
Hinge and pGEX-6P-1-AR-DBD-Hinge-LBD vectors was achieved using the appropriate 
restriction enzymes (Figure 6.7b and c). The recombinant vectors were sequenced to 
ensure no point mutations had been introduced during the cloning process. Restriction 
maps and sequencing details of the vectors generated can be seen in the appendix. 
  
239 
 
 
 
 
 
Figure 6.7. AR C-terminal domain fragments were successfully sub-cloned 
A) The androgen receptor (AR) C-terminal domain PCR products were ligated into the pCR2.1 vector. Positive 
transformants were digested with Bam HI and either Eco RI or Xho I to release the amplicon sequences (indicated by 
the red boxes). B) The restriction enzyme digested AR-DBD and DBD-Hinge fragments were ligated into the pGEX-6P-
1 vector via Bam HI and Eco RI restriction sites. Recombinant vectors were assessed by digestion with Bam HI and 
Eco RI (indicated by the red boxes). C) The restriction enzyme digested AR-DBD-Hinge-LBD was ligated into the pGEX-
6P-1 vector via Bam HI and Xho I restriction sites. Recombinant vectors were assessed by digestion with Bam HI and 
Xho I (indicated by the red box).  
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6.4.1.2 Purification of recombinant GST-tagged AR C-terminal domain 
proteins 
The next stage, once the pGEX-6P-1 vectors were generated and verified, was to 
produce large quantities of our GST-tagged AR C-terminal domain proteins in bacterial 
cells. These proteins could then be purified using affinity chromatography. As a 
comparison for protein induction and quality of purification, the pGEX-6P-1 empty 
vector which would generate the recombinant GST-tag alone was included in the 
purification series alongside the AR C-terminal domain vectors. Recombinant GST-tag 
would also be useful for subsequent in vitro experiments as a control. Figure 6.8 shows 
a schematic of the GST-tagged proteins to be generated and the approximate 
molecular weight of each of these proteins. 
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Figure 6.8. Schematic of the GST-tagged recombinant proteins generated by bacterial expression of the pGEX-6P-
1-AR C-terminal vectors. 
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Firstly, the pGEX-6P-1 empty vector and pGEX-6P-1-AR-DBD  were transformed into 
the XA90 strain of E. coli, a strain commonly used for production of large quantities of 
recombinant proteins. Then, to test the protein production capabilities of this bacterial 
strain, a small-scale protein induction was performed. A 10 ml culture of each vector 
was grown overnight at 37 oC before 500 μl was added to fresh culture medium and 
grown for a further 3 hours. Protein production was induced by addition of 1M IPTG, a 
non-hydrolysable lactose analogue that can be used by the lac operon to drive 
transcription, and propagated for a further 4 hours. Samples from the culture were 
collected before induction and after each hour of IPTG treatment for analysis by SDS-
PAGE and Coomassie staining.  
As seen in Figure 6.9a, low levels of corresponding weight GST protein was present 
before treatment with IPTG, but was induced after one hour of treatment and was 
greatest after 4 hours. This was also the case for the recombinant GST-tagged AR-DBD; 
although the overall levels of protein were much lower (Figure 6.9b). 
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Figure 6.9. Small-scale induction of recombinant GST-tag and GST-tagged AR-DBD protein in XA90 E. coli. 
XA90 bacterial cultures transformed with pGEX-6P-1 empty vector or pGEX-6P-1-AR-DBD were induced to produce 
recombinant GST-tagged proteins by treatment with 1 M IPTG for 4 hours. The input (In) sample represents the un-
stimulated culture and was collected before treatment. Samples were collected after 1, 2, 3 and 4 hours of IPTG 
stimulation. Samples were analysed by SDS-PAGE and Coomassie staining. A) Small-scale protein induction of pGEX-
6P-1 empty vector. Recombinant GST-tag was induced with addition of IPTG (indicated by the red box). B) Small-
scale protein induction of pGEX-6P-1-AR-DBD. Recombinant GST-tagged AR-DBD was induced with addition of IPTG 
(indicted by the red box). 
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Once satisfied that the addition of IPTG drove production of recombinant proteins, 
large-scale inductions were set up. Similar to the small-scale cultures, a 10 ml culture 
for each vector was grown overnight at 37 oC. 5 ml of this culture was added to 500 ml 
of fresh culture medium and grown until an optical density 600 (OD600) of 0.5 was 
achieved. Protein production was induced by addition of 1M IPTG and the culture 
grown for a further 4 hours. Bacterial cells were then pelleted by centrifugation and 
resuspended in PBS. At this stage protease inhibitors and PMSF were added to block 
proteolytic degradation of the proteins. Soluble and non-soluble proteins were 
released from the cells by a series of sonication steps and the sample was loaded onto 
a freshly prepared glutathione sepharose column. The sample was incubated on the 
column for 5 minutes before it was allowed to flow through. After washing, the bound 
proteins were eluted from the column using reduced glutathione. At each stage, a 
sample was taken for analysis by SDS-PAGE and Coomassie staining. Protein elution 
fractions were pooled together and subject to buffer exchange by dialysis overnight 
into dialysis buffer A. 
Figure 6.10a and b show the purification profiles of recombinant GST and GST-tagged 
AR-DBD respectively. Little protein of interest is lost in the column flow through (FT) or 
washes indicating that these proteins have successfully bound to the column. The 
eluted fractions of the GST-tag purification show large amounts of recombinant 
protein present (expected size approximately 26 kDa)(Figure 6.10a), however the 
amount present in the fractions of the GST-tagged AR-DBD is much smaller (expected 
size approximately 33 kDa)(Figure 6.10b). It is also important to note that a large 
amount of background proteins were also eluted from the columns; in the case of the 
GST-tagged AR-DBD these background proteins are of similar size and amount to the 
protein of interest making it difficult to determine whether this purification had been 
successful. 
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Figure 6.10. Purification of recombinant GST-tag and GST-tagged AR-DBD from XA90 E.coli cultures by GST 
affinity chromatography. 
XA90 bacterial cultures transformed with pGEX-6P-1 empty vector or pGEX-6P-1-AR-DBD were subject to large-scale 
culturing and protein induction by treatment with 1 M IPTG for 4 hours. Bacterial cells were pelleted and 
resuspended in PBS before addition of protease inhibitors and PMSF. Suspensions were loaded onto a glutathione 
sepharose column and allowed to flow through. Columns were washed with PBS before bound proteins were eluted. 
Eluted recombinant proteins are indicated by the red boxes. The input (In) sample represents the un-stimulated 
culture and was collected before IPTG treatment. Samples were collected from the flow through (FT), washes and 
eluted fractions. Samples were analysed by SDS-PAGE and Coomassie staining. A) Purification profile of recombinant 
GST-tag. B) Purification profile of recombinant GST-tagged AR-DBD.  
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In order to address the problems highlighted above, the expression vectors were 
transformed into another E. coli strain, BL21, and subject to the same process 
described above. The BL21 strain of E. coli is useful for protein expression, as similar to 
the XA90 strain, it produces T7 polymerase upon IPTG treatment. However, this strain 
lacks several proteases thus potentially reducing the amount of background 
breakdown products that may be seen during the purification process. 
Initial small-scale induction tests were successful for the GST-tag, GST-tagged AR-DBD 
and GST-tagged AR-DBD-Hinge with protein induction observed after 1 hour of IPTG 
treatment (Figure 6.11a, b and c). Unlike the XA90 inductions, however, increased time 
of treatment did not appear to increase the amount of protein induction observed. 
GST-tagged AR-DBD-Hinge-LBD induction was not detectable on Coomassie stained 
gels (Figure 6.12a), however induction was clearly visible via Western blot (Figure 
6.12b). As Western blot is the end-point assay for the in vitro ubiquitination assays, 
large scale culturing for this protein was continued. 
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Figure 6.11. Small-scale induction of recombinant GST-tag, GST-tagged AR-DBD and GST-tagged AR-DBD-Hinge 
proteins in BL21 E. coli. 
BL21 bacterial cultures transformed with pGEX-6P-1 empty vector, pGEX-6P-1-AR-DBD or pGEX-6P-1-AR-DBD-Hinge 
were induced to produce recombinant GST-tagged proteins by treatment with 1 M IPTG for 4 hours. The input (In) 
sample represents the un-stimulated culture and was collected before treatment. Samples were collected after 1, 2, 
3 and 4 hours of IPTG stimulation. Samples were analysed by SDS-PAGE and Coomassie staining. A) Small-scale 
protein induction of pGEX-6P-1 empty vector. Recombinant GST-tag was induced with addition of IPTG (indicated by 
the red box). B) Small-scale protein induction of pGEX-6P-1-AR-DBD. Recombinant GST-tagged AR-DBD was induced 
with addition of IPTG (indicted by the red box).C) Small-scale protein induction of pGEX-6P-1-AR-DBD-Hinge. 
Recombinant GST-tagged AR-DBD-Hinge was inducted by addition of IPTG (indicated by the red box).  
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Figure 6.12. Small-scale induction of recombinant GST-tagged AR-DBD-Hinge-LBD in BL21 E. coli. 
BL21 bacterial cultures transformed with pGEX-6P-1-AR-DBD-Hinge-LBD were induced to produce recombinant GST-
tagged AR-DBD-Hinge-LBD by treatment with 1 M IPTG for 4 hours. The input (In) sample represents the un-
stimulated culture and was collected before treatment. Samples were collected after 1, 2, 3 and 4 hours of IPTG 
stimulation. Samples were analysed by SDS-PAGE, Coomassie staining and Western blot. A) Small-scale protein 
induction of pGEX-6P-1-AR-DBD-Hinge-LBD was not detected by Coomassie staining (indicated by the red box). B) 
Western blot analysis of small-scale protein induction of pGEX-6P-1-AR-DBD-Hinge-LBD samples with anti-GST 
antibodies (indicted by the red box). 
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Samples for SDS-PAGE were collected as described previously, in addition to samples 
were collected after the sonication and filtering steps. Figure 6.13 shows the 
purification profiles of the recombinant GST-tag, GST-tagged AR-DBD and GST-tagged 
AR-DBD-Hinge proteins (Figure 6.13a, b and c respectively). In each case little protein 
was lost into the flow through (FT) or during the washing stages, again indicating good 
binding of the GST-tagged proteins to the affinity column.  
Compared to the previous purifications performed in the XA90 E. coli strain, there was 
a reduction in the amount of recombinant GST-tag eluted from the column (Figure 
6.13a). Also, there appears to be a greater amount of GST-tagged AR-DBD produced 
although this could in part be accredited to the reduction in the total number of 
background proteins also being produced and eluted from the column (Figure 6.13b). 
The purification for GST-tagged AR-DBD-Hinge generated similar amounts of protein as 
the GST-tagged AR-DBD (Figure 6.13c), whilst GST-tagged AR-DBD-Hinge-LBD was 
barely visible on Coomassie stained gels particularly in the later elution fractions 
(Figure 6.14a). Western blot analysis of these samples with anti-GST antibodies 
revealed that protein was present in small amounts in all fractions (Figure 6.14b). The 
elution fractions 2-5 and 6-16 for each protein were pooled together and subject to 
buffer exchange by dialysis into dialysis buffer A. The protein elutions were then 
aliquoted into stocks for use in in vitro ubiquitin assays and stored at -80 oC. 
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Figure 6.13. Purification of recombinant GST-tag, GST-tagged AR-DBD and GST-tagged AR-DBD-Hinge from BL21 
E.coli cultures by GST affinity chromatography. 
BL21 bacterial cultures transformed with pGEX-6P-1 empty vector, pGEX-6P-1-AR-DBD or pGEX-6P-1-AR-DBD-Hinge 
were subject to large-scale culturing and protein induction by treatment with 1 M IPTG for 4 hours. Bacterial cells 
were pelleted and resuspended in PBS before addition of protease inhibitors and PMSF. Suspensions were loaded 
onto a glutathione sepharose column and allowed to flow through. Columns were washed with PBS before bound 
proteins were eluted. Eluted recombinant proteins are indicated by the red boxes. The input (In) sample represents 
the un-stimulated culture and was collected before IPTG treatment. Samples were collected from the flow through 
(FT), washes and eluted fractions. Samples were analysed by SDS-PAGE and Coomassie staining. A) Purification 
profile of recombinant GST-tag. B) Purification profile of recombinant GST-tagged AR-DBD. C) Purification profile of 
recombinant GST-tagged AR-DBD-Hinge. 
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Figure 6.14. Purification of recombinant GST-tagged AR-DBD-Hinge-LBD from BL21 E.coli cultures by GST affinity 
chromatography. 
BL21 bacterial cultures transformed with pGEX-6P-1-AR-DBD-Hinge-LBD were subject to large-scale culturing and 
protein induction by treatment with 1 M IPTG for 4 hours. Bacterial cells were pelleted and resuspended in PBS 
before addition of protease inhibitors and PMSF. Suspensions were loaded onto a glutathione sepharose column and 
allowed to flow through. Columns were washed with PBS before bound proteins were eluted. Eluted recombinant 
GST-tagged AR-DBD-Hinge-LBD is indicated by the red boxes. The input (In) sample represents the un-stimulated 
culture and was collected before IPTG treatment. Samples were collected from the flow through (FT), washes and 
eluted fractions. Samples were analysed by SDS-PAGE, Coomassie staining and Western blot. A) Purification profile 
of recombinant GST-tagged AR-DBD-Hinge-LBD. B) Western blot analysis of the purification profile of recombinant 
GST-tagged AR-DBD-Hinge-LBD with an anti-GST antibody. 
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6.4.1.3 MDM2 ubiquitinates the AR C-terminal in vitro 
As a preliminary assay to test whether the recombinant AR C-terminal domain proteins 
were suitable for in vitro ubiquitination assays, GST-tagged AR-DBD-Hinge-LBD was 
incubated with the E1 enzyme UBE1, the E2 enzyme UbcH5a and the E3 ligase enzyme 
MDM2 for 4 hours at 37 oC in the presence and absence of the reaction activator 10 
mM ATP. This reaction also contained mutant ubiquitin which is incapable of forming 
poly-ubiquitin chains due to mutation of all seven ubiquitin acceptor lysine residues to 
arginine, termed K7R ubiquitin.  
As expected, Coomassie staining of the resultant reaction detected both AR and 
MDM2 (Figure 6.15a). Although ubiquitination of the GST-tagged AR-DBD-Hinge-LBD, 
as evidenced  by higher molecular weight species, was not clearly detected by 
Coomassie staining, it is interesting that the band corresponding to the AR C-terminal 
protein became more pronounced after the addition of ATP to the reaction (Figure 
6.15a). Additionally, auto-ubiquitination of MDM2 was observed upon activation of the 
reaction, this is an internal positive control and indicates that the reaction was indeed 
activated (Figure 6.15a). Analysis of the reaction by Western blot with an anti-C-
terminal AR antibody revealed the presence of a 10 kDa larger molecular weight band 
above the GST-tagged AR-DBD-Hinge-LBD indicating a possible mono-ubiquitination 
event by addition of a single K7R ubiquitin molecule (Figure 6.15b). Further work is 
required to elucidate whether the AR C-terminus is indeed a site of ubiquitination by 
MDM2 and also the other C-terminal domain proteins can be utilised to pin-point the 
exact domains involved. Importantly, this experiment did not include the recombinant 
GST-tag protein as a negative control and so it cannot be determined whether the 
ubiquitination event seen is directly on an AR domain or on part of the GST-tag.  
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Figure 6.15. MDM2 ubiquitinates GST-tagged AR-DBD-Hinge-LBD in vitro. 
In vitro ubiquitination assays were set up containing 100 nM UBE1, 5 μM UbcH5a, 1 μM  MDM2, GST-tagged AR-
DBD-Hinge-LBD and 200 μM K7R ubiquitin. Reactions were activated by addition of 10 mM ATP (+). Control reactions 
contained all components but were not stimulated with ATP (-). Reactions were incubated for 4 hours at 37 
o
C before 
being terminated by addition of stop buffer. Samples were analysed by SDS-PAGE, Coomassie staining and Western 
blot. A) Coomassie staining of in vitro ubiquitination assay samples. AR-DBD-Hinge-LBD and MDM2 are indicated by 
blue arrows. Ubiquitinated MDM2 (MDM2-Ub) was observed in the + ATP reaction (indicated by a blue arrow). B) 
Western blot analysis of the in vitro ubiquitination assay samples with anti-AR  antibodies. AR is indicated by a blue 
arrow. A potentially mono-ubiquitinated form of AR (AR-Ub?) was observed in the + ATP reaction (indicated with a 
blue arrow). 
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6.4.2 Generation of recombinant USP10 
Previous studies of USP10 have revealed that it is a direct interacting partner of the AR 
acting to stimulate transcriptional activity through regulation of Histone H2A.Z 
ubiquitination (Draker et al., 2011). Data presented within this thesis is contradictory 
to these previous reports; showing USP10 does not interact with the AR and has some 
negative effect on transcriptional activity.  
The specificity of USP10 towards different types of poly-ubiquitin chain is unknown 
and could provide an insight into which type of linkages are preferentially recognised 
by USP10. Furthermore, once established, in vitro deubiquitination assays utilising 
USP10 or other DUBs could be used to address whether the AR is a direct target of 
these DUB enzymes. Enzymatically active recombinant GST-tagged USP10 was cultured 
and purified using a modification of the protocol described above. This work was 
performed by Miss Susan Hill under my supervision. 
pGEX-6P-1-USP10 was firstly sequenced to verify that it did not contain any point 
mutations or other alterations that would affect the enzymatic activity of recombinant 
USP10 protein (Faus et al., 2005). Secondly, this vector was transformed into BL21 
bacterial cells and a small-scale protein induction performed to ensure that protein 
was induced with IPTG treatment similar to those above. Figure 6.16 shows that USP10 
protein was induced after 1 hour of IPTG treatment and was greatest after 4 hours of 
treatment. 
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Figure 6.16. Small-scale induction of recombinant GST-tagged USP10 in BL21 E. coli. 
BL21 bacterial cultures transformed with pGEX-6P-1-USP10 were induced to produce recombinant GST-tagged 
USP10 by treatment with 1 M IPTG for 4 hours. The input (In) sample represents the un-stimulated sample and was 
collected before treatment. Samples were collected after 1, 2, 3 and 4 hours of IPTG stimulation. Samples were 
analysed by SDS-PAGE and Coomassie staining. Recombinant GST-tagged USP10 was induced with addition of IPTG 
(indicated by the red box). This work was performed by Miss Susan Hill. 
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Unlike the AR C-terminal domain proteins which were intended to be used as 
substrates in the in vitro ubiquitination assays, the in vitro deubiquitination assays 
required functional enzymatic activity of purified USP10 hence large-scale induction 
and purification of GST-tagged USP10 was performed consecutively to avoid 
unnecessary freezing and thawing of samples and the dialysis buffer was altered to 
contain glycerol to help preserved the protein structure and function. This work was 
performed by Miss Susan Hill under my supervision. 
Figure 6.17 shows the purification profile of recombinant GST-tagged USP10. Once 
again, production of USP10 was induced with addition of IPTG and, like the previous 
purifications, very little protein was lost in the flow through and washes (Figure 6.17a). 
GST-tagged USP10 was successfully eluted from the column in the early fractions 
(elutions 2-5), although it was hardly visible in the later fractions (Figure 6.17a). In 
agreement with the Coomassie gel, analysis of the samples by Western blot showed 
large amounts of GST-tagged USP10 were present in elutions 2-5, while elutions 6-16 
contained markedly less USP10 (Figure 6.17b). The elution fractions 2-5 and 6-16 were 
pooled together and subject to buffer exchange by dialysis overnight in dialysis buffer 
B. 
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Figure 6.17. Purification of recombinant GST-tagged USP10 from BL21 E.coli cultures by GST affinity 
chromatography. 
BL21 bacterial cultures transformed with pGEX-6P-1-USP10 were subject to large-scale culturing and protein 
induction by treatment with 1 M IPTG for 4 hours. Bacterial cells were pelleted and resuspended in PBS before 
addition of protease inhibitors and PMSF. Suspensions were loaded onto a glutathione sepharose column and 
allowed to flow through. Columns were washed with PBS before bound proteins were eluted. Eluted recombinant 
GST-tagged USP10 is indicated by the red boxes. The input (In) sample represents the un-stimulated culture and was 
collected before IPTG treatment. Samples were collected from the flow through (FT), washes and eluted fractions. 
Samples were analysed by SDS-PAGE, Coomassie staining and Western blot. This work was performed by Miss Susan 
Hill. A) Purification profile of recombinant GST-tagged USP10. B) Western blot analysis of the purification profile of 
recombinant GST-tagged USP10 with an anti-GST antibody. 
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6.4.2.1 USP10 deubiquitinates penta-ubiquitin chains in vitro 
To test the enzymatic activity of the purified recombinant GST-tagged USP10, an in 
vitro deubiquitination assay was utilised. Varying amounts of GST-tagged USP10 (2.5–5 
μl) were incubated with 50 ng/μl of either K48-linked or K63-linked penta-ubiquitin 
chains for up to 4 hours at 37 oC. Control reactions containing all of the necessary 
components but no recombinant USP10 were also set up. Reactions were terminated 
by addition of SDS sample buffer and analysed by Western blotting using the anti-K48 
ubiquitin or K63 ubiquitin specific antibodies (Figure 6.18). This work was performed 
by Miss Susan Hill under my supervision. 
Figure 6.18a shows the results of the in vitro deubiquitination assay for the K48-linked 
penta-ubiquitin chains. It is important to note that tetra-ubiquitin chains were 
observed under all conditions suggesting that this cleavage of one ubiquitin moiety 
was not due to addition of USP10 (Figure 6.18a). Moreover, addition of recombinant 
GST-tagged USP10 to these reactions had no effect of cleavage of these ubiquitin 
chains. 
Interestingly, addition of recombinant USP10 to K63-linked penta-ubiquitin chain 
reactions did have an effect on chain cleavage with the appearance of mono- and di-
ubiquitin chains (Figure 6.18b). Similar to K48 penta-ubiquitin, some cleavage products 
were present before the addition of enzyme, tetra- and tri-ubiquitin chains. 
Deubiquitination was also increased with time as more prominent mono- and di-
ubiquitin bands were observed after 4 hours reaction time (Figure 6.18b). 
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Figure 6.18. GST-tagged USP10 deubiquitinates K63-linked penta-ubiquitin chains in vitro. 
In vitro deubiquitination assays were set up containing GST-tagged USP10 and 50 ng/μl K48- or K63-linked penta-
ubiquitin chains. Increasing volumes of GST-tagged USP10 were added to the reactions and reactions without GST-
tagged USP10 served as controls. Reactions were incubated for up to 4 hours at 37 
o
C before being terminated by 
addition of SDS sample buffer. Samples were analysed by SDS-PAGE and Western blot with anti-K48- and K63-
specific ubiquitin antibodies. Penta-, tetra-, tri-, di- and mono-ubiquitin chains are indicated by the blue arrows (Ub5, 
Ub4, Ub3, Ub2 and Ub1 respectively). This work was performed by Miss Susan Hill. A) Western blot analysis of in 
vitro deubiquitination assays containing K48-linked penta-ubiquitin chains with anti-K48 ubiquitin specific 
antibodies. B) Western blot analysis of in vitro deubiquitination assays containing K63-linked penta-ubiquitin chains 
with anti-K63 ubiquitin specific antibodies. 
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6.5 Discussion 
Three GST-tagged AR C-terminal fragments were cloned and purified alongside the 
GST-tag control. These proteins were intended to serve as substrates for in vitro 
ubiquitination assays to help elucidate sites of the AR targeted for ubiquitination. An in 
vitro mono-ubiquitination assay was established as a valid starting point for 
identification of novel sites of AR ubiquitination by candidate E3 ubiquitin ligase 
enzymes. Use of the AR fragments generated in this Chapter would potentially identify 
domains of the receptor that are modified and thus provide protein for subsequent 
unequivocal site identification by mass spectrometry. 
Although time constraints did not allow for investigation of the AR NTD to be 
performed, this is another key area for exploration. Xu et al., reported two 
ubiquitination sites within the LBD but their study did not include the NTD. 
Interestingly, the NTD is the site of the majority of phosphorylation events on the AR 
and confers more transcriptional activity than the C-terminal AF-2 domain (Gelmann, 
2002). Two of these modifications, phosphorylation at S515 and Y534 have been linked 
to AR stability (Ponguta et al., 2008; Chymkowitch et al., 2011). Mutation of the S515 
phosphorylation site increases AR stability due to reduced recruitment of MDM2 
(Chymkowitch et al., 2011). Conversely, phosphorylation of Y534 by Src reduces AR 
ubiquitination by reducing the interaction with CHIP (DaSilva et al., 2009). To enable 
study of the ubiquitination sites of this domain purified recombinant GST-tagged AR 
NTD protein has been obtained from Iain McEwan (University of Aberdeen). 
Unfortunately, the AR substrates which were purified in this Chapter would not be 
suitable for proteomic analysis. Although the in vitro assay performed with GST-tagged 
AR-DBD-Hinge-LBD revealed a potential ubiquitination event by Western blot analysis 
(Figure 6.15b) this band was not visible on the respective Coomassie stained gel 
(Figure 6.15a). To identify the exact residues that are the targets for modification, 
bands must be excised precisely from the gels and subject to analysis by proteomic 
techniques. To achieve this more concentrated AR substrates are required. One 
possibility is to immunoprecipitate the recombinant AR C-terminal proteins from the 
elution fractions using an AR C-terminal specific antibody thereby allowing 
concentration of the proteins whilst removing any residual non-specific proteins. 
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Although, the identification of the sites of AR ubiquitination is a key area of research it 
has not been the main focus of the current study. In vitro ubiquitination assays, in this 
case, would serve as a tool to examine the validated DUBs in their ability to remove 
ubiquitin from AR. Using this we can learn about the complex interactions between 
different E3 ligases and DUBs. For example, MDM2-induced ubiquitination may be 
removed exclusively by theoretical DUB X whereas CHIP-induced ubiquitination may be 
removed by both DUBs X and Y. Steinkamp et al., identified androgen ablation therapy-
inducted mutations in the AR NTD and LBD of patients with CRCaP (Steinkamp et al., 
2009). Importantly, one mutation in the CHIP interaction motif within the NTD, E255K, 
led to stabilisation of AR and increased ligand-independent nuclear translocation 
(Steinkamp et al., 2009). The consequences of mis-regulated DUB association or 
expression could provide a parallel mechanism of aberrant AR activation and 
potentially targets for CaP therapy. 
Recombinant GST-tagged USP10 was successfully purified using an adapted 
purification protocol. Although the purification process did not yield high 
concentrations of protein (Figure 6.17) it was found to be enzymatically active (Figure 
6.18). The results of the current study and the previously published work on USP10 
and the AR have been contradictory (Faus et al., 2005; Draker et al., 2011). In vitro 
deubiquitination assays were set up incorporating USP10 and penta-ubiquitin chains of 
the most studied lysine linkages, K48 and K63. Intriguingly, USP10 failed to elicit DUB 
activity towards the K48-linked penta-ubiquitin chains whereas the K63-linked chains 
were disassembled to di- and mono-ubiquitin moieties. K63-linked ubiquitin chains are 
associated with increased transcriptional activation(Hochstrasser, 1992); therefore the 
consequence of disassembly of these chains would be a decrease in activity. This data 
suggests that USP10 may have a role in removing transcriptionally activating 
ubiquitination events from the AR although much more thorough investigation is 
required to support this conclusion. 
USP12 was also identified by the siRNA screen as a DUB which effected AR 
transcriptional activity. Unlike USP10, USP12 was not a candidate for purification and 
in vitro deubiquitination assays in this study as it requires UAF1 and WDR20 to increase 
its enzymatic activity that would have required substantial work (Cohn et al., 2009; Kee 
et al., 2010). Instead, to investigate the specificity of USP12, an in-cell ubiquitination 
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assay could be a more efficient method for studying enzymatic activity. Ectopic 
expression of USP12, in the presence or absence of UAF1, WDR20 and ubiquitin 
followed by immuno-precipitation of AR could provide an insight into whether USP12 
directly affects the ubiquitination status of AR. This type of experiment is also 
important to test the activity of USP10 as in vitro assays do not recapitulate the 
physiological complexity of the ubiquitination-deubiquitination systems. Indeed, the in 
vitro system utilised here is stripped of other factors that may affect the process of 
ubiquitin removal, such as USP10 may not be contained within the same cellular 
compartment as AR or it may be sequestered by interacting-proteins. Nonetheless, in 
vitro assays can be used as a relatively high-throughput methodology providing 
preliminary results for further characterisation experiments in cell-line based studies. 
In conclusion, purification of the GST-tagged AR-DBD, DBD-Hinge, DBD-Hinge-LBD and 
USP10 was successful. The AR C-terminal domains are suitable for exploratory 
experiments looking at the general region of ubiquitination but are not concentrated 
enough for proteomic analysis of the exact sites of ubiquitination. GST-tagged USP10 
was found to be enzymatically active towards K63-linked penta-ubiquitin chains. To 
continue this study, the potential of direct AR deubiquitination by USP10 would be 
assessed and if this process was inherently linked with controlling transcriptional 
activity of the receptor.  
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7 Chapter 7: General Discussion 
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7.1 USP12 as a co-activator of AR transcriptional activity 
USP12 was identified as a regulator of AR activity as a result of a siRNA library screen 
investigating at the effect of DUB enzyme knockdown on AR-regulated gene 
transcription in LNCaP cells. Depletion of USP12 resulted in decreased PSA mRNA and 
protein expression whilst also decreasing the expression of the other androgen-
responsive genes KLK2, TMPRSS2, NKX3.1 and NDRG1. USP12 expression was found 
not to be regulated by androgen and AR mRNA and protein levels remained unaffected 
by USP12 knockdown.  
Luciferase reporter assays in the LNCaP-7B7 pPSA cell line following USP12 depletion 
confirmed that USP12 regulated AR transcriptional activity. Furthermore, over-
expression of ectopic USP12 increased AR transcriptional activity upon the ARE3 
luciferase reporter in COS-7 cells, and this transcriptional activation was dependent on 
the deubiquitinase activity of USP12. 
In order to investigate the potential mechanism by which USP12 regulated AR activity, 
characterisation of the effect of USP12 on AR movement and promoter binding was 
assessed. Cytoplasmic-nuclear fractionation of USP12-depleted LNCaP cells following 8 
hours DHT stimulation demonstrated an increased level of AR in the nucleus of 
untreated LNCaP cells as well as lower AR in the nucleus after 8 hours DHT stimulation. 
These results suggested that USP12 may have a role in retaining or stabilising the AR in 
the nucleus. This result is in conjunction with recent evidence implicating USP12 in 
histone deubiquitination and thus it was hypothesised that USP12 may affect AR 
recruitment at androgen-regulated gene promoters in response to androgen 
treatment. Knockdown of USP12 resulted in reduced AR association at the ARE I of the 
proximal promoter and ARE III of the enhancer of the PSA gene providing evidence of a 
direct role for USP12 in regulation of AR-mediated gene transcription. Moreover, a 
direct interaction between USP12 and AR was observed in COS-7 cells with ectopic 
over-expression suggesting USP12 may potentiate AR recruitment to target promoters 
by physically tethering the receptor to cis-regulatory elements. Use of RNAi rescue to 
incorporate wild-type and deubiquitinase-dead USP12 in similar chromatin 
immunoprecipitation experiments would address whether the deubiquitinase activity 
of USP12 is required for this effect on AR recruitment to target gene promoters. 
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Post-translational modification of histones provides an important mechanism for 
controlling gene transcription (Zhang and Reinberg, 2001; Weake and Workman, 
2008). Furthermore, epigenetic events have been shown to influence the transcription 
of AR-responsive genes. JHDM2A, a JmjC-containing histone H3K9 demethylase, is 
recruited to AR-target gene promoters in response to androgen treatment resulting in 
removal of mono- and di-methylation marks on histone H3K9 and activation of 
transcription (Yamane et al., 2006). USP12 directly deubiquitinates histones H2A and 
H2B, directly linking USP12 transcriptional regulation at the epigenetic level in Xenopus 
(Joo et al., 2011) although this has not been studied in human cells. Investigation of 
histone ubiquitination status at AR-responsive gene promoters, such as PSA and 
TMPRSS2, by chromatin Immunoprecipitation utilising anti-ubiquitinated histone H2A 
and H2B antibodies in cells subject to USP12 depletion would be important in 
elucidating if USP12 influences AR-mediated transcriptional events through 
deubiquitination of histone H2A and H2B.  
Several difficulties were encountered in the characterisation USP12 including a lack of 
available reagents. A purchased HA and FLAG-tagged USP12 mammalian expression 
vector (Addgene) (Sowa et al., 2009) did not over-express an HA or FLAG-tagged 
protein corresponding to the predicted size of USP12. Generation of a FLAG-tagged 
USP12 vector was therefore undertaken to facilitate the project. Unfortunately, no 
commercially available USP12 antibodies were able to detect endogenous or 
ectopically expressed USP12, and hence the confirmation of USP12 knockdown at the 
protein level could not be performed as well as, restricting the types of 
characterisation experiments that could be performed utilising endogenous USP12. 
Although, immunoprecipitation of ectopically expressed FLAG-tagged USP12 with an 
anti-FLAG antibody identified an interaction between USP12 and AR, repeating this in 
LNCaP cells would be critical in confirming that this interaction is genuine under 
physiological conditions. Moreover, immuno-fluorescence studies of the cellular 
localisation of USP12 have not been performed but this could further confirm a role 
forUSP12 in regulation of AR nuclear function. 
The effect of USP12 on the ubiquitination status of the AR was not studied due to time 
constraints, however this in an important area that requires addressing. Performing 
immunoprecipitation of AR in the presence and absence of USP12 under denaturing 
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conditions would give an insight into whether the enzyme directly affects AR 
ubiquitination. Furthermore, purification of USP12 from cells by IP and incorporation 
into in vitro deubiquitination assays could elucidate which type of ubiquitin chain 
USP12 recognises and catalyses. The above data would suggest that USP12 reverses 
ubiquitination events that lead to AR repression however as USP12 does not affect the 
protein levels of AR it is unlikely that it reverses lysine 48-linked degrading chains.  
Examination of PSA protein levels in response to USP12 depletion in LNCaP cells 
showed a reduction in α-tubulin, suggesting USP12 may have an effect on LNCaP cell 
proliferation or viability. SRB staining of LNCaP cells, measuring total protein, 
confirmed this finding. Moreover, flow cytometry analysis of LNCaP cells following 
USP12 depletion caused G1 arrest and increased subG1 suggestive of apoptosis. 
Caspase-3 specific flow cytometry, as well as cleaved PARP-1 Western blotting, showed 
an increase in LNCaP apoptosis after USP12 knockdown. These data, taken together, 
suggests that USP12 may have a pro-proliferative and anti-apoptotic role which may 
be attached to its role in AR regulation, as AR is pro-proliferative. These results imply 
that USP12 may be a prospective therapeutic target in prostate cancer. Repeating the 
phenotypic experiments in an AR-negative cell line would elucidate whether the 
effects of USP12 observed in LNCaP cells are directly linked to the function of USP12 in 
the AR signalling cascade or an indirect effect. One simple experiment to address this 
question would be to combine USP12 and AR knockdown in LNCaP cells to examine if 
the effect of USP12 depletion is further potentiated by reduction to AR levels. 
Another important area for expansion in this study is the interplay between USP12 and 
PHLPP, an Akt phosphatase. Sowa et al., identified PHLPP as an interacting partner of 
USP12 in mass spectrometry analysis of 75 DUBs but did not validate or characterise 
this interaction (Sowa et al., 2009). Immunoprecipitation studies would be important 
for validating that this interaction is genuine. Preliminary data showed that USP12 
depletion in LNCaP cells resulted in a decrease in Akt phosphorylation at serine 473, 
which would theoretically result in a down-regulation of Akt pro-proliferative activity. 
This reduction in phospho-Akt could result from a potential increase in the activity of 
PHLPP. If USP12 counteracts PHLPP-mediated de-phosphorylation of Akt, the 
knockdown of PHLPP in combination with USP12 may result in a rescue of the 
phosphorylation levels of Akt and the phenotypic effects observed with USP12 
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depletion alone. As Akt-mediated phosphorylation of both AR and MDM2 have been 
demonstrated to cooperate in AR down-regulation and degradation (Lin et al., 2002b), 
USP12 may have an additional role in this pathway. Figure 7.1 illustrates the known 
dynamics between the above mentioned proteins and the AR and highlights where 
USP12 may fit into this model (Figure 7.1, red lines). 
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Figure 7.1. The potential role of USP12 in the AR signalling cascade.  
USP12 co-activates AR transcriptional activity but may also have a role in direct deubiquitination of AR and 
regulating the activity of PHLPP towards Akt. 
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7.2 USP10 as an AR co-repressor 
USP10 was identified as a regulator of AR activity in the same siRNA library screen 
described above. Unlike, USP12 however, USP10 depletion increased the expression 
and protein levels of PSA in LNCaP cells. Knockdown of USP10 had a similar effect on 
the expression of KLK2, TMPRSS2 and NDRG1 but had little effect on NKX3.1. USP10 
knockdown had no effect on AR protein levels as demonstrated by Western blotting 
and did not appear to be androgen regulated.  
USP10 over-expression in ARE3 luciferase reporter assays in three cell lines, COS-7, PC-
3 and U2OS, had a repressive effect on AR activity, suggesting that USP10 is a co-
repressor of AR transcriptional activity. These data are contrary to the published 
literature implicating USP10 in AR signalling, where USP10 is reported to increase AR 
activity (Faus et al., 2005; Draker et al., 2011). However, use of stably transfected AR-
null cell lines, different reporter constructs and insufficient knockdown may account 
for these discrepancies.  
PC-3 cells are AR-null and although they have been shown to respond to androgens 
upon reintroduction of AR, they are known not to behave identically to AR-positive 
prostate cancer cell lines. Therefore, stable over-expression of AR in PC-3 cells is not a 
valid model for the role of USP10 in AR signalling. Further to this, USP10 and AR have 
been shown to be interacting partners in PC-3/AR cells (Faus et al., 2005), which could 
not be confirmed in the endogenously expressing LNCaP cell line in this study, 
suggesting the interaction may be either cell type-dependent or an artefact of over-
expression. 
USP10 was recently observed to counteract MDM2-mediated ubiquitination of p53 in 
unstressed cells and in response to DNA damage (Yuan et al., 2010). Given that MDM2 
is an E3 ligase that down-regulates AR activity and promotes degradation it was 
hypothesised that in the context of AR signalling MDM2 and USP10 may cooperate in 
repressing AR activity. Verification of the repressive nature of MDM2 towards AR in 
luciferase-based reporter assays was initially problematic; increasing levels of MDM2 
had no effect on AR activity in COS-7 cells with the ARE3 luciferase reporter and the 
pPSA-luc reporter used in the Gaughan et al., study showed no androgenic stimulation 
of AR activity. Once the effect of MDM2 was confirmed in U2OS cells with the ARE3 
reporter, an experiment to test the above hypothesis was performed. Unfortunately, 
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due to time constraints only one experimental repeat was completed and in this 
experiment USP10 did not have the previously observed repression of AR activity. 
However, with further optimisation and repeats, this experiment could provide the 
preliminary evidence to support or disprove the hypothesis and warrant further 
investigation.  
In vitro ubiquitination and deubiquitination experiments will allow for further 
investigation of whether USP10 and MDM2 cooperate to lead to the K48-linked poly-
ubiquitination of AR. Initial in vitro ubiquitination assays testing the activity of MDM2 
towards the AR-DBD-Hinge-LBD indicated that mono-ubiquitination of the C-terminal 
of AR can be catalysed by MDM2 (Figure 6.15b). Studies conducted with specific 
mutant ubiquitin molecules will identify which, if any, lysine-linked poly-ubiquitin 
chains are catalysed by MDM2 on the AR. Furthermore, in vitro deubiquitination 
assays testing the enzymatic activity of USP10 showed a preferential disassembly of 
K63-linked penta-ubiquitin chains (Figure 6.18). This data may suggest that USP10 
removes transcriptionally activating ubiquitination events from AR. One hypothesis 
may be that MDM2-mediated ubiquitination and degradation of AR may require the 
removal of K63-linked poly-ubiquitin chains from the AR by USP10. Figure 7.2 
illustrates the hypothesis that USP10 may counteract MDM2-mediated auto-
ubiquitination leading to its stabilisation and therefore increased ability to act upon AR 
and repress its activity. 
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Figure 7.2. The potential role of USP10 in the AR signalling cascade.  
USP10 has a repressive effect on AR transcriptional activity and may counteract MDM2 auto-ubiquitination and 
degradation to exert this effect. 
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Given that the investigation into the interplay between USP10 and MDM2 and AR 
signalling are incomplete and that no direct interaction between USP10 and AR in 
LNCaP cells was observed, a large knowledge gap still remains and interpretation of 
the results is made more difficult by the discrepancies between the current study and 
the two previous studies of USP10 and AR (Faus et al., 2005; Draker et al., 2011). To 
this end, investigation of both AR and MDM2 ubiquitination status in the presence and 
absence of USP10 may provide an insight into whether USP10 is stabilising MDM2, 
allowing potentiation of its activity towards AR, or whether USP10 is an AR-specific 
DUB removing activating ubiquitin chains mediated by another E3 ubiquitin ligase. 
Furthermore, USP10, like USP7, may have altered affinities towards its substrates 
under different cellular conditions. USP7 preferentially deubiquitinates MDM2, 
allowing increased degradation of p53, in unstressed cells whereas under stress p53 is 
the preferred substrate for USP7 (Vucic et al., 2011). 
7.3 Conclusion 
In conclusion, USP12 and USP10 were identified by the Solid Tumour Target Discovery 
Group, Newcastle University, as DUB enzymes that could modulate AR-mediated 
transcription. USP12 acts as a transcriptional activator of AR which also appears to 
protect AR-positive prostate cancer cells from apoptosis driving proliferation. Further 
studies into whether this effect is directly linked with AR activity may provide 
therapeutic potential of USP12 inhibitors in prostate cancer. On the other hand, USP10 
was found to be a co-repressor of AR activity for the majority of androgen-regulated 
genes studied with the exception of NKX3.1. This effect is potentially through 
mediation of MDM2 activity, although this DUB requires much more extensive 
investigation in both AR ubiquitination and MDM2 regulation. 
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8.1 Expression vectors maps 
8.1.1 Generation of p3xFLAG-CMV-10™-USP12 and p3xFLAG-CMV-10™-
USP12C48A mammalian expression vectors 
 
 
 
 
 
Figure 8.1. Restriction map of the p3xFLAG-CMV-10™ vector. 
A schematic representation of the features of the p3xFLAG-CMV-10™ vector including the position of the 3xFLAG 
tag. Taken from (Sigma-Aldrich., 2012). 
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Figure 8.2. Sequence of the p3xFLAG-CMV-10™ vector multiple cloning site. 
Sequence of the 3xFLAG tag and multiple cloning site of the p3xFLAG-CMV-10™ vector. Restriction enzyme 
recognition sites are indicated. Taken from(Sigma-Aldrich., 2012).  
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Figure 8.3. Sequencing of p3xFLAG-CMV-10™-USP12 expression vector. 
USP12 was amplified by PCR from the pDEST-FLAG-HA-USP12 vector and ligated into the pCR2.1 vector. Positive 
transformants were digested with Xba I and Bam HI to release the USP12 sequence which was subsequently ligated 
into the p3xFLAG-CMV-10™ vector via Xba I and Bam HI restriction sites. Sequencing of p3xFLAG-CMV-10™-USP12 
was performed by Cogenics (UK) using the CMV forward sequencing primer. The 3xFLAG tag, vector sequence and 
USP12 insert are indicated by green, black and blue text respectively. The underlined region represents the initial PCR 
primer site used to introduce the Xba I restriction enzyme site. Restriction enzyme recognition sites are indicated. 
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Figure 8.4. Sequencing of the p3xFLAG-CMV-10™-USP12C48A expression vector. 
USP12C48A was generated by site-directed mutagenesis of p3xFLAG-CMV-10™-USP12. Sequencing of p3xFLAG-
CMV-10™-USP12C48A was performed by Cogenics (UK) using the CMV forward sequencing primer. The 3xFLAG tag, 
vector sequence and USP12 insert are indicated by green, black and blue text respectively.  The region underlined 
with a dashed line is the area of annealing of the site-directed mutagenesis primers. The mutated region is indicated 
by orange text; cysteine (TGC) at position 48 has been mutated to alanine (GCC). Restriction enzyme recognition 
sites are indicated.  
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8.1.2 Generation of the pGEX-6P-1-AR C-terminal domain bacterial expression 
vectors 
 
 
 
 
 
Figure 8.5. Restriction map of the pGEX-6P-1 expression vector 
A schematic representation of the features of the pGEX-6P-1 vector including the position of the glutathione-S-
transferase (GST) tag and sequence of the multiple cloning site. Restriction enzyme recognition sites are indicated. 
Taken from(GE healthcare., 2012). 
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Figure 8.6. Sequence of the pGEX-6P-1-AR DBD expression vector 
AR DNA-binding domain (DBD) was amplified by PCR from the pYFP-AR vector and ligated into the pCR2.1 vector. 
Positive transformants were digested with Bam HI and Eco RI to release the AR-DBD sequence which was 
subsequently ligated into the pGEX-6P-1 vector via Bam HI and Eco RI restriction sites. Sequencing of pGEX-6P-1-AR-
DBD was performed by Cogenics (UK) using the pGEX forward sequencing primer. The vector sequence is indicated 
by black text. AR-DBD (indicated by blue text) was found to have no alterations compared to with the known AR 
sequence. Underlined regions represent the initial PCR primer sites used to introduce the Bam HI and Eco R1 
restriction enzyme sites. Restriction enzyme recognition sites are indicated. 
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Figure 8.7. Sequence of the pGEX-6P-1-AR DBD-Hinge expression vector. 
AR DNA-binding domain (DBD) and Hinge were amplified by PCR from the pYFP-AR vector and ligated into the 
pCR2.1 vector. Positive transformants were digested with Bam HI and Eco RI to release the AR-DBD-Hinge sequence 
which was subsequently ligated into the pGEX-6P-1 vector via Bam HI and Eco RI restriction sites. Sequencing of 
pGEX-6P-1-AR-DBD-Hinge was performed by Cogenics (UK) using the pGEX forward sequencing primer. The vector 
sequence is indicated by black text. AR-DBD and Hinge (indicated by blue and green text respectively) were found to 
have no alterations compared to with the known AR sequence. Underlined regions represent the initial PCR primer 
sites used to introduce the Bam HI and Eco R1 restriction enzyme sites. Restriction enzyme recognition sites are 
indicated 
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Figure 8.8. Sequence of the pGEX-6P-1-AR DBD-Hinge-LBD expression vector. 
AR DNA-binding domain (DBD), Hinge and ligand-binding domain (LBD) were amplified by PCR from the pYFP-AR 
vector and ligated into the pCR2.1 vector. Positive transformants were digested with Bam HI and Xho I to release the 
AR-DBD-Hinge-LBD sequence which was subsequently ligated into the pGEX-6P-1 vector via Bam HI and Eco RI 
restriction sites. Sequencing of pGEX-6P-1-AR-DBD-Hinge-LBD was performed by Cogenics (UK) using the pGEX 
forward sequencing primer. The vector sequence is indicated by black text. AR-DBD, Hinge and LBD regions 
(indicated by blue, green and orange text respectively) were found to have no alterations compared to with the 
known AR sequence. Underlined regions represent the initial PCR primer sites used to introduce the Bam HI and Eco 
R1 restriction enzyme sites. Restriction enzyme recognition sites are indicated. 
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